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Summary  
 
Malaria causes an estimated one million deaths annually although it is a curable disease if 
treated promptly and correctly. Most cases occur in young children in sub-Saharan Africa, 
supporting a vicious circle of disease and poverty. Hence, ensuring access to malaria 
treatment is a major public health and development priority.  
 
The purpose of this research was to evaluate the ACCESS programme, which aimed at 
understanding and improving access to malaria treatment in rural Tanzania. The programme 
was implemented in the Kilombero and Ulanga Districts in Southern Tanzania in two phases. 
This evaluation focuses on the first phase, which covered the years between 2004 and 2008. 
The ACCESS strategy is based on a set of integrated interventions at three levels: 1) 
community level; 2) public heath facilities; and 3) commercial drug sector. The interventions 
are accompanied by a comprehensive set of monitoring and evaluation activities.  
 
Between 2004 and 2007 the ACCESS programme’s main intervention at community level 
was a social marketing campaign for improved recognition of the disease and more effective 
care seeking. Various communication channels were used and material developed to 
disseminate information on malaria transmission, symptoms and prevention as well as to 
stress the importance of prompt and effective treatment. Road shows were the main activity 
and included role plays, public lectures and quizzes. In addition, promotional materials (e.g. 
stickers, leaflets, t-shirts) were distributed, and billboards and posters displayed in public 
places. The programme also organised special campaigns targeted at pregnant women and 
mothers of young children in Mother and Child Health (MCH) clinics.  
 
In health facilities the ACCESS programme intervened to improve quality of care. The main 
activity was refresher training for health facility staff based on Integrated Management of 
Childhood Illness (IMCI) algorithms conducted in 2004 and 2005. In addition the study period 
saw the change of the first line treatment for malaria. In 2006 the Government of Tanzania 
switched from Sulphadoxine Pyrimethamine (SP) to the highly efficacious Artemether 
Lumefantrine (ALu), due to the high levels of resistance to SP. As ALu (trade name 
Coartem®) would be unaffordable at its market price the manufacturer Novartis sold it at-cost 
to Tanzania. Through support from the Global Fund to fight AIDS, TB and Malaria (GFATM) 
the drug was provided free to all government health care facilities. 
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In parallel the Accredited Drug Dispensing Outlets (ADDOs) programme was rolled out in the 
study area from 2006 onwards to improve access to treatment and quality of care in 
commercial drug shops. ACCESS undertook the local evaluation and monitoring of the 
programme. The private retail sector plays a very important role in the delivery of antimalarial 
treatment in most African countries as retailers tend to be more accessible and flexible, 
especially with regards to opening hours and charges. However, unqualified staff invariably 
sell drugs they are not allowed to stock, which often includes antimalarials. The aim of the 
ADDO programme is to improve access to quality care in drug shops with a mix of dispenser 
training, incentives, accreditation and regulation. ALu was made available to the programme 
at a highly subsidised price towards the end of 2007. 
 
Findings from the monitoring and evaluation activities showed that access to malaria 
treatment improved in the study area following the interventions in health facilities and drugs 
shops. Drug shops became more available to the community (from 24 shops for every 
100,000 people in 2004 to 39 in 2008) and more accessible (from 71% of households within 
5km of a shop in 2004 to 87% in 2008) following the ADDO roll-out. In addition, the 2006 
change of treatment policy from SP to ALu led to an increase in the availability of antimalarial 
drugs in health facilities (from 40% to 80% of months in stock of the drug). Treatment was 
generally more expensive in drug shops compared to health facilities and prices increased by 
50-80% in shops between 2004 and 2008. Nevertheless, antimalarial sales in private retail 
grew (from 49% to 59% of market shares). This is likely to be a result of increased availability 
and accessibility of shops but better quality of care may also have played a role. 
Unfortunately the ADDO programme was not able to promote widespread availability of ALu 
in its outlets (only one third of outlets were found to stock the drug in 2008). This resulted in a 
low uptake of the new drug (19% of all malaria treatments sold or dispensed) despite the fact 
that it was available in almost all the health facilities in the area.  
 
Results from treatment seeking surveys conducted in the community showed an 
improvement in malaria treatment between 2004 and 2008. This was ascribed to: 1) 
improved access to treatment; and 2) a better understanding of the importance of prompt 
treatment thanks to social marketing campaigns. The proportion of fever cases treated with 
an antimalarial increased (from 86% to 96% between 2004 and 2008) as well as the 
proportion of cases treated promptly (80% to 93-97% doses started within 24 hrs). However, 
there was no improvement in the reported adherence to the recommended dosage of drugs 
(43-76% of treatments dosed appropriately between 2004 and 2008). Moreover, the 
proportion of cases taking a recommended treatment was only 53% in 2008 since many 
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cases were treated in the private retail sector where the first line treatment ALu was not 
widely available.  
 
Improved treatment appears to have had an impact on malaria morbidity and mortality, both 
at community and health facility level. At community level there was evidence of a 28% 
decrease in the incidence of fever (from 2.5 to 1.8 average cases per person per year 
between 2005 and 2008) while convulsions in children under the age of five (a sign of 
progression into severe malaria) decreased by 45% (from 4.3 to 2.3 cases for every 10 
children per year). Under-five mortality decreased by 17% after the ACCESS interventions 
(from 28.4 cases per 1000 person years in the period 1997-2004 to 18.9 cases in 2008). 
However, due to the absence of a control it is difficult to know how much the ACCESS 
interventions contributed to this decrease compared to other malaria control strategies 
implemented in the area. The coverage with Insecticide Treated Nets (ITNs) is extremely 
high in the area (over 90% of household own at least one net). Although ITN ownership did 
not increase between 2004 and 2008 when the ACCESS interventions were implemented, 
they are likely to have continued to impact on transmission. Health facility fever rates 
decreased by 2-3% but the the absolute number of fever cases visiting health facilities 
remained unchanged due to population growth.  
 
In conclusion this thesis has shown that an integrated approach tackling both users and 
providers can lead to tangible improvements in terms of access to malaria treatment and 
treatment seeking for the disease. This can in turn have a substantial impact on both 
morbidity and mortality. Interventions targeting providers in sub-Saharan Africa should 
recognise the important role of the private sector since. This thesis has shown that if drugs 
are not available in the private sector their uptake remains low. As far as user interventions 
are concerned, social marketing has proven to be a successful strategy to sensitise the 
population on the importance of prompt treatment but more efforts are needed to improve 
adherence to treatment regimens. 
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Zusammenfassung 
 
Malaria verursacht schätzungsweise eine Million Todesfälle pro Jahr, obwohl es sich um eine 
heilbare Krankheit handelt, wenn sie schnell und richtig behandelt wird. Die meisten Fälle 
treten bei Kindern auf, die in Afrika südlich der Sahara leben, was den dort herrschenden 
Teufelskreis aus Krankheit und Armut verstärkt. Daher ist die Sicherung des Zugangs 
(access) zu Malaria-Behandlungen für das Gesundheitswesen und die Entwicklung von 
grosser Bedeutung. 
 
Der Zweck dieser Arbeit war es, das ACCESS-Programm zu beurteilen, welches darauf 
abzielt das Verständnis und die Verbesserung des Zugangs zu Malaria-Behandlungen im 
ländlichen Tansania zu verbessern. Das Programm wurde im Kilombero und Ulanga Distrikt 
in Süd-Tansania in zwei Phasen durchgeführt. Die hier vorliegende Bewertung konzentriert 
sich lediglich auf die erste Phase, die in die Jahre zwischen 2004 und 2008 fällt. Die 
ACCESS-Strategie basiert auf einer Reihe von integrierten Interventionen auf dreierlei 
Ebenen: 1) der kommunalen Ebene, 2) den Einrichtungen des öffentlichen 
Gesundheitssystems, und 3) dem gewerblichen Medikamentenbereich. Die Interventionen 
werden durch ein umfassendes Paket zur Überwachung und Bewertung der Aktivitäten 
begleitet. 
 
Zwischen 2004 und 2007 war die wichtigste Maßnahme des Access-Programms auf 
kommunaler Ebene eine soziale Marketing-Kampagne für eine bessere Erkennung der 
Krankheit und ein erfolgreiches Bemühen um Behandlung durchzuführen. Verschiedene 
Kommunikationskanäle wurden genutzt und Material entwickelt, um Informationen über 
Malaria-Übertragung, Symptome und Vorbeugung zu verbreiten, sowie die Bedeutung einer 
schnellen und wirksamen Behandlung hervorzuheben. Strassenvorführungen waren dafür 
die wichtigsten Aktivitäten. Sie beinhalteten Rollespiele, öffentliche Vorträge und Ratespiele. 
Darüber hinaus wurden Werbematerialien (z.B. Aufkleber, Flugblätter, T-Shirts) verteilt und 
Informationen auf Reklametafeln und Plakaten veröffentlicht. Das Programm organisierte 
auch spezielle Kampagnen welche speziell auf schwangere Frauen und Mütter mit kleinen 
Kindern in Mutter-Kind-Kliniken (MCH) abzielten. 
 
In Gesundheitseinrichtungen hatte das ACCESS-Programm zum Ziel die Qualität der 
Versorgung zu verbessern. Die Haupttätigkeit bestand dabei in Auffrischungskursen für das 
Personal basierend auf  den „Integrated Management of Childhood Illness“ (IMCI) 
Algorithmen aus den Jahren 2004 und 2005. Während der Studiendauer kam es zudem zu 
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einer Anpassung der Hauptbehandlung von Malaria. Aufgrund der vielen Resistenzen gegen 
Sulphadoxine Pyrimethamin (SP)  wechselte die Regierung von Tansania im Jahr 2006 von 
SP zu dem hochwirksamen Artemether Lumefantrin (ALu) . Da ALu (Handelsname Coartem 
®) zu den Marktpreisen des Herstellers Novartis unerschwinglich wäre verkaufte es das 
Unternehmen zum Herstellungskostenpreis nach Tansania. Durch die Unterstützung des 
Global Funds zur Bekämpfung von Aids, Tuberkulose und Malaria (GFATM) wurde das 
Medikament kostenlos an alle öffentlichen Einrichtungen des Gesundheitswesens 
bereitgestellt. 
 
Parallel dazu wurde seit 2006 das Accredited Drug Dispensing Outlets (ADDOs) Programm 
im Untersuchungsgebiet durchgeführt, das den Zugang zu Behandlungen und die Qualität 
der Pflege bei gewerblichen Medikamenten-Geschäften zu verbessern sucht. ACCESS 
verpflichtete sich zur lokalen Auswertung und Überwachung des Programms. Der private 
Einzelhandel spielt eine sehr wichtige Rolle bei der Bereitstellung von Anti-Malaria 
Behandlungen in den meisten afrikanischen Ländern, da Einzelhändler tendenziell stärker 
verfügbar und flexibel einsetzbar sind, insbesondere in Hinblick auf Öffnungszeiten und 
Gebühren. Leider verkauft nicht qualifiziertes Personal beständig Medikamente, die es nicht 
bevorraten darf, wobei es sich häufig um Malariamittel handelt. Das Ziel des ADDO 
Programms ist es den Zugang zu einer hochwertigen Gesundheitsversorgung im 
Medikamentenverkauf mittels einer Mischung aus Arzneibesteller-Ausbildung, -Förderung, -
Zulassung und -Regulierung zu verbessern. Gegen Ende des Jahres 2007 wurde ALu dem 
Programm zu einem stark subventionierten Preis zur Verfügung gestellt. 
 
Ergebnisse der Beobachtung und Bewertung der Aktivitäten zeigten, dass der Zugang zur 
Malaria-Behandlung im Studiengebiet infolge der Eingriffe in 
Gesundheitsfürsorgeeinrichtungen und Medikamentengeschäfte verbessert werden konnte. 
Nach der Einführung von ADDO wurden Arzneimittelgeschäfte verfügbarer (24 Geschäften 
pro 100.000 Menschen im Jahr 2004 und 39 Geschäfte in 2008) und zugänglicher (von 71% 
der Haushalte im Umkreis von 5km von einem Geschäft im Jahr 2004 auf 87% in 2008) für 
die Gemeinschaft. Darüber hinaus führte die Änderung der Hauptbehandlungspolitik von SP 
zu ALu in 2006 zu einem Anstieg in der Verfügbarkeit von Medikamenten gegen Malaria in 
Gesundheitseinrichtungen (Monaten mit vorrätigen Medikamenten von 40% auf 80%). In der 
Regel war die Behandlung in Arzneimittelgeschäften im Vergleich zu Einrichtungen des 
Gesundheitswesens teurer. Zudem stiegen die Preise in den Geschäften um 50-80% 
zwischen 2004 und 2008. Dennoch stieg der Umsatz an Anti-Malaria Mitteln im privaten 
Einzelhandel von 49% auf 59% der Marktanteile. Dies dürfte eine Folge der erhöhten 
Verfügbarkeit und Zugänglichkeit von Geschäften sein, allerdings kann auch die verbesserte 
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Qualität der Betreuung eine Rolle gespielt haben. Leider war das ADDO Programm nicht in 
der Lage eine weit verbreitete Verfügbarkeit von ALu in seinen Verkaufsstellen zu fördern 
(nur ein Drittel der Filialen hatte das Medikament im Jahr 2008 auf Lager). Dies führte zu 
einer geringen Nutzung der neuen Arznei (bei 19% aller Malaria-Behandlungen verkauft oder 
ausgegeben) trotz der Tatsache, dass es in fast allen medizinischen Einrichtungen in der 
Region verfügbar war. 
 
Ergebnisse von Studien über das Streben nach Behandlung in der Gemeinschaft 
durchgeführt wurden, zeigten eine Verbesserung der Malaria-Behandlung zwischen 2004 
und 2008. Dies war zurückzuführen auf 1) eine Verbesserung des Zugangs zur Behandlung 
und 2) ein grösseres Verständnis für eine schnelle Behandlung dank der Kampagnen auf 
dem sozialen Sektor. Sowohl der Anteil der Fieber-Fälle, die mit Malariamedikamenten 
behandelt wurden (von 86% auf 96% zwischen 2004 und 2008), als auch der Anteil der 
Fälle, die umgehend behandelt wurden (von 80% auf 93-97% an Einnahmen innerhalb von 
24 Stunden), erhöhte sich. Allerdings gab es keine Verbesserung zur gemeldeten Einhaltung 
der empfohlenen Dosierung von Medikamenten (43-76% der Behandlungen wurden 
zwischen 2004 und 2008 richtig dosiert). Darüber hinaus lag der Anteil an Fällen mit 
empfohlener Behandlung bei nur 53% im Jahr 2008, da viele Fälle im privaten Einzelhandel 
behandelt werden, in dem das Hauptmedikament ALu nicht überall verfügbar war. 
 
Eine verbesserte Behandlung scheint einen Einfluss auf die Morbidität und Mortalität von 
Malaria zu haben, sowohl auf der kommunalen als auch auf der Gesundheitswesen-Ebene. 
Auf kommunaler Ebene gab es Anzeichen für eine 28%-ige Abnahme der Inzidenz von 
Fieber-Fällen (von 2,5 auf durchschnittlich 1,8 Fälle pro Person und Jahr zwischen 2005 und 
2008), während Krämpfe bei Kindern unter fünf Jahren (ein Zeichen des Übergangs in die 
schwere Form der Malaria) um 45% abnahmen (von 4,3 auf 2,3 Fälle je 10 Kinder pro Jahr). 
Die Mortalität bei Kindern unter fünf Jahren sank um 17% nach den Interventionen des 
ACCESS Programms (von 28,4 Fällen pro 1.000 Personenjahre im Zeitraum 1997-2004 auf 
18,9 Fälle im Jahr 2008). Aufgrund von fehlender Kontrolle ist schwierig zu wissen, inwieweit 
die ACCESS Interventionen im Vergleich mit anderen Strategien zur Bekämpfung der 
Malaria, die ebenfalls in der Region umgesetzt wurden, zu diesem Rückgang beitrugen. Die 
Abdeckung mit Insektizid-behandelten Moskitonetzen (ITN) in der Umgebung ist extrem hoch 
(über 90% der Haushalte besitzen mindestens ein eigenes Netz). Obwohl die Abdeckung 
zwischen 2004 und 2008 nicht zugenommen hat, als die ACCESS Interventionen umgesetzt 
wurden, ist es wahrscheinlich, dass die Auswirkungen auf die Übertragung sich fortgesetzt 
haben. Auf Ebene der Gesundheitseinrichtungen blieb die Zahl der Fälle, die mit Fieber in 
den Einrichtungen erschienen, aufgrund des Bevölkerungswachstums unverändert. 
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Zusammenfassend hat diese Arbeit gezeigt, dass ein integrierter Ansatz, der sowohl Nutzer 
als auch Anbieter einbezieht, zu konkreten Verbesserungen in Bezug auf den Zugang zu 
Malaria-Behandlung und zum Streben nach Behandlung führen kann. Dies kann wiederum 
einen wesentlichen Einfluss auf Morbidität und Mortalität haben. Es ist daher wichtig, dass 
Interventionen im Anbieterbereich die zentrale Rolle des privaten Sektors anerkennen. Die 
vorliegende Arbeit hat aufgezeigt, dass bei fehlender Verfügbarkeit von Medikamenten im 
privaten Sektor die Medikamentenverwendung in der Bevölkerung niedrig ist. Im 
Nutzerbereich haben sich soziale Marketing-Kampagnen auf kommunaler Ebene zwar als 
nützliche Strategien zur Sensibilisierung der Bevölkerung bezüglich der Wichtigkeit von 
frühzeitiger Behandlung erwiesen, doch muss die Befolgung der Behandlungsrichtlinien 
weiter verbessert werden. 
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Muhtasari 
 
Malaria inasababisha takribani vifo milioni moja kila mwaka ingawa ni ugonjwa unaotibika 
iwapo tiba itachukuliwa mapema na kwa usahihi. Mashambulizi mengi yanatokea miongoni 
mwa watoto wadogo katika bara la Afrika, chini ya jangwa la Sahara, hali inayoendeleza 
mfumo mzima wa magonjwa na umasikini. Kwa mantiki hii, upatikanaji wa tiba ya malaria ni 
kipaumbele kikubwa katika swala zima la afya ya jamii na maendeleo. 
 
Lengo la taarifa hii ya utafiti ilikuwa ni kutathmini mradi wa ACCESS uliokuwa na lengo la 
kuongeza uelewa na kuimarisha upatikanaji wa tiba ya malaria maeneo ya vijijini katika nchi 
ya Tanzania. Mradi huu ulitekelezwa kwa awamu mbili katika wilaya za Kilombero na 
Ulanga, kusini mashaririki mwa Tanzania. Tathmini hii imelenga awamu ya kwanza ya mradi, 
iliyofanyika kati ya mwaka 2004 na 2008. Mkakati wa mradi wa ACCESS umelenga katika 
utekelezaji kwenye sehemu kuu tatu: 1) Ngazi ya jamii 2) Vituo vya afya, na 3) Ngazi ya 
maduka ya dawa.Utekelezaji huu unaambatana na zoezi la kina la ufatiliaji na tathmini.  
 
Kati ya mwaka 2004 na 2007, utekelezaji mkubwa katika mradi wa ACCESS kwenye ngazi 
ya jamii ulikuwa uhamasishaji wa jamii masoko kwa ajili ya kuongeza utambuzi wa ugonjwa 
wa malaria na kupata tiba sahihi. Njia mbalimbali za mawasiliano zilitumika na vifaa 
kuandaliwa kwa ajili ya kutoa ujumbe juu ya maambukizo ya malaria, dalili zake na kinga, pia 
msisitizo juu ya umuhimu wa tiba sahihi na mapema. Maonyesho kwa njia ya barabara 
ilikuwa ni kazi kubwa iliyojumuisha michezo ya kuigiza, mhadhara na maswali na majibu. Pia 
vifaa vya uhamasishaji kama vipeperushi na  fulana viligawiwa na mabango yalibandikwa 
kwenye sehemu za wazi. Mradi pia uliandaa uhamasishaji maalum uliowalenga akina mama 
wajawazito, wanawake wenye watoto wadogo na kliniki za watoto. 
 
Katika vituo vya afya, mradi wa ACCESS ulijikita katika kuimarisha ubora wa huduma. 
Shughuli kubwa iliyofanyika ilikuwa ni kutoa mafunzo rejea kwa wafanyakazi wa vituo vya 
afya kulingana na mfumo ulikuwepo wa kutibu magonjwa yanayoshambulia watoto chini ya 
miaka mitano ikiwemo malaria, mfumo wa matibabu ya magonjwa ya watoto kwa uwiano 
unaojulikama kama IMCI (kwa lugha ya kiingereza ukimaanisha Integrated Management of 
Childhood Illness) uliofanyika mwaka 2004 na 2005. Pia katika kipindi cha utekelezaji wa 
mradi, kulitokea mabadiliko ya dawa ya kwanza ya kutibu malaria isiyo kali. Mwaka 2006, 
serikali ya Tanzania iibadili dawa ya malaria kutoka Sulphadoxine Pyrimethamine (SP) 
kwenda dawa iliyo bora zaidi iitwayo Artemether Lumefantrine (ALu) kutokana na SP 
kushindwa kupambana na vimelea vya malaria. ALu (jina la kibiashara Coartem) isingeweza 
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kupatikana kwa waanchi kwa sababu gharama zake zilikuwa juu kutokana na bei kubwa ya 
soko lake kutoka kwa watengenezaji (Norvatis) iliyouzwa Tanzania, lakini kutokana na 
msaada kutoka katika nfuko wa dunia wa kupambana na Ukimwi, Kifua Kikuu na Malaria, 
dawa ziliweza kutolewa bure kwa vituo vyote vya afya vya serikali. 
 
Pamoja na hayo, mpango wa Maduka ya Dawa Muhimu (DLDM) ulizinduliwa katika eneo la 
mradi mwaka 2006 kwa ajili ya kuongeza upatikanaji wa tiba na huduma bora katika maduka 
ya dawa. Mpango wa ACCESS uliamua kufanya ufuatialji na tathmini ya mpango huu. Sekta 
binafsi inachangia kwa kiasi kikubwa katika utoaji wa tiba ya malaria katika nchi nyingi za 
Afrika kwa sababu maduka yanaweza kufikika kwa urahisi zaidi hususani kwenye kipengele 
cha muda wa kuwa wazi na suala la bei. Lakini wauzaji wasiokuwa na vigezo wamekuwa 
wakiuza dawa ikiwemo dawa za malaria. Lengo la mpango wa maduka ya dawa muhimu ni 
kuimarisha upatikanaji wa huduma bora katika maduka ya dawa na kuwapa mafunzo watoa 
huduma, motisha na kuongeza kiwango cha utendaji. Mwishoni mwa mwaka 2007 ALu 
zilipunguzwa bei katika eneo la mradi ili kusaidia jamii kuzipata kwa urahisi. 
 
Matokeo ya shughuli za ufuatiliaji na tathmini ulionyesha kuwa upatiknaji wa tiba ya malaria 
umeongezeka katika eneo la mradi kutokana na utekelezaji katika ngazi za vituo vya tiba na 
maduka ya dawa. Maduka ya dawa yaliongezeka zaidi kwa jamii (kutoka maduka 24 kwa kila 
watu 100,000 mwaka 2004 mpaka maduka 38 mwaka 2008) na zaidi upatikanaji (kutoka 
asilimia 71 ya kaya zinazoishi ndani ya kilometa 5 kutoka duka la dawa mwaka 2004 mpaka 
asilimia 87 mwaka 2008) kutokana na uanzishwaji wa mpango wa Maduka ya dawa muhimu. 
Pia ubadilishwaji wa sera ya tiba kutoka SP kwenda ALu ilisababisha muongezeko wa dawa 
za malaria katika vituo vya tiba (kutoka asilimia 40 mpaka asilimia 80 ya miezi ya akiba ya 
dawa). Kwa ujumla matibabu yalikuwa ghali zaidi kwenye maduka ya dawa kuliko katika 
vituo vya tiba na bei iliongezeka kwa asilimia 50-80 kwenye maduka kati ya mwaka 2004 na 
2008. Pamoja na hayo mauzo ya dawa za malaria kwenye maduka ya dawa ilikua (kutoka 
asilimia 49 mpaka 59 ya mgao wa masoko). Hii inaweza kuwa matokeo ya uongezekaji wa 
upatikanaji wa maduka lakini pia ubora wa huduma unaweza kuwa umechangia. Kwa bahati 
mbaya mpango wa maduka ya dawa muhimu haukuongeza uongezekaji wa ALu katika 
maduka haya (ni moja ya tatu tu ya maduka haya yalionekana kuwa na dawa za ALu mwaka 
2008). Hii ilisababisha mapokeo machache ya dawa hii mpya (asilimia 19 ya dawa za 
malaria iliuzwa) pamoja na kwamba dawa hizi zilikuwepo pia kwenye vituo vya tiba katika 
eneo la mradi. 
 
Matokeo ya tafiti za utafutaji matibabu zilizofanyika katika ngazi ya jamii zilionyesha 
kuongezeka kwa tiba ya malaria kati ya mwaka 2004 na 2008. Hii ilisababishwa na: 1) 
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kuimarika kwa upatikanaji wa tiba; 2) uelewa mzuri zaidi wa umuhimu wa tiba ya haraka 
ambao ulisisitizwa katika uhamasishaji wa masoko jamii. Kiwango cha matukio ya homa 
yaliyotibiwa kwa dawa za malaria kiliongezeka (kutoka aslimia 86 mpaka asilimia 96 kati ya 
mwaka 2004 na 2008) pamoja na kiwango cha matukio yaliyotibiwa mapema (asilimia 80 
mpaka 93-97, dozi ilimezwa ndani ya masaa 24). Lakini kulikuwa hakuna mabadiliko kwa 
wale walioripoti kumaliza dozi iliyo sahihi (asilimia 43-76 ya tiba kamilifu kati ya mwaka 2004 
na 2008). Zaidi kiwango cha matukio ya homa yaliyotumia tiba iliyopendekezwa ilikuwa 
asilimia 53 mwaka 2008 kwani matukio mengi yanatibika katika sekta binafsi ambapo dawa 
ya kwanza ya malaria (ALu) haikuwa inapatikana kwa kiasi kikubwa 
 
Kuboreka kwa tiba kumeonekana kuwa na matokeo katika magonjwa na vifo, pote katika 
ngazi ya jamii na vituo vya tiba. Katika ngazi ya jamii imedhibitika kuwa asilimia 28 ya 
matukio ya homa yalipungua (kutoka wastani wa matukio 2.5 mpaka 1.8 kwa mtu. 
 
 kwa mwaka kati ya mwaka 2005 na 2008) wakati matukio ya degedege (dalili ya kuelekea 
kwenye malaria kali) kwa watoto chini ya miaka mitano yalipungua kwa asilimia 45 (kutoka 
matukio 4.3 mpaka 2.3 kwa kila watoto kumi kwa mwaka). Vifo vya watoto chini ya miaka 
mitano vilipungua kwa asilimia 17 baada ya utekelezaji wa mpango wa ACCESS (kutoka 
matukio 28.4 kwa watu 1000 kwa kipindi cha miaka 1997-2004 mpaka 18.9 mwaka 2008). 
Pamoja nah ii, kutokuwepo na kundi ambalo halikupewa utekelezaji, ni vigumu kujua ni kwa 
kiasi gani mpango wa ACCESS umechangia katika mabadiliko haya ukilinganisha na 
mikakati mingine ya kupambana na malaria katika eneo la mradi. Utumiaji wa vyandarua 
vilivyotiwa dawa ni mkubwa katika eneo la mradi (zaidi ya asilimia 90 ya kaya zinamiliki 
angalau chandarua kimoja). Ingawa hii haikuongezeka katika kipindi kati ya mwaka 2004 na 
2008 wakati mradi wa ACCESS ulipotekelezwa, kuna uwezekano kukawa na muendelezo 
wa matokeo ya maambukizo. Katika ngazi ya kituo cha tiba idadi ya matukio ya homa 
yaliyofika vituo vya tiba hayakubadilika kutokana na muongezeko ya watu.  
 
Kwa kuhitimisha taarifa hii ya utafiti imeonyesha kuwa njia ya muingiliano unaogusa 
watumiaji na watoaji inaweza kuongeza uimarikaji wa upatikanaji wa tiba ya malaria na 
utafutaji matibabu. Kwa njia nyingine, hii inaweza kuwa na matokeo katika magonjwa na vifo. 
Utekelezaji unaolenga watoa huduma kusini mwa jangwa la Sahara unatakiwa kuzingatia 
umuhimu wa sekta binafsi kutokana na kwamba utafiti huu umeonyesha kuwa kama dawa 
hazipatikani katika sekta binafsi matumizi yake yanakuwa madogo. Kwa namna ambavyo 
utekelezaji unaolenga watumia huduma unavyohusika, mkakati wa masoko jamii 
umeonyesha kufanikiwa kuhamasisha wananchi juu ya umuhimu wa tiba ya mapema lakini 
jitihada kubwa inatakiwa kuongezwa ili kuboresha uzingatiaji wa taratibu za matibabu. 
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1.  Introduction 
 
Malaria is the most important parasitic infection in humans and a major public health and 
development problem in sub-Saharan Africa. A brief overview of the transmission, clinical 
manifestations and geographical distribution of the disease is given in Section 1.1, with a 
focus on Africa. The current global strategy for malaria control is outlined in Section1.2. and 
Section 1.3 provides an overview of the mutually re-enforcing cycles of malaria and poverty, 
which challenge malaria control efforts in developing countries. The specifics of the malaria 
situation and control efforts to date in mainland Tanzania are described in Section 1.4. 
Section 1.5 focuses on existing strategies to improve access to malaria treatment. Finally 
Section 1.6 describes the Health Access Livelihood Framework and Section 1.7 provides a 
detailed description of the Tanzanian health system in terms of this framework. 
 
1.1. Epidemiology of malaria 
Malaria is a vector-borne infection caused by protozoan parasites belonging to the genus 
Plasmodium. It is transmitted by 40 main species of female Anopheles mosquitoes. These 
differ in behaviour which explains the many epidemiological patterns of the disease seen 
worldwide. Almost all human infections are caused by P. falciparum, P. Vivax, P. malaria and 
P. ovale although occasional infections with monkey malaria parasites, such as P. knowlesi, 
also occur. P. falciparum causes the most severe and life-threatening form of the disease 
and is mainly found in Africa [1]. 
 
Infection with P. falciparum may result in a wide variety of symptoms, ranging from very mild 
symptoms to severe disease and even death. Malaria is often categorised as uncomplicated 
(initial stages) or severe/complicated (later stages). The first symptoms of uncomplicated 
malaria include headache, fatigue, muscle and joint aches, followed by fever, vomiting and 
worsening malaise. In general, uncomplicated malaria is a curable disease if diagnosed and 
treated promptly and correctly. However, treatment delay can lead to severe malaria, which 
usually manifests itself with coma (cerebral malaria), metabolic acidosis, severe anaemia, 
hypoglycaemia and, in adults, acute renal failure or acute pulmonary oedema. If untreated, 
severe malaria is almost always fatal. Estimates suggest that approximately 2% of clinical 
malaria episodes in African children are severe and of these, 50% are fatal [1].  
 
Malaria was widespread in many parts of Europe and North America but was progressively 
restricted to tropical areas in the 20th century as a result of general economic developement. 
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Cold winters facilitated the success of the control measures as they shorten mosquito life 
and prolong the time period required for the parasite to complete its life-cycle. Conversely, in 
tropical Africa and many parts of Asia, the measures to fight malaria are particularly 
challenging as the climatic conditions in these regions are more favourable for both the 
Plasmodium parasite and the Anopheles vector [2]. According to the World Health 
Organisation (WHO) malaria occurs in 108 countries and half of the world’s population or 3.3 
billion people are at risk of malaria [3]. However, it is in sub-Saharan Africa where 85-90% of 
malaria fatalities occur as most cases result from by P. falciparum infections [4].  
 
Determination of the mortality and morbidity caused by malaria is difficult to achieve due to 
the lack of reliable data and the indirect effects of malaria. Estimates of the burden of malaria 
are based on different sources and assumptions as national health statistics of the countries 
concerned are often inadequate, incomplete and non representative [5]. Most estimates 
suggest that malaria directly causes about 1 million deaths per year, nearly 90% of which 
occur in children under five years of age in Africa (Figure 1) [3]. In 2004 malaria was given a 
Disability-Adjusted Life Year (DALY) score of 34 million worldwide (2.2% of the total) and 31 
million in the African Region (8.2% of the total) [6]. However, these mortality and morbidity 
estimates do not allow sufficiently for malaria as an indirect cause of anaemia, low birth 
weight, growth retardation/undernutrition, and consequences of illness such as adverse 
reactions to treatment and neurological disabilities (Figure 2) [7, 8]. It has been estimated 
that the attributable mortality of malaria, taking into consideration its indirect effects, may be 
approaching three million, almost 3 times the WHO estimate [7]. 
 
Figure 1. Estimated deaths from malaria per 1000 population (source: RBM [4]) 
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Figure 2. Acute, chronic and pregnancy related manifestations of malaria (source: Breman et al 
[7]) 
 
1.2. Malaria control 
Following the elimination of malaria in temperate countries after the World War II, various 
malaria eradication campaigns were carried in the rest of the world with mixed outcomes. 
Countries such as the United States, Italy, Greece and Spain were the first to become free of 
autochthonous malaria in the 1930s to 1950s as a result of improved housing and intensive 
antimalarial interventions (draining of swamplands, use of DDT for indoor house spraying 
and effective case management, first with quinine and then with chloroquine). Confidence in 
the effectiveness of the available malaria control tools grew and in 1955 the World Health 
Assembly launched a global malaria eradication campaign conducted throughout the 1960s 
and 1970s. Malaria was eliminated in nations with temperate climates and seasonal malaria 
transmission, but in most countries progress was negligible or not sustained after control 
efforts ceased.   
 
Following the failure to achieve eradication, WHO abandoned the campaign and reoriented 
its policy from eradication and elimination to control. In 1985 WHO adopted a resolution 
recommending that malaria control activities be developed as an integral part of primary 
health care systems at the district level. The lack of financial support and the integration of 
malaria programmes in rapidly decentralising and deteriorating primary health services, 
combined with an increase in parasite and vector resistance to the current antimalarial drugs 
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and insecticides led to an unprecedented increase in malaria mortality and morbidity in the 
1980s [4, 7, 9].  
 
The resurgence of malaria in the 1980s led to the creation of the Roll Back Malaria (RBM) 
Partnership to coordinate renewed global efforts in combating malaria in 1998. The 
Partnership was launched by the World Health Organization (WHO), the United Nations 
Children’s Fund (UNICEF), the United Nations Development Programme (UNDP) and the 
World Bank. The partnership attempts to build upon the successes and lessons learnt from 
previous malaria control, elimination and eradication efforts by promoting universal coverage 
of effective interventions but also by strengthening health systems. The goal set by the 
partnership is to have achieved a 75% global reduction in incidence of malaria compared to 
2000 levels in 2015 [10]. 
 
The current strategy of the partnership is outlined in the Global Malaria Action Plan (GMAP) 
[4] and comprises of three components: control, elimination and research. Control is thought 
of as a two stage process, whereby initially universal coverage of locally appropriate 
prevention and therapeutic interventions is reached for all populations at risk. Universal 
coverage is then sustained over time by strengthened health systems, which eventually 
leads the country into the elimination stage. The expert consensus is that elimination of 
malaria in certain countries will require new control tools in traditionally high-transmission 
areas. Therefore, continuous research into new tools, but also to inform policy and to 
develop intervention and operational strategies is necessary at every stage (Figure 3). 
Eradication is the long-term goal of the strategy which can be achieved by eliminating 
malaria country by country as new approaches and tools expand the geographical range of 
where elimination is possible. WHO currently estimates that 82 out of 109 malarious 
countries are currently in the control stage (Figure 4). 
 
Figure 3. Three components of the global strategy (source: RBM [4]) 
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Figure 4. Country categorization by malaria status and burden (source: RBM [4]) 
 
 
The RBM Partnership advocates the universal coverage of preventive tools. The currently 
available preventive tools include Long-Lasting Insecticidal Nets (LLINs), Indoor Residual 
Spraying (IRS) and Intermittent Preventive Treatment for Pregnant women (IPTp). LLINs are 
recommended as a key vector control intervention which provides both personal protection 
with the net and the insecticide, and community protection by reducing the vector population 
when implemented at high coverage. Where LLINs are not available the use of Insecticide 
Treated Nets (ITNs) is recommended, with periodic insecticidal treatment.  IRS is an effective 
method of vector control aimed at killing mosquitoes that enter houses and rest on sprayed 
surfaces (e.g. walls and ceilings). IRS is widely used in areas of seasonal transmission, but 
is only appropriate and advised in countries where the necessary logistics can be deployed. 
In high transmission settings, all pregnant women should receive at least 2 doses of 
Sulphadoxine-Pyrimethamine (SP) for IPT to reduce the risk of contracting malaria [4]. 
 
The appropriate case management recommended by the RBM Partnership is treatment with 
appropriate antimalarial drugs on malaria. Before treatment is started parasitological 
diagnosis is recommended to confirm malaria cases through quality-assured microscopy or 
Rapid Diagnostic Tests (RDTs). All confirmed uncomplicated P. falciparum infections should 
be treated with an artemisinin-based combination (ACT) therapy within 24hrs of onset.  
Conventional antimalarial monotherapies, such as chloroquine, SP and amodiaquine are no 
longer recommended due to widespread resistance. Four ACTs are currently recommended 
for use: artemether-lumefantrine, artesunate-amodiaquine, artesunate-mefloquine and 
artesunate-sulfadoxine-pyrimethamine. The choice of the ACT should be based on the 
efficacy of the partner medicine in the country or area of intended deployment.  Severe 
1. Introduction            6 
 
 
malaria should be treated parenterally with either an artemisinin derivative or quinine until the 
patient can swallow, when a complete course of ACT must be administered [4].  
 
In its Global Strategic Plan 2005-2015 [4] the RBM Partnership set the following targets for 
2010:  
• 80% of people at risk from malaria are using locally appropriate vector control 
methods such as long-lasting insecticidal nets (LLINs), indoor residual spraying (IRS) 
and, in some settings, other environmental and biological measures; 
• 80% of malaria patients are diagnosed and treated with effective anti-malarial 
treatments; 
• in areas of high transmission, 100% of pregnant women receive intermittent 
preventive treatment (IPTp); and  
• the global malaria burden is reduced by 50% from 2000 levels: to less than 175-250 
million cases and 500,000 deaths annually from malaria. 
  
1.3. Malaria and poverty 
A strong correlation between malaria and poverty at country level and at individual/household 
level has long been recognised [11]. However, the strength and the causality of the 
relationship are still not clear. Most likely causality runs both ways and communities living in 
malaria endemic areas are trapped in reinforcing cycles of poverty and disease [11-13].  
 
Studies investigating the association between poverty and malaria at individual or household 
level have reported mixed results. Results depend on how poverty is measured and are often 
confounded by clustering and education. Certainly, the poorest are more likely than their 
better-off peers to get sick (because they are more exposed to health risks and they have 
less resistance to disease due to under-nutrition and other hazards typical in poor 
communities) and less likely to access preventive and curative health care [14]. Furthermore 
expenditures for health care are more burdensome to the poorest. But the pathways between 
poverty, economic activity and healthcare seeking are complex and multidimensional: 
farming may increase the risk of malaria, but the wealth created by the activity may allow 
farmers to protect themselves from malaria; other remunerative activities may both increase 
risk and reduce access to health services [12, 15]. 
 
At a global level, malaria incidence is undoubtedly concentrated in the world’s poorest 
countries. A study showed that countries with intensive malaria had income levels 33% that 
of countries without malaria in 1995, and grew 1.3% less per person per year between 1965 
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and 1990, controlling for confounding factors. The correlation could be explained in many 
different ways. As countries get richer, housing is improved, more public funding is available 
for control programmes (insecticide residual spraying, draining of swampland, etc) and 
strengthened health systems provide better quality of care. Conversely, it is also argued that 
malaria impedes long term economic growth and development by discouraging tourism and 
foreign investment and affecting schooling and worker productivity [11, 16].   
 
The reduction of malaria, but more generally the improvement of public health, is therefore a 
key determinant of development. The inclusion of health related targets in Millennium 
Development Goals [17] reflects an acknowledgement by the international community that 
health and access to health are intrinsically linked to development. These goals have 
contributed to mobilise resources and improve the co-ordination of initiatives to fight malaria, 
but also HIV/AIDS and tuberculosis, in many countries. International initiatives and 
foundations which have made a significant contribution to malaria control include the Global 
Fund to Fight AIDS, Tuberculosis and Malaria (GFATM), The Bill and Melinda Gates 
Foundation (BMGF), the World Bank’s Malaria Booster Programme, and the US President's 
Malaria Initiative (PMI).  
 
1.4. Malaria in Tanzania  
In Tanzania malaria is a major public health problem. Malaria is endemic in almost all parts 
of the country (Figure 5). It accounts for over 30% of the disease burden and is a threat to 
every one of the estimated 32 million people (94% of the population) living in areas where 
transmission is possible The disease is estimated to cause between 100,000 and 125,000 
deaths a year and is the leading cause of outpatient attendance for children under the age of 
five (38%) and for all other patients (32%) [18]. An estimated D 65 million is spent on the 
prevention and treatment of malaria in Tanzania each year, which amounts to 39% of all 
health expenditures and just under 1.1% of GDP [19].  
 
Malarial control strategy 
The current malarial control strategy is outlined in the National Malaria Control Programme’s 
(NMCP) Medium Term Strategic Plan (MTSP) (2002-2007) and is based on strategies and 
targets from the 2000-2001 Roll Back Malaria Action Plan [18]. The strategy mainly promotes 
the use of ITNs coverage of prompt and effective treatment for malaria and the use of IPT of 
malaria among pregnant women. However it also includes other vector control measures 
such as IRS and epidemic prevention and control.  
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Figure 5. The spatial distribution of malaria endemicity in Tanzania (source: MAP [20]) 
 
 
 
Vector control with ITNs- Tanzania’s current vector control strategy has mainly relied on 
intensive promotion of ITN use through a public private partnership approach. The National 
Insecticide Treated Nets programme (NATNETS) has four key components: 1) the ITN Cell 
in the NMCP coordinates and facilitates all ITN activities in the mainland of Tanzania; 2) the 
SMARTNET social marketing project creates demand, promotes behaviour change, supplies 
free-of-charge insecticide kits to the Tanzanian net manufacturers for bundling with all nets 
distributed on the Mainland and distributes subsidized insecticide re-treatment kits to the 
commercial sector; 3) the Tanzania National Voucher Scheme (TNVS) distributes discount 
vouchers to pregnant women and infants through clinics and dispensaries, allowing them to 
purchase ITNs from private retailers at approximately 75% discount [21-22] and 4) a mass 
“catch-up” distribution campaign to provide free LLINs to all children under five years since 
coverage of risk groups increased too slowly under the voucher scheme [23]. A national net 
re-treatment campaign is being carried out at the same time as the catch-up campaign. 
 
Malaria case management - Until 2001 chloroquine was the main antimalarial used, but due 
to high levels of chloroquine resistance it was officially withdrawn and replaced by 
sulphadoxine-pyrimethamine (SP). Amodiaquine was the second line treatment and quinine 
third line and first choice in severe malaria. In 2006, SP was in turn abandoned in favour of 
Artemether-Lumefantrine (ALu, trade name Coartem®, Novartis AG). Quinine remained the 
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drug of choice for severe malaria. Through funding from the GFTAM the drug is provided free 
to all government health care facilities in Tanzania where it should be made available free to 
children under the age of five in accordance with the exemption policy and at asubsidised 
price of TSH 300 (USD 0.25) to all other patients. Subsidised ALu is also available in the 
private retail sector in Accredited Drug Dispensing Outlets (ADDOs). In all other private drug 
retail outlets it is currently unaffordable for most of the population at its  current maker price 
of USD 8-10 for an adult dose. 
 
Intermittent Preventive Treatment (IPT) - IPT with SP is recommended for pregnant women 
during antenatal visits as a prophylactic measure during pregnancy. The two doses should 
be given as directly observed therapy at 20-24 weeks and 28-32 weeks gestational age. 
 
IRS - Although Tanzania was one of the pioneers in launching indoor residual spraying in the 
1960s and 1970s, it has never been used systematically enough to have a significant impact. 
At present, the country plans to re-introduce IRS as a complement to the ITN programme to 
prevent and control malaria epidemics in 25 epidemic prone districts [24]. 
 
Epidemic prevention and control - The Malaria Epidemic Early Detection System (MEEDS) is 
based on plotting weekly and monthly malaria cases into a monitoring chart designed with a 
threshold representing alert and action lines derived from retrospective data for each health 
facility. Through this system, epidemic prone districts are required to note and report any 
substantial increase in the number of malaria cases and deaths.  
 
Coverage achieved to date 
A nationally representative survey has been conducted to provide information on the status 
and progress of the MSTP in 2007-08 [25] and results can be compared with a similar survey 
conducted in 2004-05 [26]. Results show improvements, but targets set for 2007 have not 
been reached. More than half of the children reported to have fever were given an 
antimalarial drug to treat the fever but only 34% were treated on the same day or the next, 
which is far below the 60% target for 2007. Household ownership of nets (both treated and 
untreated) increased in the country after the implementation of the ITN programme from 46% 
in 2004-05 to 56% in 2007-08 but ownership of ITNs is much lower (23% in 2004-05 and  
39% in 2007-08). This resulted in 34-36% of children and pregnant women sleeping under a 
mosquito net and 26-27% under an ITN the night prior to the survey. This means that the 
60% target set for 2007 was not reached. In 2007-08 57% of women with a live birth in the 
two years prior to the survey reported taking IPTp but only 30% took the two recommended 
doses. The 60% target set for 2007 was therefore not reached for IPTp either.  
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Coverage with IRS and MEEDS has not been implemented on a national scale. Since 2007, 
IRS operations in Mainland Tanzania have been limited to two districts (Muleba and 
Karagwe) in Kagera Region, where repeated spraying has been carried out in more than 
10% of households. Plans are underway to scale up IRS coverage to about half the districts 
in Mainland Tanzania by the end of 2013. MEEDS mechanisms have been established in 19 
districts of the county (less than 15%) [27]. 
 
1.5. Strategies to improve access to malaria treatment 
 
Access to health services and interventions in developing countries is a much debated topic 
and has received an unprecedented level of funding in recent years. The impact of the 
Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement on access to 
essential drugs in developing countries has been debated from a legal and trade related 
point of view [28-29]. A number of Public-Private Partnerships (PPPs) have been set up to 
develop much needed new efficacious treatments and prevention tools. As far as malaria is 
concerned the Medicines for Malaria Venture (MMV) [30], created in 1999, currently 
manages the world's largest malaria research and development portfolio and has a number 
of ACTs in its pipeline. However, resource-limited governments often need support from 
donor organisations to be able to purchase the newly developed medicines. This is 
especially the case for the ACTs as this new generation of drugs can be up to 10-20 times as 
expensive as conventional antimalarial monotherapies such as SP and chloroquine. The 
GFATM is the leading donor mechanism which supports governments to purchase newly 
developed malaria medicines. Thanks to support from the GFATM by 2009 108 million 
malaria drug treatments were delivered in 140 countries [31]. 
 
However, the availability and affordability of effective drugs at country level does not 
necessarily imply that people get the care they need. This is evidenced by recent surveys 
conducted between 2007 and 2008 in 11 African countries which found that despite large 
increases in the number of antimalarial treatments supplied through the public health sector, 
only 15% of children with fever were treated with ACTs [32]. Clearly there are many other 
issues that affect access to treatment. Care not only involves drugs but also appropriate 
infrastructure, health care personnel, diagnostic capacity, effective drug procurement 
systems and functioning financing or exemption mechanisms (provider level factors). 
Willingness and ability to pay, access to alternative health care providers, proximity to points 
of health care, trust in the health care system and providers also play an important role in 
determining health care seeking (user level factors).  
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Several interventions have been proposed and tested to improve access to malaria treatment 
by targeting providers or users. Smith et al.[33] recently conducted a systematic review on 
this topic. Interventions aimed at providers included optimising case-management and 
services in health facilities or improving dispensing practices of drug shop attendants as well 
as training community health dispensers. Two general approaches to improving user malaria 
treatment practices have been pursued: health education campaigns and interventions that 
specifically provide information on how to take anti-malarials, including pre-packaging and 
pictorial and verbal instructions. 
 
The Integrated Management of Childhood Illnesses (IMCI) is a strategy designed to address 
major causes of child mortality in health facilities by targeting the behaviour of health facility 
providers. IMCI includes both preventive and curative interventions and it is designed to 
improve the case-management skills of health workers as well as to strengthen health 
system support for child health-service delivery. Studies that have tested the effectiveness of 
this strategy found higher levels of appropriate treatment of malaria in the facilities that had 
received the intervention compared with non-intervention facilities although the 
improvements were greater in Tanzania (88% versus 25%) [34] than in Uganda (49% versus 
24%) [35]. 
 
WHO’s strategy to improve access to malaria treatment has focused on the provision of 
antimalarial treatment through community health workers. This strategy, known as the Home 
Management of Malaria (HMM), [36] targets both users and providers. It comprises three 
fundamental pillars: 1) the selection and training of community members as community 
medicine distributors (CMDs) to correctly dispense anti-malarial medicines; 2) an information, 
education and communication campaign to sensitise caregivers to the importance of 
adhering to the correct treatment schedule; and 3) making effective antimalarial medicines 
available in every village, close to home, in unit-dosed and user-friendly blister packages. 
Although HMM clearly improves access to antimalarials, a review of the major studies carried 
out in Africa so far did not find substantial evidence that it has an impact on health outcomes 
[37]. However, proponents of HMM argue that the studies reviewed did not use pre-
packaged antimalarial drugs, which are a key element of the strategy. Studies to confirm the 
validity of HMM in the era of ACT are currently underway [38].  
 
A number of interventions have aimed at improving access to malaria treatment by improving 
the quality of care available in the private retail sector for drugs. The motivation for these 
initiatives comes from extensive research conducted in sub-Saharan Africa, which has 
shown that the private retail sector for drugs plays a very important role as a source of 
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antimalarial treatment [39-40]. Goodman et al. recently conducted a review of the 
interventions implemented to date [41]. A total of 16 interventions to improve malaria-related 
activities of medicine sellers in sub-Saharan Africa were identified (five in Nigeria, four in 
Kenya, two each in Uganda and Ghana and one each in Tanzania, Madagascar and 
Zambia). All involved a combination of training and job aids for providers as well as demand 
generation and consumer information components for users. Some also included pre-
packaged drugs. The two key findings from the review were 1) medicine sellers are 
interested and willing to participate and 2) targeting this sector can have a substantial impact 
on the quality of care delivered and overall treatment outcomes.  
 
On the basis of these positive experiences, a number of initiatives have been launched to 
distribute subsidised ACTs through the private sector. In 2005, MMV recognised the need for 
a concerted strategy to ensure the uptake of the products from its pipeline [42]. In 
collaboration with the Ugandan Ministry of Health, MMV Access piloted a study to assess if 
the provision of subsidised antimalarials through the private sector improves access, 
displaces ineffective products, and leads to health impact. In 2007 the Tanzanian Ministry of 
Health and Social Welfare and the Clinton Foundation [43] launched a pilot ACT subsidy 
project to assess the impact of a subsidy on the price and uptake of ACTs as well as the 
effect of a suggested retail price on those outcomes. Positive results from the Tanzanian and 
Ugandan experiences [44-45] have informed the creation of a global subsidy for the 
distribution of ACTs [46]. This subsidy, now known as the Affordable Medicines Facility for 
malaria (AMFm) is managed by the GFATM and aims to make ACTs available at the cost of 
the previous generation of antimalarials by negotiating with the manufacturers to supply very 
low-cost ACTs to first line buyers. It is expected that drugs will be available at about USD  
0.20-0.50 to patients [47]. Tanzania is among the 11 AMFm pilot countries and 
implementation is expected to start in 2010.  
 
Rapid Diagnostic Tests (RDT) for malaria have the potential to greatly improve the quality of 
management of malaria infections in areas when the main alternative form of diagnosis, high 
quality microscopy, is not readily available. It can therefore improve access by targeting 
drugs to only confirmed cases. The symptoms of malaria are very unspecific and current 
guidelines in many African countries recommend the presumptive treatment of fever with 
antimalarial drugs. However this strategy implies that the possibility that the fever is caused 
by another cause is overlooked and this leads to higher morbidity and mortality due to delay 
in giving appropriate treatment. Furthermore it leads to wastages of drugs and may foster 
parasite resistance [48]. Conversely, RDTs are easy-to-use and inexpensive and two meta-
analyses have shown high levels of sensitivity and specificity [49-50]. It has been argued that 
1. Introduction            13 
 
 
the introduction of the AMFm should be accompanied with the rollout of RDTs in drug shops 
to minimise unnecessary sales [51].  
 
1.6. The Access to Health Livelihood Framework  
 
An access to health care framework has been developed in the frame of the ACCESS 
programme as a conceptualisation of the various issues that affect access to malaria 
treatment. This framework places access to health in the broader context of livelihood 
insecurity and as such focuses on the community and health system barriers to accessing 
health care. Access is viewed as the interplay between the health care system on one side 
and individual/household’s needs and resources on the other. The degree of fit between the 
two can be examined along the five dimensions of availability, accessibility, affordability, 
adequacy, and acceptability (Table 1). However, high levels of access only result in better 
health if the services are utilised and if the technical quality of care is adequate (Figure 6). 
Each of the five dimensions of access and quality of care is discussed in the next section 
with practical examples and references to malaria case management in Tanzania and the 
study area.  
Figure 6. The ACCESS framework (source: Obrist et al. [52]) 
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Table 1. Five dimensions of access to health care services (adapted from Obrist et al. [52]) 
Dimension Definition Question 
Availability 
The existing health 
services and goods 
meet client’s needs 
What types of services exist? Which organizations offer these 
services? Is there enough skilled personnel? Do the offered 
products and services correspond with the needs of poor 
people? Do the supplies suffice to cover the demand? 
Accessibility 
The location of 
supply is in line with 
the location of clients 
What is the geographical distance between the services and the 
homes of the intended users? By what means of transport can 
they be reached? How much time does it take? 
Affordability 
The prices of 
services fit the 
clients’ income and 
ability to pay 
What are the direct costs of the services and the products 
delivered through the services? What are the indirect costs in 
terms of transportation, lost time and income, bribes, and other 
“unofficial” charges? 
Adequacy 
The organization of 
the health care meets 
the clients’ 
expectations  
How are the services organized? Does the organizational set up 
meet the patients’ expectations? Do the opening hours match 
with schedules of the clients, for instance the daily work 
schedule of small-scale farmers? Are the facilities clean and well 
kept? 
Acceptability 
The characteristics of 
providers match with 
those of the clients 
Does the information, explanation, and treatment provided take 
local illness concepts and social values into account? Do the 
patients feel welcome and cared for? Do the patients trust in the 
competence and personality of the health care providers? 
 
1.7. Access to malaria treatment in Tanzania  
 
Availability  
The health care system in Tanzania is relatively well developed compared with other sub-
Saharan African countries but treatment is not always available to people. The number of 
people per health facility/drug outlet is often used as a measure of availability of sources of 
care. In Tanzania, there is roughly one health centre for a population of 50,000 and a 
dispensary for a population of 10,000. However, the public sector is highly understaffed. The 
estimated ratios of currently active professionals per 100,000 population are 39 for nurses, 
2.5 for physicians and 25 for medical cadres (i.e. medical officers, assistant medical officers 
and clinical officers) [53].  
 
In addition, drug stock-outs are a recurrent problem in dispensaries and health centres. A 
study carried out in two districts in 2007 found that drug availability, defined as the presence 
of tracer items on the day of the survey, was on average 75% in hospitals and only 53% in 
public health facilities [54]. The Medical Stores Department (MSD) is responsible for the 
procurement, storage and supply of drugs to hospitals and health care facilities. MSD 
currently administers three different supply chains: 1) bulk distribution of essential drugs; 2) 
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distribution of kits and Indent packs and 3) and vertical programmes. The kit is a “push” 
system whereby each level of health facility receives a pre-determined quantity of medicines. 
In the indent “pull” system facilities decide on the quantity of products required and order 
them accordingly. Tanzania is in the process of converting the entire country to an Integrated 
Logistics Systems (ILS) which is an extension of the Indent system. Public health facilities 
experience regular stockouts in both kit and Indent systems but availability is much better 
with vertical programmes. Reasons for frequent stockouts include errors in quantification and 
forecasting by MSD (kit system) or by health facility staff (indent system) [55]. Stockouts also 
frequently cascade down from regional and central stores as MSD has to comply with long 
and complicated tendering procedures and does not always receive timely funds from the 
Ministry of Health and Social Welfare.(MOHSW). Generally stock-outs are more severe in 
dispensaries and health centres than in hospitals as the latter can more easily procure from 
the private drug market [54].   
 
Given the shortcomings of the health care system commercial retail outlets also play an 
important role in the provision of malaria treatment close to people. The private retail sector 
for drugs in Tanzania includes three types of licensed drug shops and general shops. 
Although pharmaceutical regulation does not reach its targets, the retail market for drugs in 
Tanzania is fairly well ordered, even in rural areas [56]. Pharmacies have to be run by a 
pharmacist and are allowed to sell all registered prescription only drugs which are referred to 
as Part I drugs. Drug shops (also know as duka la dawa baridi) may sell Part II drugs such as 
analgesics and need to be staffed with a medically trained vendor. In addition since 2008 a 
new class of registered outlets known as Accredited Drug Dispensing Outlets (ADDOs) (also 
known as duka la dawa muhimu) is being rolled out country-wide. ADDOs are allowed to sell 
all Over the Counter (OTC) drugs, antimalarials and a selection of antibiotics and are staffed 
by formally trained retailers [57]. According to Goodman et al. [58], general shops are legally 
not authorized to stock any drugs but are in practice tolerated to sell common OTC drugs 
such as painkillers. Mobile drug sellers are not common in most of Tanzania. There are 
around 350 Part I pharmacies in Tanzania, mostly in the urban areas, and over 8000 Part II 
drug shops [59]. 
 
Affordability  
In 1993 the Government of Tanzania introduced a policy of cost-recovery for health care as 
part of a Health Sector Reform (HSR). The rationale for the reform was to generate 
additional revenues to improve the availability and quality of health care services. One of the 
key components of the cost recovery scheme was the introduction of user fees for health 
care in public facilities. The reform also included schemes to protect the vulnerable and very 
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poor, such as exemptions (free public health care for children under five years, pregnant 
mothers and the elderly) and waivers (temporary entitlement to free care to those considered 
in need but unable to pay). Financing mechanisms such as the Community Health Fund 
(CHF), a district-level pre-payment scheme for primary care services, were also introduced to 
support the rural population and those working in the informal sector [60]. 
 
Findings from the study area show that the introduction of user fees has made health care 
less affordable because exemption, waiver and pre-payment mechanisms are not 
implemented properly. This is in line with various reviews which suggest that the introduction 
of user fees is more likely to reduce utilisation in the long term [61-63]. A study found that 
families visiting government facilities in a district (Kilombero) which had implemented a user-
fee system were found to pay up to 15 times more than families in a district without (Ulanga) 
[64]. The least poor paid 2.5 times more than the poorest in seeking care for their child. 
Given that there is no evidence of differences in morbidity, this suggests that poorer people 
are not getting the care that they need because they cannot afford it. Experience to date also 
shows that the CHF fails to support the most vulnerable in meeting the costs of health care 
because of its low level of enrolment (10% of  the  target population after more than 10 years 
of operation) and due to various management issues [65]. 
 
In addition to all the official charges directly related to care and treatment, patients need to 
meet many other costs. A study was carried out in Tanzania in 2001 in two districts where 
cost sharing had been introduced (Kilombero and Ulanga) and one where there were no 
official fees in dispensaries (Rufiji) [66]. Results showed that on average about three quarters 
of the costs of treatment for fever is for drugs, the remainder spent on transport, food and 
lodging and non-drug fees such as registration, consultation, laboratory tests and syringes. 
Payments were reported in some government facilities where cost sharing had not been 
introduced, indicating that patients may have been unaware that payments were unofficial.  
 
Accessibility 
Tanzania has a fairly extensive network of health facilities throughout the country, but they 
are not evenly spread. The proportion of people living within a 5 km range from a source of 
care or treatment is usually used as a measure of accessibility. In Tanzania, it has been 
estimated that 75% of the people live less than 5 km from a health unit providing both 
curative and preventive services (68% in rural areas, 98% in urban areas) [53]. However 
most health facilities are found in the larger population and market centres. Usually the least 
poor are clustered near large centres while the poorest are widely dispersed and face the 
longest journeys to sources of care. A study carried out in southern Tanzania found that 
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children living over 5 km from a health facility had lower vaccine coverage, fewer nets, more 
anaemia, poorer care-seeking and higher infant mortality than those living closer [67].  
 
The role of the private retail sector is crucial in terms of accessibility since shops can extend 
the coverage of treatment to very rural areas. A study carried out in the study area before the 
introduction of ACTs reported that over 85% of households live within a 5 km range of a 
commercial outlet selling antimalarials, although they often do not reach out into small 
villages or very remote areas [68]. The introduction of highly subsidised ACTs as a first line 
treatment for malaria in Tanzania in 2006 has sparked many debates on the best way to 
deploy these new and efficacious antimalarials in the retail sector. Confining ACTs to 
registered pharmacies, 76% of which are all concentrated in the major cities, would have 
substantially reduced accessibility. 
 
Ensuring accessibility to sources of health care to mobile or dispersed communities is 
especially challenging. There are thought to be approximately 1.2 million pastoralists in 
Tanzania who move to very distant pastures to find suitable land and therefore live a 
nomadic or semi-nomadic existence [69]. Moreover, in many parts of the country such as in 
the study area, people move to sometimes very distant temporary shelters in their fields 
during the cultivation period. Geographical distance translates therefore not only in transport 
cost but also loss of income. The extent to which these factors influence access to malaria 
care has not been fully explored.  
 
Acceptability  
According to an early study carried out in the study area [70] the community gives great 
weight to inter-personal skills and perceptions of technical skills are conditioned by the 
judgement of inter-personal skills. The most severe community criticisms concerned the 
rudeness and insensitivity of staff. The poor attitudes of health staff was directly linked to the 
poor state of the infrastructure, lack of emergency curative services and to the late opening 
hours and long waiting times. Patients were also concerned about the lack of diagnostic 
facilities. The process of curative care is expected to begin with diagnosis, although obtaining 
drugs is amongst the most important factors determining health care use.  
 
Adequacy 
A study carried out on people’s ability and willingness to pay for health care good provides a 
good example of how the organisation of the health care system is not adapted to client’s 
socio-economic situation. The study showed that meeting the costs of a traditional treatment 
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is usually less burdensome to the individual or the household for two reasons: family and kin-
members are under social pressure to contribute towards the payment of the type of 
diseases for which traditional treatment is sought; and many healers offer alternatives to 
cash payments, such as compensation in kind or in work, or payment on a credit basis. 
Malaria is a disease for which bio-medical treatment is considered the most effective and is 
usually treated in health facilities. Consequently people seeking malaria care usually do not 
benefit from wide community support and are faced with rigid payment modalities which are 
difficult to manage [71].  
 
Technical quality of care 
A number of problems with regards to the quality of care provided in the formal health sector 
have been reported in Tanzania. A report published in 2002 stated that between 56% and 
80% of patients dying of suspected malaria had attended formal health services during their 
final illness and only 50% of children under-five years of age with uncomplicated malaria and 
54% with severe malaria were correctly treated in the health facilities [18]. This was 
attributed partly to lack of diagnostic capacity, since laboratory services were inadequate and 
malaria parasitological confirmation was carried out in only 5-7% of total malaria reported 
cases. In addition, staff was often poorly trained and not adequately supervised. Only 11% of 
health workers had been trained in improved malaria case management in the previous two 
years. Council Health Management Teams had skills on supervisory activities but were 
lacking specific tools for malaria control issues and few of them had been trained on malaria 
case management. IMCI has now been integrated into all district health plans in Tanzania 
[64] but no nationwide assessment of its impact has been conducted to date. In addition 
since 2009 Tanzania is rolling out RDTs in the country’s health facilities.  
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2. Study description 
 
The ACCESS programme is a collaborative undertaking between the Ifakara Health Institute 
(IHI) in Tanzania and the Swiss Tropical and Public Health Institute (Swiss TPH), supported 
by the Novartis Foundation for Sustainable Development (NFSD). The aim of the programme 
is to improve access to prompt and effective malaria treatment with a set of integrated 
interventions targeting both users and providers. The programme was implemented in two 
phases and this thesis is concerned with the evaluation of its first phase (2004-2008). 
Section 2.1 outlines the aims and specific objectives of this thesis. The study area is 
described in section 2.2 with a focus on its physical and human geography since details on 
the health system have already been outlined in Section 1.7. Section 2.3 provides a detailed 
description of the interventions that are evaluated. This includes ACCESS interventions and 
the nation-wide change of treatment policy for malaria and the roll-out of the Accredited Drug 
Dispensing Outlets (ADDOs). Section 2.4. describes the data collection activities on which 
this evaluation is based.  
 
2.1. Aims and objectives 
The overall aim of this thesis is to provide an evidence base to assess effectiveness of the 
ACCESS interventions implemented between 2004 and 2008. This assessment is based on 
the input-output-outcome-impact framework [72]. For a programme to achieve its goals, 
inputs such as money or staff time must result in outputs showing that the programme is 
being implemented as planned. If these outputs reach the populations for which they were 
intended, the programme is likely to have positive short term effects or outcomes. These 
positive short-term outcomes should lead to a longer term impact on the health and wellbeing 
of the targeted populations. 
 
Based on this framework the specific objectives of the studies presented here is to  
1. Assess the output of the programme in terms of  
• accessibility 
• availability 
• affordability  
• use 
of malaria treatment from both the private retail sector and public health facilities 
(Chapter 3); 
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2. Assess the health outcome of the programme by estimating the proportion of fever 
cases in children under the age of five and in the whole population which were 
treated with an antimalarial/recommended antimalarial within 24 hours of onset of 
fever (Chapter 4); 
 
3. Asses the impact of the programme on the community and health facility burden of 
malaria by measuring changes in the  
• incidence of community reported fever and convulsions in children less 
than five years (two week recall) 
• under five mortality rates 
• health facility utilisation for fever 
(Chapters 5 and 6). 
 
2.2. Study area 
The programme's intervention area comprises the two districts of Kilombero and Ulanga in 
the south-east of Tanzania (Figure 7). The Kilombero River separates the two districts and 
forms the vast Kilombero Valley floodplain. Large parts of this valley are flooded during the 
rainy season which usually lasts from November to May. The valley is delimited by the 
Udzungwa Mountains in the north and the Mahenge Mountains in the south. In 2002, there 
were 517,000 people living in the 109 villages of the two districts. Ifakara, the administrative 
capital of Kilombero, is the major settlement in the valley with a population of approximately 
46,000. Ulanga's capital Mahenge is smaller with 7,300 inhabitants.  
 
Most people rely on subsistence farming for their livelihoods. Over 95% of the population 
reported farming as their main activity [73]. Rice is the main staple food and the most 
important cash crop in the area. Maize and cassava are also grown, but mainly for household 
consumption. Over 80% of total farmed land is used for growing paddy and farmers sell 
about 50% of what they grow [74]. Most of the rice paddies are lowland rainfed and 
production per hectare is fairly low compared to its potential [75]. This is explained partly by 
the low uptake of new high yield varieties, the reduced use of fertilisers and the reliance on 
manual labour for land preparation and weeding [74, 76]. As a consequence rice production 
and people’s livelihood in the area is extremely dependant on adequate rainfall.  
 
The climatic and ecological conditions in the floodplain are favourable for mosquito breeding. 
Malaria transmission in the area is intense and perennial with differences between the rural 
and semi-urban settings. Overall transmission has been declining over the past 10 years.  A 
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study conducted in the area between 2001 and 2003 reported an Entomological Inoculation 
Rate (EIR) of 349 infective bites per person per year (ib/p/y) [77], but according to recent 
data it has declined to 81 ib/p/y [78]. EIR data for Ifakara town suggest that the transmission 
rate is about a log order smaller than in the surrounding rural areas [79].  
 
Figure 7. The Kilombero and Ulanga DSS area 
 
 
2.3. Interventions 
The ACCESS programme’s interventions are conducted and studied at user and provider 
level:   
• at user level a social marketing approach aims at creating demand for appropriate 
malaria diagnosis and treatment in the community; 
• at provider level health facility and drug shop training, quality management, improved 
supportive supervision and new diagnostics aim to strengthen the supply of quality 
malaria case-management. 
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In addition to the activities implemented directly by the programme ACCESS also takes into 
consideration national interventions such as the 2006 changes of first line treatment from SP 
to ALu.   
 
The main areas of intervention that are evaluated in this thesis are described below and 
summarized in Figure 8.  
 
Figure 8. Timeline with ACCESS I interventions and monitoring and evaluation activities  
 
 
Intervention area 1: Behaviour change campaigns for prompt and appropriate health 
care seeking 
A social marketing approach was implemented to improve knowledge and awareness of 
malaria and to promote prompt and appropriate treatment seeking from reliable sources. The 
main target audience of the campaign were mothers and caretakers of children under five 
years of age and pregnant women. Messages stressed the importance of prompt recognition 
of malaria symptoms and immediate correct treatment with the recommended first-line drug, 
i.e SP until end 2006 and ALu from 2007 onwards. Health facilities and licensed drug stores 
(pharmacies, part II drug stores and Accredited Drug Dispensing Outlets i.e. ADDOs) were 
promoted as sources of proper treatment and advice. Prevention methods, such as the use 
of ITNs and IPTp were also advocated. Finally, one set of messages highlights high fever 
with convulsions (locally known as "degedege") as a sign of severe malaria that can and 
should be treated at health facilities (rather than by traditional healers) [80-81]. ACCESS 
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messages were in line with malaria-related messages on key family practices promoted by 
the community-based IMCI [82]. 
 
Communication channels and materials to disseminate behaviour change messages were 
developed to reach a poor rural audience. Road shows were the main vehicle for the 
campaign and included: 
1. Dancing competitions to attract a large audience; 
2. Comedies and role plays portraying appropriate treatment seeking and 
consequences of delaying treatment; 
3. Public lectures on malaria transmission, signs and symptoms, dangers of malaria for 
young children and pregnant women, prevention and correct treatment. A question-
and-answer sessions at the end of each part allowed interaction with the audience 
and distribution of promotion-materials (e.g. stickers, leaflets, T-shirts); 
4. Cinema shows featuring stories on prompt and effective malaria treatment. 
 
Other social marketing activities were developed to complement the road shows. Remote 
villages that were inaccessible with the truck were reached by a small 4WD vehicle branded 
with behaviour change slogans and airing radio spots. In addition permanent billboards were 
erected in major villages along the main road and posters affixed in public places. Special 
campaigns were implemented in Mother and Child Health clinics. They were targeted 
especially at pregnant women and mothers of young children who may not attend road 
shows if they overlap with household duties. During special sessions, ACCESS health 
promoters and MCH clinic staff informed mothers about malaria, its prevention and its proper 
treatment. The benefits of malaria prevention using ITNs and IPTp were particularly 
emphasised.  
 
Intervention area 2: Improved quality of malaria treatment in health facilities  
Health care services of good quality are a core element for the delivery of effective diagnosis 
and treatment for malaria. As a result of the social marketing activities, the demand for 
quality services is expected to increase. In order to meet this demand, health facility staff 
must be in the position and willing to deliver good quality of care. The ACCESS programme 
aimed to improve quality of care with a focus on the following areas:  
1. Correct diagnosis through the proper use of  the IMCI algorithm and/or with improved 
laboratory diagnosis; 
2. Rational prescription of antimalarials, antipyretics and other drugs; 
3. Appropriate advice on prescribed treatment and malaria prevention. 
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Key activities of this component include initial refresher training for health facility staff on 
malaria treatment, followed by the strengthening of routine supportive supervision and the 
implementation of a quality management scheme in all health facilities. Training was based 
on IMCI algorithms for diagnosis and treatment, which have been shown to be cost-effective 
in improving quality and efficiency of child health care in rural Tanzania [34]. A protocol for 
the refresher training was developed in close collaboration with the Council Health 
Management Teams (CHMT) of Kilombero and Ulanga. The training was targeted at clinical 
staff, lab technicians, and medical aids of public as well as private health facilities. It was 
carried out by the CHMT, appointed trainers and ACCESS staff with financial resources from 
the district and ACCESS. 
 
Intervention area 3: Improved malaria case management in drug selling shops 
Drug shops are often preferred to health facilities as a first treatment action [39-40]. 
However, despite the important service they offer drug shops are often poorly regulated. 
Common opportunistic practices include illegal stocking of prescription-only medicines, the 
use of unqualified staff and referral by health facility staff to private outlets in which they have 
a financial stake [56, 83-84].  This not only leads to bad treatment outcomes but can also 
foster the development of resistance to drugs. Experiences in Kenya [85] and Mali [86]) 
showed that training private drug retailers can considerably improve the services they offer. 
The programme’s original plan to train general shop keepers had to be withdrawn because 
Tanzanian drug regulations do not allow general shops to sell the first-line antimalarial drugs 
(SP; or ACT since end 2006). Instead the ACCESS programme supported the Accredited 
Drug Dispensing Outlets (ADDOs).  
 
The aim of the ADDO programme is to improve access to basic medicines by upgrading all 
Part II drug stores to well regulated and properly operated private medicine outlets manned 
by trained personnel [57]. ADDOs are the result of an innovative public-private partnership 
headed by the Ministry of Health and Social Welfare (MOHSW) through the Tanzanian Food 
and Drug Administration (TFDA) and with technical assistance from Management Sciences 
for Health (MSH). The ADDO programme involves a combination of dispenser training, 
incentives, accreditation and regulation with efforts to increase customer demand for quality 
products and services. ADDO operating standards include premise upgrades, minimum 
entry-level education and completion of a five week training curriculum. Incentives for owners 
to upgrade their existing premises and to open new outlets in underserved areas include 
business management training and link with a microfinancing bank [87]. The BMGF provided 
initial funding for the pilot projects in the Ruvuma region in 2002-2005 [88]. Motivated by the 
positive results from the pilot region, TFDA and the MOHSW rolled out the programme to 
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Rukwa and Mtwara Regions with funding from the government of Tanzania and to Morogoro 
region with financial support from USAID. Currently the MOHSW/TFDA plans are to convert 
most Part II drug stores into ADDOs by 2010 [89].  
 
ADDOs are allowed to dispense a limited range of prescription-only drugs. Ideally at least 
one ACT should be available through this channel, most logically the one recommended as 
first-line treatment in the country (ALu, brand name Coartem®). For the districts of Kilombero  
and Ulanga, ACCESS could successfully negotiate the introduction of highly subsidized ALu 
in ADDOs. Subsidised ALu was made available in ADDOs in mid 2007 at the recommended 
retail price of ALu of TSH 500 (approximately USD 0.40) for children doses and TSH 1500 
(approximately USD 1.30) for other patients. The ACCESS social marketing campaign 
promotes ADDOs as source of quality malaria treatment. 
 
The programme’s inputs – coverage achieved by 2008 
Between 2004 and 2008 the ACCESS and ADDO programmes achieved very high coverage. 
The ACCESS Social marketing road shows for improved treatment were conduced in 96% 
(78/81) of the villages in the Kilombero District and 95% (62/65) in the UIanga District. In 
2004 and 2005 93% (39/42) of clinical officers in the Kilombero District and 91% (94/97) of all 
health workers in the Ulanga District attended a refresher training on malaria case-
management organised jointly organised by ACCESS and the CHMT. Between 2006 and 
2008 135 ADDOs were opened the Kilombero district and 55 in the Ulanga district 
(equivalent to approximately three shops per 10 000 people in both districts). The switch 
from SP to ALu was successfully implemented in health facilities although actual introduction 
of ALu in health facilities was delayed until January 2007. Subsidised ALu was made 
available in ADDOs in the study area around July 2007.  
 
2.4. Monitoring and evaluation 
Monitoring and evaluation (M&E) activities provide the evidence base to ensure that 
programmes are fulfilling their objectives and to assess their effectiveness. Monitoring refers 
to the routine tracking of key elements of programme performance and epidemiological 
trends through record keeping, regular reporting and surveillance systems. Evaluation is the 
episodic assessment of the change in targeted results related to the programme’s 
intervention. In other words, evaluation attempts to link outputs, outcomes and impact 
directly to an intervention (Figure 7) [72].  
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As experimental designs are often impossible or inadequate to evaluate large-scale 
programmes, this study relied on plausibility assessments [90].  With this type of design 
improvements are attributed to the programme and all other explanations can be formally 
discarded if improvements are found in every step of the causal pathway between 
intervention and impact. In an attempt to control for possible confounders, all other malaria 
control activities in both districts as well as other relevant parameters such as temperature 
and rainfall were closely monitored. A basic assumption was that the malaria transmission 
and other relevant epidemiological parameters remain largely unchanged during the period 
of observation with the exception of the factors that were monitored in the frame of the 
programme. 
 
Figure 9. The Monitoring and Evaluation framework (source: GFTAM [72]) 
 
 
The M&E of the ACCESS programme was conducted in the area of the local Demographic 
Surveillance System (DSS) [73, 91]. The DSS served as a comprehensive epidemiological 
framework for the M&E activities. In the absence of a vital registration system, DSS field 
workers routinely record births, deaths and migrations for every household in a defined 
geographical area of 2400 km2 (Figure 7). Each household is visited every four months. The 
DSS area comprises 12 villages in Ulanga District and 13 in Kilombero District. The 
population in mid-2004 was around 74 000 people and increased at an average rate of 5% 
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per year, resulting in a population of just over 92 200 in mid-2008. There are six health 
facilities (three public dispensaries, one public health centre and two faith-based 
dispensaries) in the Kilombero DSS area and eight health facilities (five public dispensaries, 
one health centre and two faith-based dispensaries) in the Ulanga DSS area. The 
Designated District Hospital in Ifakara serves as a referral point for all the facilities in the 
study area. The DSS did not include Ifakara town at the time of the study but ACCESS 
monitoring and evaluation activities were also implemented there.  
 
The M&E activities of ACCESS comprised qualitative and quantitative surveys, but this 
evaluation is based on a set of qualitative surveys which assessed the outputs, outcomes 
and impact of the programme. All the data from this evaluation was collected between 2004 
and 2008. An overview of the timeline of the different M&E activities in relation to the 
programme’s interventions is given in Figure 8. They are described in detail below and 
summarised in Table 2. 
 
Table 2. Summary of ACCESS Monitoring and Evaluation (M&E) plan.  
 Aim Primary Indicators Surveys 
Output 
Assess a difference in 
level of access to 
malaria treatment from 
private retail sector and 
health facilities  
• Availability  
• Accessibility 
• Affordability 
• Use  
1. Monitoring of drug 
stock in health facilities 
2. Shop censuses 
3. Retail audits 
Outcome Assess changes in treatment seeking  
• Proportion fever cases in 
children under five and in 
all ages treated with an 
antimalarial within 24 
hours of onset of fever 
1. Treatment seeking 
surveys  
Impact 
Assess changes in the 
community and health 
facility burden of malaria  
• Community fever and 
convulsions rate 
• Under-five mortality rate 
• Health facility and fever 
and malaria rate 
1. DSS based surveys 
2. Routine monitoring of 
health facility utilisation 
 
 
Outputs  
Output data was collected to assess a difference in the level of access to malaria treatment 
from the private retail sector and health facilities before and after the implementation of the 
interventions studied by ACCESS. This includes the 2006 change of treatment policy and the 
roll-out of ADDOs in the Kilombero and Ulanga districts. Results are presented in Chapter 3. 
 
2. Study description           28 
 
 
Indicators - Output indicators were based on the access to health framework developed 
within the ACCESS programme by Obrist et al. [52] (cf. Section 1.5 for details). The routine 
monitoring in health facilities and the shop censuses, combined with DSS data, provided 
information on availability and accessibility of sources of antimalarial drugs. The retail audits 
provided data on prices (and therefore, indirectly, on affordability) and use of antimalarial 
drugs. Separate studies which are not part of this evaluation assessed the quality of care in 
the private retail sector by using mystery shoppers [92].  
 
Survey 1 : Routine monitoring of drug stock in health facilities - Every other month a team of 
trained field workers visited the ten public health facilities in the DSS area to collect end-of-
month drug stock data from the Health Management and Information System (HMIS) ledger 
books, using validated data collection tools. Data could not be collected from the faith based 
facilities as they are not legally required to record drug stock in ledger books, rendering 
systematic collection of the data difficult. In 2004 the GPS locations of all the health facilities 
in the area were recorded with a hand-held GPS unit.  
  
Survey 2:  Shop censuses  - Repeated cross sectional shop censuses were carried out every 
year in the Rural DSS area and in Ifakara town.  All shops potentially selling drugs (general 
stores, kiosks, Part II drug stores and ADDOs) were visited by a team of nine trained field 
workers who recorded the outlet’s stock and location.  
 
Survey 3: Retail audits - Two retail audits of antimalarial drugs were conducted in the rural 
DSS areas during the shop censuses of 2005 and 2008. The retail audit included all outlets 
selling or dispensing drugs, i.e. all health facilities (public and faith-based) and drug shops 
(Part II drug shops and ADDOs), as well as the few general shops found to stock antimalarial 
drugs during the shop census. The retail audits enabled to estimate the prices and total 
antimalarial sales volume in the study area. 
 
Outcomes 
Outcome data was collected at community level to assess changes in treatment seeking 
following increased access to treatment and the implementation of a social marketing 
campaign which sensitised the community on the importance of prompt and effective 
treatment for malaria. Results are presented in Chapter 4. 
 
Indicators - The primary outcome of interest was the proportion of fever cases in children 
under the age of five and in all ages treated with an antimalarial within 24 hours of onset of 
fever which is the indicator recommended by the Roll Back Malaria (RBM) partnership [93]. 
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Other indicators related to the links of the community effectiveness chain developed by 
Hetzel et al. [88] as well as sources and actions for the treatment of fever.  
 
Treatment seeking surveys - Three consecutive cross sectional surveys were conducted in 
the DSS areas and Ifakara Town in 2004, 2006 and 2008 to investigate treatment seeking for 
malaria and understanding of the disease. The interviewees included children and adults 
who had recently suffered a fever episode (caretakers responded to questions for children 
under the age of 12).  The tool for data collection was a locally adapted Explanatory Model 
Interview Catalogue (EMIC) [94] which provided qualitative and quantitative data on patients’ 
signs and symptoms associated with the fever episode (patterns of distress), as well as 
perceived causes and treatment seeking.  
 
Impact 
Health facility and community data was collected to assess changes in the community and 
health facility burden of malaria as a result of improved access to treatment and better 
treatment seeking for malaria. Results are presented in Chapters 5 and 6.   
 
Indicators – The community burden of malaria is based on the monitoring of under five 
mortality rates and morbidity rates, which includes community reported fever and convulsion 
rates. Under-five mortality is a good indicator of the burden of malaria since malaria mortality  
is overwhelmingly concentrated in young children in malaria endemic countries. Therefore 
under five mortality is sensitive to changes in malaria-associated risk and captures both the 
direct and indirect effects of malaria [95]. Whereas fever refers to the incidence of un-
complicated malaria, convulsions are a sign of progression towards cerebral malaria in 
children [96]. Both signs are not highly specific for malaria, but with other causes remaining 
stable, they provide useful markers of malaria morbidity. The health facility burden of malaria 
is based on health facility fever and malaria rates in children under the age of five. 
 
Survey 1: DSS morbidity and mortality monitoring – Under five mortality rates were obtained 
from the DSS database.  In addition ACCESS integrated the collection of community 
reported fever and convulsions cases (based on a two week recall) within the routine DSS 
data collection activities.  
 
Survey 2: Routine monitoring of health facility utlisation data – Health facility utilisation data 
were collected continuously by the ACCESS project field workers from the Health 
Management and Information System (HMIS) records of all the private and public health 
facilities in the DSS area. Standard forms allowed rapid transcription of data from the health 
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facility records. The data collected included all in-patient and out-patient diagnoses 
disaggregated by age group (children under the age of five and all other patients) on a 
monthly basis. The combination of this data with population data from the DSS enables the 
calculation of fever and malaria health facility rates (where a fever is defined as any case 
diagnosed as either malaria pneumonia, respiratory infections, measles, typhoid fever or 
urinary tract infection). 
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3.1. Abstract   
Background 
To improve access to treatment in the private retail sector a new class of outlets known as 
Accredited Drug Dispensing Outlets (ADDO) was created in Tanzania. Tanzania changed its 
first line treatment for malaria from Sulphadoxine-Pyrimethamine (SP) to Artemether-
Lumefantrine (ALu) in 2007. Subsidized ALu was made available in both health facilities and 
ADDOs. The effect of these interventions on access to malaria treatment was studied in rural 
Tanzania.  
Methods 
The study was carried out in the villages of Kilombero and Ulanga Demographic Surveillance 
System (DSS) and in Ifakara town. Data collection consisted of 1) yearly censuses of shops 
selling drugs; 2) collection of monthly data on availability of antimalarials in health facilities; 
and 3) retail audits to measure antimalarial sales volumes in all public, mission and private 
outlets. The data were complemented with DSS population data.  
Results 
Between 2004 and 2008 access to malaria treatment greatly improved and the number of 
antimalarial treatment doses dispensed increased by 78%. Particular improvements were 
observed in the availability (from 0.24 shops per 1000 people in 2004 to 0.39 in 2008) and 
accessibility (from 71% of households within 5km of a shop in 2004 to 87% in 2008) of drug 
shops. Despite no improvements in affordability this resulted in an increase of the market 
share from 49% of antimalarial sales 2005 to 59% in 2008. The change of treatment policy 
from SP to ALu led to severe stock-outs of SP in health facilities in the months leading up to 
the introduction of ALu (only 40% months in stock), but these were compensated by the wide 
availability of SP in shops. After the introduction of ALu stock levels of the drug were 
relatively high in public health facilities (over 80% months in stock), but the drug could only 
be found in 30% of drug shops and in no general shops. This resulted in a low overall 
utilisation of the drug (19% of all antimalarial sales). 
Conclusions 
The public health and private retail sector are important complementary sources of treatment 
in rural Tanzania. Ensuring the availability of ALu in the private retail sector is important for 
its successful uptake. 
3. Improvements in access – a provider perspective     33 
 
 
3.2. Background   
It is increasingly recognised that the Roll Back Malaria (RBM) Partnership target of “80% of 
malaria patients receiving effective treatment within 24 hours” cannot be achieved in sub-
Saharan Africa unless antimalarial drugs are made available outside the formal health sector 
[85, 97-98]. The public health sector plays a central role in the delivery of key curative and 
preventative interventions for malaria in most African countries. However, health facilities 
alone do not guarantee satisfactory levels of access in countries where malaria is endemic. 
Surveys conducted between 2007 and 2008 in 11 African countries found that despite large 
increases in the number of antimalarial treatments supplied through the public health sector, 
only 15% of children with fever were treated with Artemisinin Combination Therapies (ACTs) 
[32].  
 
As a result, it has been argued that the delivery of antimalarials needs to be supplemented 
by additional distribution mechanisms. This can be achieved through (1) community case 
management and (2) strengthening the role of the private retail sector.  The World Health 
Organisation (WHO) is increasingly promoting the provision of antimalarial drugs through 
community health workers with its Home Management of Malaria (HMM) strategy [38]. 
However, the WHO also recognises the importance of private retailers [99] and various 
interventions aiming at improving their services have been developed and piloted in different 
country settings [41].  
 
Reviews of the available literature reveal that shops are often preferred to health facilities as 
a first treatment action [39-40]. Retailers tend to be more accessible, have longer and more 
flexible opening hours, are willing to negotiate charges and offer credit, are more polite and 
friendlier and are generally perceived as being cheaper. Patients also seek treatment in the 
private sector out of necessity since public health facilities experience frequent stock-outs. 
However, the private retail sector is often poorly regulated in low and middle income 
countries. Common opportunistic practices include illegal stocking of prescription-only 
medicines, the use of unqualified staff and referral by health facility staff to private outlets in 
which they have a financial stake [56, 83-84]. The advent of ACTs compounds the problem 
further. In absence of regulation people are likely to buy cheaper and less effective drugs 
from the private retail sector. Furthermore the misuse of ACTs and the use of artemisinin 
monotherapies could contribute to the emergence and spread of artemisinin resistance. 
 
In the past five years two major interventions which directly affect access to malaria 
treatment have been implemented in Tanzania. Firstly, in 2002 the Tanzanian Food and 
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Drug Administration (TFDA) registered a new class of drug shops known as Accredited Drug 
Dispensing Outlets (ADDOs). With over 8000 outlets nation wide, drug shops are an 
important source of antimalarial treatment in Tanzania but unqualified staff invariably sells 
drugs they are not legally authorised to stock [57, 59, 100].  The aim of ADDOs is to address 
this poor state of regulation by upgrading existing drug shops (known as Part II) to properly 
operated outlets through a combination of dispenser training, financial incentives, 
accreditation and regulation [87]. Motivated by the experience of pilots conducted in the 
Ruvuma Region with support from the Bill and Melinda Gates Foundation (BMGF),  the 
Ministry of Health  and TFDA have planned the conversion of all Part II drug shops in the 
country by 2010 [89]. 
 
Secondly, in 2006 SP was abandoned in favour of Artemether-Lumefantrine (ALu, trade 
name Coartem®, Novartis AG) as first line treatment for malaria due to high levels of 
resistance to SP. The actual introduction of ALu in health facilities was delayed until January 
2007.  ALu is currently unaffordable for most of the population because of the high market 
price of USD  8-10 for an adult dose. Thanks to support from the Global Fund to Fight AIDS 
TB and Malaria (GFATM) the drug is provided free to all government health care facilities, 
where it should be made available free to children under the age of five and pregnant 
women; and at subsidised price of TSH 300 (USD  0.25) to other patients.  Subsidised ALu 
was also made available in ADDOs in mid 2007. Initial plans to upscale this scheme are 
likely to be superseded in 2010 by the Affordable Medicines Facility for malaria (AMFm). The 
AMFm aims to make ACTs available at the cost of the previous generation of antimalarials 
by negotiating with the manufacturers to reduce the price of their ACTs and subsidising them 
heavily for purchase by specified national importers. It is expected that drugs will be available 
at about USD 0.20-0.50 to patients. Tanzania and Zanzibar are among the 10 countries 
invited to pilot a first phase of this subsidy as from mid 2010 [47].  
 
This study presents a unique set of longitudinal data on availability, accessibility, costs and 
uptake of antimalarial treatment in both the private retail and public health sectors. The data 
were collected between 2004 and 2008 in two districts of the Morogoro Region in the frame 
of the ACCESS programme, which aims at improving and understanding access to malaria 
treatment [101]. The results presented here are complemented by treatment seeking surveys 
which evaluated changes in treatment outcomes (i.e. the user perspective) [102] (cf. Chapter 
4).This experience is of great relevance to other settings, as ACTs are being adopted 
throughout most of Africa as first line treatment for malaria and ACT subsidies will be 
introduced widely in the private sector through the AMFm.  
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3.3. Methods 
 
Study setting 
The study was carried out between 2004 and 2008 in the rural villages of the Kilombero and 
Ulanga Demographic and Surveillance System (Ifakara Rural DSS) and in the semi-urban 
setting of Ifakara town in south-central Tanzania (Figure 10). The Ifakara Rural DSS area 
covers 25 villages (13 in the Kilombero District and 12 in Ulanga District). The population in 
mid-2004 was 73,977 and increased at an average rate of 5% per year, resulting in a 
population of just over 92 203 in mid-2008. The population of Ifakara Town was 45,518 in 
2002 according to the last national census [103].  
 
Figure 10. Map of Kilombero and Ulanga Districts showing Ifakara Town and the Demographic 
Surveillance System (DSS). 
 
 
 
 
Malaria transmission in the area is intense and perennial with differences between the rural 
and semi-urban settings. Overall transmission has been declining over the past 10 years.  A 
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study conducted in the area between 2001 and 2003 reported an Entomological Inoculation 
Rate (EIR) of 349 infective bites per person per year (ib/p/y) [77], but according to recent 
data it has declined to 81 ib/p/y [78]. EIR data for Ifakara town suggest that the transmission 
rate is about a log order smaller than in the surrounding rural areas [79]. Treatment seeking 
surveys carried out in 2004, 2006 and 2008 within the frame of the ACCESS programme 
found on average twice as many fever cases in the rural areas compared to Ifakara Town 
(Alba et al., unpublished data).  
 
There are six health facilities (three public dispensaries, one public health centre and two 
faith-based dispensaries) in the Kilombero DSS area and eight health facilities (five public 
dispensaries, one health centre and two faith-based dispensaries) in the Ulanga DSS area. 
The Designated District Hospital in Ifakara serves as a referral point for all the facilities in the 
study area. There is only one Part I pharmacy in the study area, which is located in Ifakara 
town. The area has been described in more detail elsewhere [73, 101]. 
 
Data collection activities are summarised in Table 3 and described in detail below. The 
routine monitoring in health facilities and the shop censuses, combined with DSS data, 
provided information on availability and accessibility of sources of antimalarial drugs. The 
retail audits provided data on prices and uptake of antimalarial drugs.  
 
Table 3. Summary of data collection activities 
Activity Collection period 
(month.year or year) 
Sample Location 
Routine monitoring in health facilities 
   
• Collection of monthly data on 
availability of antimalarial drugs in all 
public health facilities from ledger 
books 
• GPS location of each health facility 
1.2005 – 12.2008 10 Rural 
villages 
(DSS) 
Shop census 
   
5.2004 – 7.2004 758 
3.2005 – 7.2005 790 
4.2006 – 7.2006 878 
4.2007 – 8.2007 1074 
Census of all shops potentially selling drugs 
providing quantitative data on 
• Availability of shops selling 
antimalarial drugs 
• Availability of antimalarial drugs  
• GPS location of each shop 
4.2008 – 9.2008 1082 
Rural 
villages 
(DSS) and 
Ifakara 
Town 
Retail audits 
   
4.2005 – 7.2005 78 • Measurement of antimalarial sales 
during a two-week period in all outlets 
(shops and health facilities) 
• Retail prices of each antimalarial drug 
4.2008 – 7.2008 66 
Rural 
villages 
(DSS) 
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Routine monitoring in health facilities  
Every other month a team of  trained field workers visited the ten public health facilities in the 
DSS area (four in Kilombero and six in Ulanga) to collect end-of-month antimalarial drug 
stock data from the Health Management and Information System (HMIS) ledger books, using 
validated data collection tools. Data could not be collected from the faith based facilities as 
they are not legally required to record drug stock in ledger books, rendering systematic 
collection of the data difficult. In 2004 the GPS locations of all the health facilities in the area 
were recorded with a hand-held GPS unit (Garmin® e-Trex, Garmin® Ltd). 
The percentage of facility-months in stock of a given antimalarial over the year was 
calculated as an indicator of drug availability. First an average estimate of yearly drug 
availability was calculated for each drug and each health facility. Unfortunately, the data on 
drug availability were missing in the ledger books for many months. Anecdotal evidence 
suggests that facility staff tended not to fill in the entry on end-of-month stocks when the drug 
was not available. As a result, and in the absence of any other information, months with 
missing data were considered as “out of stock”. If a health facility had more than 25% 
missing values it was excluded from the average to avoid skewing estimates of yearly drug 
availability towards unrealistically low values. Then an average estimate of antimalarial 
availability for the area was calculated by averaging the yearly estimates from all the health 
facilities. The estimate was deemed inconclusive if more than 25% facilities had to be 
excluded from the average estimate.  
 
The health facility data were complemented with population numbers and household 
locations to provide standardised indicators of availability and accessibility of health facilities.  
Population counts down to village level were available for every year between 2004 and 
2008 from the DSS database. GPS positions were available from the DSS database for 85% 
(16141/18840) of households in 2004 and 90% (18580/20579) of households in 2008. An 
indicator of availability of health facilities was constructed as the number of shops per 1000 
population, and an indicator of accessibility as the average distance between households 
and the nearest health facility. 
Shop census 
Repeated cross sectional shop censuses were carried out every year in the Rural DSS area 
and in Ifakara town. All shops potentially selling drugs (general stores, kiosks, Part II drug 
stores and ADDOs) were visited by a team of nine trained field workers who recorded the 
outlet’s stock and location using tools and methodology developed and previously applied in 
the area  [98][68]. The only Part I pharmacy was not visited. The primary aim of the census 
was to assess the type and brand of drugs available in each type of outlet. The analysis of 
the baseline study in 2004 was published by Hetzel et al [68] and the results presented here 
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provide a longitudinal assessment of the changes between 2004 and 2008. The secondary 
aim of the census was to assess shopkeepers’ knowledge about signs, symptoms and 
treatment of malaria. Results will be presented elsewhere (Dillip et al., in preparation). 
 
Data were collected using a structured questionnaire and the location of each shop was 
recorded with a hand-held GPS unit. The field work was overseen by the same supervisor in 
all years. The supervisor visited all the village and hamlet leaders prior to the censuses to 
inform them and to answer any queries. Every year, field interviewers were provided with an 
inventory of all the outlets identified in the previous year’s census and were instructed to visit 
every outlet on the list, as well as any new outlet they encountered. Random quality checks 
were performed by a research scientist who visited the field sites shortly after the field 
workers.  
 
Estimates of availability and accessibility of shops stocking drugs were constructed using the 
methodology outlined for health facilities. Population counts were estimated for Ifakara Town 
by adjusting the 2002 census count with the annual growth rate in the DSS area.   
 
Retail audits 
Two retail audits of antimalarial drugs were conducted in the rural DSS areas during the shop 
censuses of 2005 and 2008. The methodology developed by Goodman et al. [104, 105] was 
applied. The retail audit included all outlets selling or dispensing drugs, i.e. all health facilities 
(public and faith-based) and drug shops (Part II drug shops and ADDOs), as well as the few 
general shops found to stock antimalarial drugs during the shop census. The aim of the study 
was to estimate total antimalarial sales volume in the study area and to compare the share of 
sales of each antimalarial drug across each type of outlet. 
 
The retail audit data were collected over two consecutive visits two weeks apart. On the first 
visit, which coincided with the shop census visit, field interviewers recorded stock levels for 
each antimalarial drug. On the second visit they recorded stock levels and any deliveries 
since their last visit, as well as any drugs that had been given out for any other reason e.g. 
thrown away or returned to wholesalers. Two weeks was considered a reasonable recall 
period for wholesale deliveries. The exact number of tablets, bottles or vials was counted 
where possible. When tablets were kept in tins the following information was collected in 
order to estimate the number of tablets present: the height of the tablets in the tin when full, 
the height of tablets on the day of visit and the number of tablets in a full tin. In addition the 
reported retail price per single unit (be it a tablet, bottle or vial) was recorded. The retail audit 
was carried out once a year (in approximately the same months) as no significant seasonal 
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differences were found in the previous study in which two surveys per year were conducted 
[105]. 
 
Daily sales were calculated or estimated for each antimalarial. Sales between the two visits 
were calculated as: Sales = (total at first visit) + (deliveries between first and second visit) - 
(stocks thrown away or transferred to other shops/facilities) - (total at second visit).  The 
number of tablets, bottles of syrup and vials was converted into the equivalent number of 
adult doses in order to calculate the total antimalarial sales of different types of antimalarials. 
Daily sales were calculated by scaling down up or down pro rata according to the number of 
days between the two audit visits.  If total sales volumes could not be calculated (because 
drug levels were not recorded on the first or the second visit), they were estimated by a 
multiple imputation. With this statistical technique missing values are imputed several times 
based on random draws from the conditional distribution of the missing observations given 
the observed data and covariates (drug levels on the first or second visit, type of outlet, type 
of drug and drug formulation). In this case three draws were considered enough and the 
average between the three imputations kept for analysis. Multiple imputation was deemed 
appropriate as there were no indications that the data were not missing at random.  
 
Reported drug prices were adjusted for inflation to reflect actual changes in purchasing 
power. The 2005 drug prices were inflated to real 2008 values on the basis of consumer 
price indices [106]. An inflation factor of 1.25 was derived from the mean yearly inflation 
values published by the Tanzania National Bureau of Statistics (NBS) [107]. 
 
Data entry and analysis 
Data were double entered using Microsoft  FoxPro and Microsoft  Access (Microsoft  Corp. 
Seattle, USA)  and checked for coding errors and consistency.  Intercooled Stata 10 (Stata 
Corp., College Station, TX, USA) was used for data management and analysis. Logistic and 
Poisson regressions provided Odds Ratios (OR) and Incidence Rate Ratios (IRR) to estimate 
changes over time or differences between areas. ORs and IRRs indicate an average 
increase per year between the years of observation (“year” is entered in the regression as a 
linear variable) unless it is explicitly stated that the increase is not linear and is from a given 
year to another (“year” is entered as a categorical variable). Differences in medians between 
years were tested using a two-sample Wilcoxon rank-sum (Mann-Whitney) test. Distances 
were calculated with ArcMap Version 9.1 (ESRI Inc.). 
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Ethics 
The National Institute for Medical Research of the United Republic of Tanzania 
(NIMR/HQ/R.8a/Vol.IX/236, 16th September 2003) granted ethical clearance for the study 
Shop keepers and health facility staff gave informed consent to participating in the study and 
were given feedback of the study results.  
 
3.4. Results   
Availability and accessibility of antimalarials in public health facilities 
Drug availability data were collected for ten facilities over four years for four drugs (two years 
for ALu) i.e. 1680 facility-months but only 1380 facility-months of observation could be 
included in the analysis. As a result out of the 14 yearly overall availability estimates were 
deemed inconclusive (Figure 11).  
 
Figure 11. Availability of antimalarial drugs in public health facilities in the rural DSS area 
(Note: ALu was introduced in January 2007).  
 
 
Towards the end of 2006, just before the introduction of to ALu, health facilities experienced 
severe stock-outs of SP. On average throughout the year the drug was only available 40% 
(38/96) of the months with three facilities reporting stockouts for more than 10 months. This 
was mainly due a delay in the introduction of ALu without additional SP orders to 
compensate. The availability of quinine and amodiaquine was much higher as the drugs 
were reported to be available 66% (78/120) and 58% (70/120) of the time, respectively. 
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However, four facilities were out of stock of all three antimalarials for 2.8 (sd=1) months of 
the year. Since the introduction of ALu availability of antimalarial drugs has greatly improved. 
In 2007 and 2008 ALu was available for more than 80% of the months of the year (90/108 in 
2007 and 88/108 in 2008).  
 
The availability and accessibility of health facilities was only slightly affected by population 
growth. The availability of public health facilities decreased slightly but not significantly. In 
2004 there were 0.13 facilities per 1000 people (10/73977) and in 2008 this figure declined to 
0.11 (10/92203) (IRR=0.81 p=0.712 from 2004 to 2008). The median distance from a 
household to a facility marginally increased from 2.25 km (IQR=4.31) to 2.37 km (IQR=4.75) 
(z=-5.388 p<0.001) and the proportion of households located within 5km of a health facility 
decreased from 73% (11858/16141) to 70% (12990/18580) in 2008 (OR=0.90 p<0.001 from 
2004 to 2008).  
Availability and accessibility of malaria treatment in drug shops 
The number of shops included in the census increased on a yearly basis (Table 4). Every 
year general shops (permanent structures and kiosks) consistently accounted for 95% of all 
shops potentially selling drugs, while the rest were Part II drug shops and ADDOs. The 
number of Part II drug shops decreased considerably after 2006 as they were progressively 
upgraded to ADDOs. Overall the number of drug shops (Part II drugs stores and ADDOs) 
increased from 34 to 59 between 2004 and 2008.  
 
Table 4. Number of shops censused, by type  
  
2004 2005 2006 2007 2008 
Kilombero DSS  343 293 313 385 442 
Ulanga DSS 201 199 180 213 201 
Ifakara Town 185 256 341 421 380 
General shops 
(including kiosks) 
Total  729 748 834 1019 1023 
Kilombero DSS  16 22 17 8 6 
Ulanga DSS 3 9 4 2 3 
Ifakara Town 10 11 17 1 1 
Part II drug stores 
Total  29 42 40 11 10 
Kilombero DSS  0 0 0 18 22 
Ulanga DSS 0 0 4 8 7 
Ifakara Town 0 0 0 17 20 
ADDOs 
Total 0 0 4 43 49 
Kilombero DSS  359 315 330 412 470 
Ulanga DSS 204 208 190 223 211 
Ifakara Town 195 267 358 439 400 
Total 
 
Total  758 790 878 1074 1083 
 
Across all years a high proportion of general shops stocked some type of drug and a high 
proportion of drug shops stocked antimalarials, but a varying and much smaller proportion of 
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general shops stocked antimalarials (Figure 12). Between 2004 and 2008 an average of 68% 
of general shops stocked drugs (mainly antipyretics), with no significant differences between 
districts or between the rural areas and Ifakara Town. However, few of these were found to 
sell antimalarial drugs. The proportion of general shops selling antimalarials never exceeded 
a peak of 9% (18/199 in Ulanga and 23/293 in Kilombero) in 2005 in the DSS villages and 
3% in Ifakara in 2004 (5/185) and decreased considerably thereafter to 3% (5/501 in Ulanga 
and 10/442 in Kilombero) in the DSS and to 0% (0/380) in Ifakara in 2008 (DSS IRR=0.87 
p=0.018, Ifakara IRR=0.64 p=0.013 between 2004 and 2008). The proportion of drug shops 
(Part II and ADDOs) storing antimalarial drugs was 86% (31/36) in 2004, 100% (42/42) in 
2005, 84% (37/44) in 2006 and over 98% in 2007 (54/55) and 2008 (58/59) (Figure 14). 
 
Table 5. Number of drugs shops per population1 
Village Drug shops Population Shops per 1000 people 
 2004 2008 2004 2008 2004 2008 Change 
Ulanga DSS 
            
Idunda 0  0  1837  1896  0  0   
Igota 0  0  1533  1506  0  0   
Igumbiro 0  0  2311  2220  0  0   
Iragua 1  0  3704  4676  0.26  0  - 
Kichangani 0  2  3103  3236  0  0.62  + 
Kidugalo 0  2  2539  4389  0  0.46  + 
Kivukoni 0  1  5612  5581  0  0.18  + 
Lupiro 1  2  4009  4085  0.25  0.48  + 
Mavimba 0  1  2417  2896  0  0.34  + 
Milola 1  1  1282  1783  0.77  0.56  - 
Minepa 0  1  1964  2908  0  0.34  + 
Nakafulu 0  0  919  891  0  0   
Subtotal 3  10  31230  36067  0.10  0.27  + 
Kilombero DSS 
               
Idete 1  3  4661  4884  0.21  0.64  + 
Igima 4  2  3793  5278  1.05  0.37  - 
Ikule 3  3  2244  3587  1.34  0.86  - 
Kisegese 0  1  1370  1928  0  0.52  + 
Lukolongo 0  2  3821  4329  0  0.46  + 
Mbingu 1  3  5380  7141  0.18  0.42  + 
Mchombe 3  3  4452  4758  0.67  0.63  - 
Miwangani 0  1  1702  2173  0  0.46  + 
Mkangawalo 1  2  4675  6215  0.21  0.32  + 
Mngeta 2  2  3399  3767  0.58  0.53  - 
Mpofu 0  0  1897  2331  0  0   
Namawala 1  5  3675  7750  0.27  0.65  + 
Njagi 0  1  1678  1995  0  0.50  + 
Subtotal  16  28  42747  56136   0.37   0.50  + 
Ifakara  10  21  48343  59057  0.21  0.36   
 
There is evidence of greater availability of drug shops, even accounting for population 
growth. While the absolute number of antimalarial retail points (drug shops and general 
                                               
1
 This table was not included in the published version of this manuscript 
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shops) increased over the study period from 58 in 2004 to 74 in 2008, the number of shops 
per 1000 people did not change significantly over the years and fluctuated around 0.73 
shops per 1000 people in rural DSS areas and 0.34 in Ifakara Town (Figure 13). In contrast, 
the availability of drug shops alone did increase over the years, although not linearly, from 
0.23 (29/123260) shops per 1000 people in 2004 to 0.39 (59/151260) in 2008 (IRR=1.72 
from 2004 to 2008 p=0.019). Average rates mask differences at district and village level. The 
Kilombero District generally had higher availability of both general shops selling drugs 
(IRR=0.71 p=0.005) and drug shops (IRR=0.53, p=0.001) compared to the Ulanga District. 
Moreover, half of the 14 villages which did not have drug shops in 2004 still did not have any 
in 2008 (Table 5). Three of these did not have any health facilities either, and this accounts  
for 6% (5442/92203) of the total rural DSS population. 
 
Figure 12. Proportion of general stores selling any drugs and antimalarials (Note: vertical axis 
differs between two graphs) 
 
 
Amodiaquine and SP were the most commonly available antimalarials in both general shops 
and drug shops (Figure 14). In drug shops the antimalarial most commonly available was SP 
(90% of shops i.e. 210/234 over the study period), closely followed by amodiaquine (86% i.e. 
200/234) and quinine (80% i.e. 187/234). ALu was available in 2% (1/43) of the drugs stores 
in 2006 (unsubsidised), 7% (4/54) in 2007 and 29% (17/58) in 2008. Interestingly, 
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chloroquine could still be found in 2004 and in 2005 in one drug shop in a remote village of 
the Kilombero DSS area. Figure 14 gives a break down by year of these figures.  
While artemisinin monotherapies were mainly found in the drug shops of Ifakara, ALu was 
also available in the more rural areas. The proportion of shops storing artemisinin 
monotherapies grew until 2007, when up to 11 out of 55 (20%) shops stored drugs 
containing either artesunate, artemether or dihydroartemisinin (Figure 14). In 2008 this 
proportion decreased to 12% (7/59), probably as a result of tighter national and international 
regulations on the distribution of artemisinin monotherapies. However, it is worth noting that 
these artemisinin derivatives could be found in Ifakara but hardly reached the more rural 
villages, most likely because of their very high prices. ALu tended to be more available in 
Ifakara than in rural areas (Ifakara 8/13 i.e. 38.1% of drug shops stored ALu, Kilombero DSS 
7/27 i.e. 25.9%, Ulanga DSS 2/10 i.e. 20%).  
 
Figure 13. Availability of retail outlets selling drugs, per 1000 population  
 
 
Drug shops became more accessible after the introduction of ADDOs. Across all years drugs 
shops were more likely to be found in the most populous areas, but different patterns were 
noted for ADDOs and drug shops. Both in 2004 and in 2008 a significant association was 
found between the presence of any drug shop in a village and the size of the village (2004 
OR=2.6 for every 1000 increase in population p=0.016, 2008 OR=2.6 p=0.048). However, in 
2008 the association between the presence of an ADDO in a village and the size of the 
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village was much smaller (OR=1.7 p=0.077) suggesting that ADDOs were also opened 
purposefully in less populous areas. This resulted in an increase in the number of 
households located within 5 km from a drug shop from 71 % (3848/16141) to 87% 
(11662/18580) (OR= 5.38 p<0.0001 from 2004 to 2008) (Figure 15). The median distance 
from a drug shop to a household nearly halved during the study period, decreasing from 
2.2km (IQR=4.8) to 1.2km (2.6) (z=32.234 p<0.0001).  
 
Figure 14. Availability of different antimalarial drugs in private retail outlets (Note: vertical axis 
differs between two graphs) 
 
Figure 15. Cumulative percentage of households within a given distance to the nearest drug 
shop.  
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Sales of antimalarial drugs in shops and health facilities 
In 2005 a total of 366 antimalarial products were followed from 77 retail outlets (31 drug 
stores, 37 general stores, five kiosks and 14 health facilities). In 2008 a total of 409 products 
were followed from 66 outlets (10 drug stores, 12 general stores, three kiosks, 27 ADDOs 
and 14 health facilities). Sales levels could not be calculated and were estimated for 6% 
(44/775) items because drug levels were not recorded either in the first or in the second visit 
(see methods).  
 
The analysis of daily sales revealed a near doubling in the number of antimalarials doses 
dispensed between 2005 and 2008 and the increasing importance of drug shops as a source 
of antimalarials. An estimated 315 equivalent adult antimalarial doses were dispensed per 
day from all facilities and shops in the DSS areas in 2005 while 560 doses were dispensed in 
2008 (78% increase). The proportion of antimalarial drugs sold in drug shops increased from 
49% (153.5/315.3) in 2005 to 59% (330.2/560.3) in 2008 (OR=1.51 p=0.036) (Table 6 and 
 Figure 16). The increase in the use of drug shops was not at the expense of public health 
facilities, but at the expense of general shops and faith based facilities. Indeed, the 
proportion of doses sold in general shops and faith based health facilities decreased but 
there was no significant difference in terms of antimalarials dispensed in health facilities 
(79.4/315.3 i.e. 25% in 2005 vs. 169.9/560.3 i.e. 30% in 2008 OR=1.29 p=0.115). 
 
Table 6. Number of equivalent adult doses sold per day in all shops and health facilities (HF) in 
the DSS rural areas and share out of total in the type of outlet 
 
2005 2008 
 
Public 
HF 
Faith 
Based 
HF 
Drugs 
shops 
General 
shops Total 
Public 
HF 
Faith 
Based 
HF 
Drugs 
shops 
General 
shops Total 
Amodiaquine 22.4 
(28.2%) 
21.0 
(42.4%) 
43.4 
(28.3%) 
10.8 
(32.8%) 
97.6 
(30.9%) 
64.7 
(38.1%) 
9.6 
(29.2%) 
62.1 
(18.8%) 
4.3 
(21.2%) 
140.7 
(25.1%) 
Chloroquine   0.9 
(0.6%) 
 0.9 
(0.3%) 
    - 
SP 54.9 
(69.2%) 
26.8 
(54.2%) 
97.9 
(63.8%) 
21.9 
(66.6%) 
201.5 
(63.9%) 
26.6 
(15.7%) 
7.9 
(24.0%) 
233.6 
(70.7%) 
15 
(78.8%) 
284.1 
(50.7%) 
Quinine 2.1 
(2.6%) 
1.7 
(3.4%) 
11.3 
(7.3%) 
0.2 
(0.6%) 
15.3 
(4.9%) 
7.5 
(4.4%) 
7.5 
(22.8%) 
16.1 
(4.9%) 
<0.1 
(<0.1%) 
31.1 
(5.1%) 
Alu 
- - - 
- - 71.1 
(41.8%) 
14.8 
(50%) 
18.1 
(5.5%) 
 104.0 
(18.6%) 
Artemisinin 
monotherapy - - - 
- - 0.1 
(<0.1%) 
 0.3 
(<0.1%) 
 0.3 
(<0.1%) 
Total  79.4 49.5 153.5 32.9 315.3 169.9 32.9 330.2 20.3 560.3 
 
 
The sales of SP remained very high in 2008 despite the change of treatment policy to ALu. In 
2005 64% of all antimalarial sales consisted of SP and in 2008 it still accounted for 51% of all 
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antimalarial sales. ALu only accounted for 19% of total sales in 2008, 68% (71.1/104.0) of 
which were in public health facilities, 14% (14.8/104.0) from faith based health facilities and 
17% (18.1/104.0) from drug shops.   
 
Figure 16. Share of total antimalarial sales through each outlet type 
 
 
Prices were generally higher in drug shops where they also increased considerably over 
time. Prices of antimalarials were compared between 2005 and 2008 in drug shops and 
public health facilities only (Table 7) although six out of 10 health facilities did not provide any 
pricing information. In 2005 health facilities reported selling SP adult doses at an average of 
USD 0.25 (USD 0.32 in 2008 prices) whereas it was sold for USD 0.37 (USD 0.45 in 2008 
prices) on average in drug shops. In 2008 two of the facilities which provided prices reported 
dispensing ALu packs for children under the age of eight free, whereas two reported selling 
them for USD 0.25.  Adult ALu and SP doses were reported to be sold for USD 0.25 in health 
facilities. Both SP and ALu were much more expensive in shops where sellers reported 
selling an ALu dose for USD 1.27 and SP doses for USD 0.67.  Adjusting for inflation these 
price differences translate into a 20% decrease in the price of the first line treatment in public 
health facilities. In drug shops prices increased by 51% when comparing the price of SP in 
2005 and in 2008 and by 84% when comparing the price of SP in 2005 and the price of ALu 
in 2008. 
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Table 7. Reported retail price in US Dollars (TSH) in drug shops and public Health Facilities 
(HF) of a single adult antimalarial dose - unless otherwise specified (USD 1= TSH 1180 in 2008 
and USD  1= TSH 1130 in 2005)  
 2005 2008  
 
Drugs shops Public HF Drug Shops Public HF 
 
N Median  
(IQR) 
N Median  
(IQR) 
N Median  
(IQR) 
N Median  
(IQR) 
Amodiaquine         
 Tablets 35 0.35 
(0.35 to 0.94) 
4 0.35 
(0.32 to 0.44) 
31 0.42 
(0.42 to 0.67) 
 - 
 syrup 1 36 0.72  
(0.62 to 0.83) 
1 0.25  
(0.25 to 0.25) 
38 0.99  
(0.78 to 0.99) 
 - 
Chloroquine 
tablets 
1 0.26  
(0.26 to 0.26) 
 -  -  - 
SP 10
0 
0.37  
(0.26 to 0.79) 
5 0.26  
(0.26 to 0.26) 
103 0.67  
(0.25 to 1.27) 
4 0.25 
(0.13 to 0.25) 
Quinine         
 Tablets 26 1.85 (1.85 to 1.85) 3 
1.85  
(1.85 to 1.85) 
28 3.56  
(3.56 to 3.56) 
3 2.85 
(1.78 to 3.56) 
 syrup 1 15 3.35 (2.79 to 4.18)  - 
38 5.34  
(5.34 to 5.34) 
  
 Injection 2 18 9.29 (7.43 to 9.29) 5 
7.43 
(5.58 to 9.28) 
30 8.90 (8.90 to 
0.68) 
2 8.89 (8.89 to 
8.89) 
Artemether-Lumefantrine       
 3 m – 3 y 
 -  - 
8 0.42  
(0.42 to 1.06) 
4 0.05  
(0 to 0.18) 
 3 – 8 y 
 -  - 
9 0.42  
(0.42 to 0.84) 
3 0.25  
(0 to 0.25) 
 8 – 12 y 
 -  - 
8 1.27  
(1.14 to 6.99) 
4 0.13  
(0 to 0.13) 
 12 y + 
 -  - 
7 1.27  
(1.27 to 1.69)      
4 0.25  
(0.13 to 0.25) 
Artemisinin 
monotherapies - 
 - 
2 4.68 
(4.29 to 5.08) 
  
1 dose for a child between 1 and 3  years of age 
2 calculated assuming a full course of quinine is taken intra-muscularly for 7days 
 
3.5. Discussion  
The findings presented here provide an independent assessment of the changes in access to 
antimalarial treatment in the private and the public sector after the roll-out of ADDOs and the 
introduction of ACTs in the Kilombero and Ulanga Districts of Tanzania. A framework 
recently published by Obrist et al. views access as the degree of fit between providers’ 
services and users’ means along the five dimensions of availability, accessibility, 
affordability, adequacy and acceptability [52]. Appropriate levels of access lead to utilisation 
of treatment and eventually to improved health, provided the treatment is of high quality. This 
study has concentrated on the provider side of access. Changes in levels of availability, 
accessibility and affordability of treatment in both the private health sector and the 
commercial retail sector are summarised in Table 8 and Table 9. These access indicators 
can be viewed as outputs in the standard evaluation terminology [72] whereas the treatment 
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seeking surveys conducted alongside this study focused on treatment outcomes [102] (cf. 
Chapter 4). 
 
Table 8. Summary of changes in access to malaria treatment from the public health sector  
Dimension Indicator Difference Change 
Facilities per 1000 population  0.13 in 2004 vs. 0.11 in 2008 (p=0.712)  
Proportion of months in stock 
of antimalarial  drugs  Data not conclusive  Availability 
Proportion of months in stock 
of the first line antimalarial 
40% SP stock in 2006 vs. 81% ALu 
stock in 2008  
(p<0.001) 
+ 
Affordability Median price of an adult 
antimalarial dose 
SP TSH 375 (in 2008 prices) in 2005 
vs. SP TSH 300 in 2008 and ALu 
TSH 300 in 2008  
- 
Population within 5 km from a 
facility 
73% in 2004 to 70% in 2008 
(p<0.001)  - Accessibility 
Median distance from a 
household to a facility 
2.2 km in 2004 vs. 2.3 km in 2008 
(p=0.457)   
 
   
Number of equivalent adult 
doses dispensed per day  79 in 2005 vs. 170  in 2008 + 
Utilisation 
Share of total sales through 
public health facilities 
25% in 2005 vs. 30% in 2008 
(p=0.115)  
 
Table 9. Summary of changes in access to malaria treatment from the private retail sector 
Dimension Indicator Difference Change 
Shops per 1000 population  0.24 in 2004  vs. 0.39 in 2008 (p=0.05) + 
Proportion of licensed drug 
shops storing antimalarials 
86% in 2004 vs. 98% in 2008 
(p=0.019) but not a constant trend 
over the years 
 Availability 
Proportion of licensed drug 
shops storing the first line 
antimalarial 
86% selling SP in 2004 vs. 29% 
selling ALu in 2008   
(p<0.001)       
- 
Affordability Median price of adult 
antimalarial dose 
SP TSH 493 (in 2008 prices) in 2005 
vs. SP TSH 800  in 2008 and ALu 
TSH 1500 in 2008  
- 
Population within 5 km from a 
shop 
72% in 2004 vs. 87% in 2008 
(p<0.001)  + 
Accessibility 
Median distance from a 
household to a shop 
2.2 km in 2004 vs. 1.2 km in 2008 
(p<0.001) + 
    
Number of equivalent adult 
doses dispensed per day  154 in 2005 vs. 330 in 2008 + Utilisation 
Share of total sales through 
drug shops 
49% in 2005 vs. 59% in 2008 
(p=0.036) + 
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Overall there has been a great improvement in access to malaria treatment. The number of 
antimalarial doses dispensed nearly doubled over the three years of observation. Major gains 
were made in the private retail sector in terms of availability and accessibility of treatment, 
but availability of drugs also improved in health facilities following the introduction of ALu. 
The treatment seeking surveys [102] (cf. Chapter 4) conducted in the study area found that 
this was accompanied by an increase in the promptness of treatment. The data show that the 
proportion of antimalarial doses taken within 24 hours of symptom onset increased from form 
80% in 2004 to 93-97%.  
 
A great improvement was noted in the public health sector as far as the availability of the first 
line treatment is concerned. In 2008 health facilities were in stock of ALu in over 80% of the 
months of the year compared to 40% in stock of SP in 2006. It is worth noting that the value 
of 80% ALu stock was determined using a very conservative method of estimation whereby 
missing values were considered out of stock (see methods). A more liberal calculation of 
estimation which excludes missing values from any calculation yields values of 94% stock in 
2007 and 91% in 2008 compared to 60% SP stock in 2005. This presents a noteworthy 
improvement compared to previous years.  There is still room for improvement though, and 
ACCESS is continuously working with the District Health Management Teams to close the 
gap. The severe stock-outs of SP in 2006 during the months leading up to the introduction of 
ALu showed the importance of having an alternative source of antimalarials in the 
community.  
 
The high levels of stock of ALu in 2007 and 2008 are the result of the “push” system of 
delivery which was implemented as a temporary measure for the distribution of ALu to 
ensure its wide availability. Although this system has led to high levels of stock, it is argued 
not to be desirable in the long as it leads to wastages when number of malaria patients is 
lower than expected (e.g. as a result of malaria control or the introduction of diagnostics). 
The National Malaria Control Programme (NMCP) has been progressively integrating the 
delivery of ALu into the national drug delivery system and by the beginning of 2010 all 
facilities should be placing orders for ALu along with other items (Dr Mkude, NMCP, personal 
communication). The impact of this change on stock levels need to be closely monitored and 
evaluated. 
 
Two other issues concerning the public health sector emerged from the retail audits: 1) the 
low rate of prescription of ALu and 2) the non-adherence to user fee exemptions. Although 
ALu was widely available in public health facilities, it only accounted for 42% of antimalarials 
dispensed in health facilities. Similar findings have been documented in Kenya [108-109]. In 
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this study amodiaquine was still largely dispensed (32%), although the drug was no longer in 
stock (which does not exclude it from being in the dispensing room). These findings differ 
from information extracted from user surveys carried out a few months later (June to August) 
according to which 63% of patients who were treated in health facilities received ALu, 17% 
SP and 6% amodiaquine. A deliberate attempt by health facility staff to clear out any 
remaining stocks of amodiaquine in the first half of the year could be an explanation for this. 
This would be consistent with reasons documented in Kenya for low ALu prescription. 
Indeed, factors determining low prescription of ALu by health workers were not so much 
related to distrust in the drug, but more with concerns over the cost of ALu, fears of future 
stockouts and excess stocks of non-recommended antimalarial drugs [108]. The data 
presented here clearly suggested a non-adherence to the user fee exemption given that half 
of the health facilities reported selling ALu packs for children under the age of eight. 
However, the findings are not conclusive as only four out of 10 health facilities provided 
pricing.  
 
As far as the private sector is concerned both availability and accessibility of drug shops 
greatly increased after the introduction of ADDOs. Interestingly,  there is evidence that 
ADDOs were opened in less populated areas where there were previously no Part II drug 
shops, suggesting that the programme may have succeeded in encouraging shop owners to 
open ADDOs in more remote areas.  
 
General shops no longer play an important role in the provision of antimalarial treatment in 
the study area.  A study carried out in 2001 found that 27% of the general shops selling 
drugs had antimalarials in stock [98] . This study found that the proportion of general shops 
selling antimalarial drugs decreased constantly between 2004 and 2008. There are a few 
possible explanations for this. On one hand this may be due to tighter supervision by district 
authorities as a result of the ADDO pilot in the area. However market mechanisms could also 
be operating. General shops may have been competed out of the market by the increase in 
the number of licensed drug shops or the increase in prices of antimalarials.  
 
The use of the private retail sector for malaria treatment increased despite increases in 
prices and much higher prices than in health facilities. Although prices of antimalarials alone 
do not serve as an indication of affordability, price changes over a relatively short period of 
time provide a good indication of relative changes in affordability. The price of the first line 
treatment for malaria increased by 84% and the price of SP by 51% in drug shops whereas 
both decreased by 20% in health facilities.  Nevertheless, the share of doses sold in the 
private retail sector increased from 49% to 59%. There are many possible reasons behind 
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this. Certainly improvements in availability and accessibility of shops must have contributed 
to their increased use. It might also be the result of greater demand for ADDO products 
compared to the previous Part II drug shops. Indeed, results from mystery shopper surveys 
conducted in parallel to the shop censuses suggest a major improvement in the quality of 
care in drug shops after the introduction of ADDOs. The percentage of mystery shoppers 
reporting with malaria symptoms increased from just above 30% to nearly 80% between 
2004 and 2008 (Dillip et al., unpublished data). Another possible explanation could be the 
referral by health facility staff to shops in which they have a financial stake in, given that 
many ADDOs and Part II drug shops are owned directly or indirectly by health facility 
workers, but data from treatment seeking surveys suggest that this was not a major problem 
in the study area.  
 
Despite the many improvements seen, the low availability of ALu in ADDOs is a major 
concern. Most ADDO shop keepers reported selling ALu at its recommended retail price of 
TSH 500 (approximately USD 0.40) for children doses and TSH 1500 (approximately USD 
1.30) for other doses. The results presented here indicate that this level of subsidy did not 
result in widespread availability of the drug. Discussions with ADDO dispensers highlighted 
two main reasons for this: firstly the drug can only be procured from one wholesaler in 
Morogoro, a city approximately 200km from Ifakara; secondly the drug is too expensive and 
leads to low profit margins. A typical pre-packaged adult dose of SP was bought for TSH 900 
(USD 0.80) and sold for TSH1500 (USD 1.30). Un-packaged SP was bought at the lower 
price of TSH 180 (USD 0.15) and sold for TSH 300 (USD 0.25). Conversely, a dose of ALu 
was bought for TSH 1150 (USD 1) which leaves a much lower profit margin than for other 
drugs. The experience from two studies which piloted the AMFm in Tanzania and Uganda 
where retail mark-ups were higher found higher stocking rates [44-45].  
 
The findings presented here are highly relevant to the imminent roll-out of the AMFm and 
confirm that ensuring wide availability of ALu in the private retail sector is paramount to its 
uptake. ADDOs are a suitable distribution channel for ALu, since in the districts where they 
exist, they are available, accessible and highly utilised in both the district town and rural 
areas. The data presented here suggest that the low affordability of ALu in ADDOs ultimately 
restricted its availability. Cheaper drugs such as amodiaquine and SP were still the most 
dispensed drugs. AMFm plans to subsidise ACTs high in the distribution chain and to 
facilitate their distribution at competitive prices along the same channels as other 
antimalarials could present a viable solution to the problems encountered in the study area.  
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3.6. Conclusions  
The public and private retail sector are important complementary sources of malaria 
treatment in rural Tanzania and efforts to improve access to prompt and effective malaria 
treatment should take both sectors into account. This duality of sources also offers a backup 
solution when drugs are out of stock in the public heath system. A high proportion of patients 
seek treatment for malaria from shops rather than health facilities despite higher prices 
possibly since shops are more available and more accessible. The introduction of subsidised 
ACTs in the private retail sector was piloted in the study area through the ADDO programme 
but did not lead to high availability of the drug, probably because the final price was not 
affordable.  This resulted in a low uptake of ACTs despite its wide availability in public health 
facilities. If a high quality of services is ensured in the private sector the public health impact 
of ACTs can be maximised by making this class of drugs available in at affordable prices in 
the private sector. 
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4.1. Abstract  
Background 
The ACCESS programme aims at understanding and improving access to prompt and 
effective malaria treatment. Between 2004 and 2008 the programme implemented a social 
marketing campaign for improved treatment seeking.  To improve access to treatment in the 
private retail sector a new class of outlets known as Accredited Drug Dispensing Outlets 
(ADDO) was created in Tanzania in 2006. Tanzania changed its first line treatment for 
malaria from Sulphadoxine-Pyrimethamine (SP) to Artemether Lumefantrine (ALu) in 2007 
and subsidized ALu was made available in both health facilities and ADDOs. The effect of 
these interventions on understanding and treatment of treatment was studied in rural 
Tanzania. The data also enabled an investigation of the determinants of access to treatment.  
Methods 
Three consecutive treatment seeking surveys were conducted in 2004 2006 and 2008 in the 
rural areas of the Ifakara Demographic Surveillance System (DSS) and in Ifakara Town. 
Each survey included approximately 150 people who had suffered a fever case in the 
previous 14 days were interviewed. 
Results 
Treatment seeking and awareness of malaria was already high at baseline, but various 
improvements were seen between 2004 and 2008, namely: better understanding causes of 
malaria (from 62% to 84%); an increase in health facility attendance as first treatment option 
for patients older than five years (27% to 52%); higher treatment coverage with antimalarials 
(86% to 96%) and more timely use of antimalarials (80% to 93-97% treatments taken within 
24 hrs). Unfortunately, the change of treatment policy led to a low availability of ALu in the 
private sector and therefore to a drop in the proportion of patients taking a recommended 
malaria treatment (85% to 53%). The availability of outlets (health facilities or drug shops) is 
the most important determinant of whether patients receive prompt and effective treatment, 
whereas affordability and accessibility contribute to a lesser extent.  
Conclusions 
An integrated approach aimed at improving understanding and treatment of malaria has led 
to tangible improvements in terms of people’s actions for the treatment of malaria. However, 
progress was hindered by the low availability of the first line treatment after the switch to 
ACTs. 
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4.2. Background  
The cornerstone of the World Health Organisation’s malaria control strategy is prompt and 
effective treatment for all episodes of malaria [3] [4]. Largely thanks to international support 
through the Global Fund to Fight AIDS Tuberculosis and Malaria (GFATM) and the World 
Bank’s Malaria Booster programme, most sub-Saharan African countries have now switched 
to the highly efficacious artemisinin-combination therapies (ACT). International initiatives 
such as Medicines for Malaria Venture (MMV) are increasingly speeding up the development 
of new antimalarials. However, the public health impact of such drugs relies to a large extent 
on patient’s ability to access them and little progress will be made unless broader access 
issues are tackled. Despite large increases in the number of antimalarial drugs supplied 
internationally, surveys conducted between 2007 and 2008 in 11 African countries found that 
only 15% of fever cases were treated with ACTs [3].  
 
Several strategies have been proposed and tested to improve access to malaria treatment by 
targeting providers or users. Smith et al.[33] recently conducted a systematic review of the 
effectiveness of various such interventions in improving prompt and effective treatment of 
malaria. Interventions reviewed included optimising case-management and services in health 
facilities [34-35, 110-112] or improving dispensing practices of drug shop attendants and 
private practitioners [85, 113-117] as well as community based approaches [86, 118-119]. 
Two general approaches to improving user malaria treatment practices have been pursued 
1) health education campaigns [120-121] and 2) interventions that specifically provide 
information on how to take anti-malarials [122], including pre-packaging and pictorial and 
verbal instructions [123-125]. The main finding from the review is that most interventions so 
far have been conducted on a rather small scale and that few have been appropriately 
evaluated. As a consequence, despite the wealth of research conducted on the topic, little is 
known about interventions that can promote sustained change.  
 
The ACCESS programme in the Kilombero and Ulanga Districts in southern Tanzania aims 
to improve understanding of and access to prompt and effective malaria treatment through 
an integrated approach targeting both users and providers [101]. The programme’s activities 
are based on a conceptual framework which defines access as the degree of fit between the 
needs and means of patients (users) and the existing services (providers) along the five 
dimensions of availability, accessibility, affordability, adequacy and acceptability [52]. 
Interventions are carried out at three levels: 1) the community, 2) the formal health sector 
and 3) the private retail sector for drugs. A comprehensive monitoring and evaluation plan 
accompanied each of these interventions. The implementation of the programme started in 
2004 and the second phase will be completed in 2011. 
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Between 2004 and 2007 the ACCESS programme’s main intervention at community level 
was a social marketing campaign for improved recognition of the disease and more effective 
care seeking. It followed on the work by the KINET project which used a social marketing 
approach to promote the use of insecticide treated nets in the same area [126]. Various 
communication channels were used and material developed to disseminate information on 
malaria transmission, symptoms and prevention as well as to stress the importance of 
prompt and effective treatment. Road shows were the main activity and included role plays, 
public lectures and quizzes. In addition, promotional materials (e.g. stickers, leaflets, t-shirts) 
were distributed, and billboards and posters displayed in public places. The programme also 
organised special campaigns targeted at pregnant women and mothers of young children in 
Mother and Child Health (MCH) clinics. Social marketing campaigns were conducted in 96% 
(78/81) of the villages in the Kilombero District and 95% (62/65) of the villages in the Ulanga 
District. More detailed information on the ACCESS social marketing campaigns can be found 
elsewhere [101].  
 
The ACCESS programme also intervened in the public health sector to improve quality of 
care. Key activities included strengthening of routine supervision and refresher training for 
health facility staff based on Integrated Management of Childhood Illness (IMCI) algortithms 
[101]. In 2004 and 2005 91% (94/103) of all health workers in the Ulanga District and 93% 
(39/42) of clinical officers in the Kilombero District attended a refresher training. In addition 
the study period saw a change of first line treatment for malaria.  In 2006 the Government of 
Tanzania switched from Sulphadoxine Pyrimethamine (SP) to Artemether Lumefantrine 
(ALu). Actual introduction of ALu in health facilities was delayed until 2007, with resulting 
stock-outs in the transition period [127] (Cf. Chapter 3). 
 
In parallel the Accredited Drug Dispensing Outlets (ADDOs) programme was rolled out in the 
study area from 2006 onwards to improve access to treatment and quality of care in the 
private drug retail sector [87]. ACCESS undertook the local evaluation and monitoring of the 
programme. The private retail sector plays a very important role in the delivery of antimalarial 
treatment in most African countries as retailers tend to be more accessible and flexible, 
especially with regards to opening hours and charges [39-40]. The aim of the ADDO 
programme is to improve access to basic medicines by upgrading all existing drug shops to 
well regulated and properly operated outlets manned by specifically trained personnel [57]. 
The intervention involved a combination of private drug shop dispenser training, incentives, 
accreditation and regulation. The ADDO programme greatly improved the availability and 
accessibility of drug shops and, most importantly the quality of advice and dispensing (Dillip 
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et al. unpublished data). ALu was made available to the programme at a very highly 
subsidised price towards the end of 2007, but this did not result in widespread availability of 
the drug , allegedly because of low profit margins and long distances to the wholesalers.[127] 
(cf. Chapter 3) between 2006 and 2008 55 ADDOs were opened the Ulanga District and 135 
in the Kilombero District (equivalent to approximately three shops per 10,000 people in both 
districts). 
 
The primary aim of this study was to evaluate changes in understanding and treatment 
seeking for malaria in the Kilombero and Ulanga Districts during the period 2004-2008 and to 
assess how such changes could be attributed to the three interventions evaluated by the 
ACCESS programme.  The results presented here are complemented by a study which 
focused on changes in availability, accessibility and affordability of treatment over the same 
period (i.e. the provider perspective) [127] (cf. Chapter 3). The data also provided a unique 
opportunity to apply a recent analytical framework on access to treatment [52] in a real-life 
situation and to assess the determinants of access to prompt and effective treatment.  
 
4.3. Methods 
Study setting 
The study was carried out in the Kilombero and Ulanga Demographic Surveillance System 
(Ifakara Rural DSS) and in the semi-urban setting of Ifakara town between 2004 and 2008 
(Figure 17). In the DSS area every household is visited every four months to collect a set of 
basic demographic data.  As a result, a comprehensive and continuously updated database 
of the resident population is maintained for the study area. The Ifakara Rural DSS covers 25 
villages (13 in Kilombero and 12 in Ulanga). The population in 2004 was almost 74,000 and 
just over 92,000 in 2008. The population of Ifakara Town was 45,700 according to the 
national census of 2002 [103]. A study conducted in the area between 2001 and 2003 
reported an Entomological Inoculation Rate (EIR) of 349 infective bites per person per year 
(ib/p/y) [77], but according to recent data it has declined to 81 ib/p/y [78]. EIR data for Ifakara 
town suggest that the transmission rate is about a log order smaller than in the surrounding 
rural areas [79]. The area has been described in more detail elsewhere [73, 101].  
 
The formal health sector - There are six health facilities in the Kilombero DSS area and eight 
health facilities in the Ulanga DSS area. The Designated District Hospital in Ifakara serves as 
a referral centre for the entire area and there are also two other health facilities in town. 
Government and faith-based facilities in Kilombero and Ulanga charge user fees. In the 
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Ulanga District the Community Health Fund (CHF) offers a form of risk protection to its 
members but very few people were enrolled during the study period  (around 3% of the 
population in 2005 - personal communication from the District Medical Officer). Children 
under five years of age, pregnant women and elderly people should receive services and 
drugs free of charge but there is ample evidence that the exemption mechanism is not 
properly implemented [64, 88].  
 
Figure 17. Map of Kilombero and Ulanga Districts showing Ifakara Town and the Demographic 
Surveillance System (DSS). 
 
 
 
Retail sector for drugs - By 2008 90% (49/54) of drug shops in the study area were ADDOs.  
Between 2004 and 2008 the number of shops per 1000 people increased from 0.24 to 0.39 
and as a result the proportion of people living within 5km from a shop increased from 71% in 
2004 to 87% in 2008. The roll out of ADDOs coincided with a stark decrease in the 
availability of antimalarial drugs in non-licensed general shops. Mystery shopper surveys 
showed that the proportion of customers with malaria symptoms who got correct advice and 
treatment in drug shops increased from just above 30% to nearly 80% between 2004 and 
2008 (Dillip et al., unpublished data) after the introduction of ADDOs. Although ALu was 
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made available in ADDOs in mid 2007 with a high level of subsidy by 2008 it was only 
stocked by a third of shops. SP and other older antimalarials remained much more widely 
available and sold [127] (cf. Chapter 3). 
Treatment seeking surveys 
Three cross sectional surveys were conducted in the DSS areas and Ifakara Town in 2004, 
2006 and 2008 to investigate treatment seeking for malaria and understanding of the 
disease. The interviewees included children and adults who had recently suffered a fever 
episode (caretakers responded to questions for children under the age of 12).  Data 
collection was carried out every other year between May and August, a time of the year 
which coincides with the dry season and is characterised by a lower intensity of transmission. 
An analysis of the baseline study in 2004 was published by Hetzel et al. [88] and the results 
presented here provide a longitudinal assessment of the changes between 2004 and 2008.   
 
Sampling procedure - Different sampling procedures were applied in the DSS area and in 
Ifakara Town. In the DSS area, a village-stratified random sample of households was drawn 
from the existing comprehensive DSS register. Only households with at least one child under 
the age of five years were eligible. In Ifakara such a sampling frame was not available. 
Therefore, the local administrative structure was used to draw a two-stage random sample of 
households, using ten-cell leaders (balozi) as first level of sampling.  Given a background of 
decreasing fever incidence rates (cf. Chapter 5), every year a greater number of households 
were sampled to ensure that approximately 150 fever cases could be followed up (Table 10). 
All individuals from the sampled households who reported an episode of fever within the 
previous 14 days were included in the study. Patients who had not recovered clinically were 
not included and they were instead advised to seek care from a health facility. More details 
on the sampling and interviewing procedure can be found in the baseline paper [88]. 
 
Table 10. Sample size and number of fever cases followed up in each survey round 
 DSS areas Ifakara Town 
 
Households 
sampled 1 
People 
interviewed 
Households sampled 
(ten-cells x households per ten-
cell) 2 
People 
interviewed 
2004 318 110 223 (40 x 6) 44 
2006 561 103 410 (50 x 9) 50 
2008 750 86 739 (75 x 10) 41 
1
 Village-stratified sampling proportional to number of households per village 
2
 Two-stage sampling of households within ten-cells. The final number of households is lower than the 
product of the parts as some ten-cells have less than the chosen number of households 
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Data collection tool - The tool for data collection was a locally adapted Explanatory Model 
Interview Catalogue (EMIC) [94] based on focus group discussions and prior research 
carried out in the study area [81, 128]. This semi-structured questionnaire provides 
qualitative and quantitative data on patients’ signs and symptoms associated with the fever 
episode (patterns of distress), as well as perceived causes and treatment seeking. Patients 
were also asked to label the disease according to their own understanding. In the study area 
most cases were labelled as malaria, homa (fever) and degedege (fever-related disease with 
neurological involvement [81]).  
 
Distance from households to nearest point of care - Distances from households to the 
nearest health facility or drug shop were calculated by combining the Global Positioning 
System (GPS) locations of households from the DSS database and the GPS positions of 
outlets obtained from providers surveys [127] (cf. Chapter 3). The households GPS values 
were available for 91% (100/110) households in 2004 97% (100/103) in 2006 and 87% 
(73/87) in 2008. 
 
Measuring socio-economic status - A relative index of socioeconomic status (SES) was 
calculated for the households in the DSS villages using asset ownership and household 
characteristics data stored in the DSS database. A principal components analysis (PCA) 
defined the weights of an SES index [129] [130] for the households in the survey, relative to 
all other households in the area. Households were divided into five wealth quintiles based on 
their SES score. The score was available for 97% (107/110) households in 2004, 93% 
(96/103) in 2006 and 93% (81/87) in 2008. The variables included in the analysis and the 
weight given to each is shown in Table 11.  
 
The variables collected for SES assessment in 2004 differed from the ones collected in 
subsequent years but this was not considered to bias analyses.  Comparing SES quintile 
groupings in the DSS households showed similar year on year comparability across all years 
in the poorest and richest category. Indeed 40% (871/2157) of households categorised as 
poorest in 2004 were categorised as poorest in 2006 and 47% (1256/2686) households 
categorised as richest in 2004 were categorised as richest in 2006. Similar, albeit higher 
values were found comparing categories in 2006 and 2008, that is 53% (1341/2540) and 
61% (1752/2882) respectively. As year on year comparability in the three middle quintiles 
was poor, the middle quintiles were grouped into one category which resulted in 66% 
(4470/6813) of household categorised as middle in 2004 also categorised as middle in 2006 
and similarly 73% (5930/8104) comparing the 2006 and 2008 groupings.  With these 
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regroupings it was assumed that the difference in the type of assets collected would not 
introduce substantial bias.  
 
Table 11. Results of principal components analysis of socio-economic status (SES) variables 
Item 2004 2006 2008 
 Mean weight Mean  weight Mean  weight 
Meals consumed per day in 
past 2 days 
2.31 0.42       
Days per week that the 
following is consumed: 
        
 Meat 0.71 0.29       
 Rice 3.92 0.23       
 Tea 2.37 0.42       
Main source of food:         
 Market 0.52 -0.34       
 Own farm 0.44 0.37       
Source of water : 1=tap 
2=well with pump 3=well 
4=river 
2.49 -0.06       
Household owns at least 1:         
 Bicycle 0.45 0.32  0.57 0.42  0.65 0.44 
 Radio  0.49 0.34  0.65 0.38  0.66 0.42 
 Animal    0.09 0.17  0.10 0.23 
 Mobile phone    0.07 0.28  0.28 0.42 
Corrugated iron roof    0.32 0.35  0.34 0.34 
Small business as source of 
income 
   0.09 0.09  0.11 0.13 
Rented accommodation    0.10 -0.02  0.10 0.02 
Number of mosquito nets     1.97 0.46  2.03 0.35 
Number of rooms  2.09 0.17  2.18 0.45  2.23 0.38 
Toilet or latrine    0.92 0.15  0.93 0.06 
Number of households 
included 14515 / 14997 16762 / 16888 17764 / 18813 
Variation explained by first 
principal component 24% 23% 24% 
 
   
 
 
Ethical clearance - All study participants provided oral informed consent prior to the 
interview. The National Institute for Medical Research of the United Republic of Tanzania 
granted ethical clearance for the study (NIMR/HQ/R.8a/Vol.IX/236, 16th September 2003). 
 
Analyses 
Various indicators were constructed and compared between 2004 and 2008. Indicators of 
understanding of malaria focused on perceived causes and patterns of distress.. Indicators of 
treatment included: actions, sources and type of drugs used for the treatment of fever and 
links of the community effectiveness chain based on the approach developed by Hetzel et al 
[88]. The community effectiveness chain breaks down the full Roll Back Malaria (RBM) [4] 
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indicator into its primary components [131] and includes: the proportion of fever cases 1) 
treated;  2) treated with a drug; 3) treated with an anti-malarial; 4) treated with a 
recommended anti-malarial; 5) treated with a recommended anti-malarial on the same or 
next day; 6) treated with a recommended anti-malarial the on same or next day and following 
the correct regimen (correct number of tablets, timely intake and duration), i.e. the full RBM 
indicator; 7) treated with a recommended anti-malarial on the same or next day, following the 
correct regimen and appropriately considering reported symptoms (with quinine if symptoms 
of severe malaria are reported). Since the change of treatment policy only effectively took 
place one year before the last 2008 survey, two scenarios were presented for 2008. The first 
scenario is strictly according to guidelines, following which only ALu qualifies as a 
recommended treatment, whereas the second scenario also allows for SP as a 
recommended treatment. Logistic regressions estimated the effect of changes over time from 
2004 to 2008 with time entered in the model as a categorical variable.  Estimates of change 
over time were reported crude as well as adjusted by SES groupings since SES score was 
higher in the last two surveys compared to the first survey. 
 
The recently developed access to treatment framework [52] was applied to the data to 
estimate the determinants of access in the study area. The framework defines five 
dimensions of access, namely availability, accessibility, affordability, adequacy and 
acceptability. Availability refers to the existence of appropriate service. Thus, an indicator of 
availability was defined as the presence of an outlet (health facility or drug shop) stocking 
anti-malarial drugs in the village of residence of the patient. Accessibility refers to the 
geographical distance between the services and the homes of intended users. The main 
indicator of accessibility was thus defined as the distance from the patient’s main residence 
to the nearest outlet stocking anti-malarials (health facility or drug shop). But since patients in 
the study area often spend a significant amount of time in farming fields far away from 
households and outlets [132], a secondary indicator of accessibility was defined as whether 
the patients were in their main residence or away in farming fields at onset of fever. 
Affordability refers to whether the prices of services fit the patients’ income and ability to pay. 
The patient’s SES quintile was taken as a surrogate indicator for income and how much they 
spent on their treatment (drug and consultation) as an indicator of their ability to pay. The 
data necessary to construct indicators of acceptability and adequacy were not available The 
analysis only included patients from the rural DSS villages as data on SES and distances to 
nearest shop or health facility were not available for households in Ifakara town.. Univariate 
logistic regressions assessed contribution of each of the access indicators on the odds of the 
patient receiving of prompt and effective treatment within 24 hours. A multivariate model was 
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built (by backward elimination of variables with a log-likelihood ratio test greater than 0.2) to 
assess the relative contribution of each of the access indicators.  
 
Epi Info 6 and Intercooled Stata 9 (College Station, Texas, USA) were used for random 
sampling procedures. Data were double entered in Microsoft FoxPro and Microsoft  Access  
(Microsoft  Corp.) and  checked  for  coding errors and consistency. Statistical analysis was 
done with Intercooled Stata 9. Distance calculations were carried out with ArcMap Version 
9.1 (ESRI Inc.). 
 
4.4. Results  
The cross-sectional samples were similar over the three years of observation in terms of age, 
sex, residence, religion and years of formal education. Despite being marginally wealthier, 
households in 2008 were located further away from drug shops and health facilities (Table 
12).   
 
Table 12. Sample characteristics 
 2004 
 
2006 
 
2008 
 
 
N n (%)* N n (%)* N n (%)* 
Age group  154  153  127  
 Under 5 years  81 (52.6%)  76 (49.7%)  50 (39.4%) 
 Over 5 years  73 (47.4%)  77 (50.3%)  77 (60.6%) 
Sex  154  153  127  
 Male  71 (46.1%)  63 (41.2%)  54 (42.5%) 
 Female  83 (53.9%)  90 (58.8%)  73 (57.4%) 
Residence  154  153  153  
 Ulanga DSS  61 (39.6%)  41 (26.8%)  40 (31.5%) 
 Kilombero DSS   49 (31.8%)  62 (40.5%)  46 (36.2%) 
 Ifakara  44 (28.6%)  50 (32.7%)  41 (32.3%) 
Religion* 154  152  125  
 Muslim  63 (40.9%)  51 (33.5%)  50 (40.0%) 
 Christian  91 (59.1%)  101 (66.4%)  75 (60.0%) 
Years of formal education** 137  150  125  
 < 7 years   56 (40.9%)  45 (30.0%)  38 (30.4%) 
 = 7 years   70 (51.1%)  99 (66.0%)  80 (64.0%) 
 > 7 year  11 (8.0%)  6 (4.0%)  7 (5.6%) 
SES score *** 107  96  81  
 Poorest  20 (18.7%)  6 (6.3%)  10 (12.4%) 
 Middle  63 (58.9%)  62 (64.6%)  52 (64.2%) 
 Richest  24 (22.4%)  28 (29.2%)  19 (23.5%) 
SES score *** [mean (SD)] 107 0.09 (1.53) 96 0.41 (1.28) 81 0.44 (1.45) 
Distance to nearest health 
facility  (km) *** [median (IQR)] 105 1.69 (2.74) 100 1.67 (3.43) 73 2.25 (3.83) 
Distance to nearest Part II or 
ADDO drug shop (km)  *** 
[median (IQR)] 105 1.70 (4.13) 100 1.79 (3.30) 73 2.49 (1.94) 
 * unless otherwise stated 
 ** of caretaker if patient <12 years 
 *** DSS only (110 observations in 2004, 103 in 2006 and 86 in 2008) 
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Understanding of malaria  
The population appears to be more aware of malaria, its causes and its prevention in 2008 
compared to 2004 (Figure 18). While in 2004 57% (80/137) of people labelled their fever 
case as malaria, the proportion rose to 80% (102/127) in 2008 (crude OR=3.14 p<0.001, 
adjusted for SES OR=2.31 p=0.008. The proportion of cases labelled malaria attributed to 
mosquito bites significantly increased from 62% (79/127) to 84% (97/116) (crude OR=3.10  
p<0.001, adjusted for SES OR=2.02 p=0.056).  The proportion of fever episodes with 
symptoms of convulsions (twitching, stiff body, delirium, white eyes, kicking limbs) labelled as 
malaria also consistently increased from 57% (16/28) to 73% (8/11), although not 
significantly so due to the small number of cases with such symptoms (OR=2.00 p=0.373). 
The proportion of fever cases believed to be preventable with the use of mosquito nets did 
not increase, most likely because of the already very high value of 81% at baseline.  
 
Figure 18. Changes in understanding of malaria 
 
 
Treatment of fever   
There was no difference in health facility attendance and treatment in children, but the 
proportion of older patients who sought treatment in health facilities increased significantly . 
Health facility attendance and treatment was already very high at baseline in children and did 
not change over the study period (health facility attendance at some point during the illness 
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148/195 i.e. 76%; health facility attendance as first treatment action 119/201 i.e. 58%; 
treatment with antimalarial from a health facility 123/207 i.e. 59%). Conversely the odds of 
older patients attending a health facility as a first treatment option increased three-fold 
between 2004 and 2008 (from 20/73 i.e. 27% to 40/77 i.e. 52% OR=2.9 p=0.002) crude and 
nearly 5-fold adjusting for SES (OR=4.6 p=0.001). The odds of older patients being treated in 
a health facility also increased although not significantly (from 23/73 i.e. 32% to 33/77 i.e. 
43% OR=1.63 p=0.152) crude and nearly three-fold adjusting for SES (OR=2.9 p=0.012).  
 
Figure 19. Sources of treatment for fever and actions undertaken (Note: HF=Health facility; 
AM=antimalarial; HMM=home management of malaria 
 
 
The receipt of treatment from the private retail sector increased over the study period. 
Overall the proportion of cases treated with an antimalarial from a drug shop significantly 
increased from 31% (47/154) in 2004 to 31% (47/153) in 2006 and  43% (54/127) in 2008 
(OR=1.68, p=0.038). Three points should be highlighted with regards to this.  Firstly, this 
effect is confounded by SES (adjusted OR=1.18 p=0.632). The proportion mainly increased 
in the three middle wealth quintiles from 19% (12/63) to 26% (12/46) and actually decreased 
in the poorest quintile from 25% (5/20) to 20% (2/10) whereas it stayed stable in the richest 
quintile (20/74 i.e. 27%). Secondly the increase was mainly in patients over the age of five 
(38% in 2004 to 52% in 2008) and not in children (25% in 2005 to 28% in 2008). Thirdly the 
increase in the use of the private sector in patients older than five was due more to an 
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increase in people who attended health facilities and obtained treatment from a shop (23/73 
i.e 31% in 2004 to 33/77 i.e. 43% in 2008) than in people who treated themselves directly 
from shops without ever visiting a health facility (23/73 i.e. 32% in 2005 to 27/77 i.e 35% in 
2008). Few patients were treated from a general shop (30/434 i.e. 7%) (Table 13). 
 
Table 13.  Breakdown of types of antimalarials received from each of the sources of treatment 
(number of cases and percentages) 
 2004 2006 2008 
 
Health 
facilities 
Drug 
shops 
General 
shops 
Health 
facilities 
Drug 
shops 
General 
shops 
Health 
facilities 
Drug 
shops 
General 
shops 
Chloroquine*  1 
(2.1%) 
       
Artemether-
Lumefantrine 
      40 
(62.5%) 
7 
(13.0%) 
1 
(16.7%) 
Sulphadoxine-
Pyrimethamine 
40 
(58.5%) 
20 
(42.6%) 
10 
(90.9%) 
41 
(51.2%) 
33 
(70.2%) 
10 
(83.3%) 
11 
(17.2%) 
35 
(64.8%) 
3 
(42.9%) 
Amodiaquine 10 
(14.7%) 
9 
(19.2%) 
 16 
(20.0%) 
9 
(19.2%) 
1 
(8.3%) 
4 
(6.3%) 
4 
(7.4%) 
 
Quinine 38 
(55.9%) 
26 
(55.3%) 
3 
(27.3%) 
24 
(42.5%) 
13 
(27.7%) 
3 
(25%) 
12 
(18.8%) 
11 
(20.4%) 
2 
(28.5%) 
Total  68 48 11 80 47 12 64 54 6 
* 2 patients took chloroquine in 2004 but information on source of treatment was available for 1 patient 
 
A breakdown of the types of antimalarials taken also shows some improvements over time 
although the low uptake of ALu is disappointing (Figure 20). Treatment coverage with 
antimalarials is extremely high in the study area. In 2004 the use of multiple antimalarials to 
treat a single fever case in children under the age of five was common but it decreased in 
2006 and 2008. The most commonly used drug over the study period was SP. In 2008, more 
than a year after the change of treatment policy, only 39% (48/124) of cases were treated 
with ALu. The low uptake of ALu is partly explained by the fact that even in health facilities 
not all cases received ALu (only 63%) and partly because most of the people who were 
treated in shops either received SP (65%), quinine (20%) or amodiaquine (7%) and only 13% 
received ALu (Table 13). Children were more likely to be treated with the new drug than older 
patients but not significantly so (23/50 i.e. 46% of children and vs. 23/77 i.e. 30% older 
patients OR=1.28 p=0.439).  Interestingly, patients in the middle quintiles were the least 
likely to be treated with ALu (poorest to middle quintiles OR=3.56 p=0.029, richest to middle 
quintiles OR=3.15 p=0.004). 
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Figure 20. Types of antimalarials taken for treatment of fever (Note: SP=Sulphadoxine-
Pyrimethamine, AQ=amodiaquine, Qu=Quinine, ALu=Artemether-Lumefantrine) 
 
Community effectiveness of malaria treatment  
The comparison of the community effectiveness of malaria treatment in 2004 and 2008 
shows a clear improvement over time (Figure 21). Despite a sharp fall in the proportion of 
people taking a recommended treatment for malaria after the switch to ALu, there were 
appreciable improvements in terms of timeliness of treatment. Comparing the number of 
people who took an appropriate anti-malarial (indicator 4) and the number who took it within 
24 hours (indicator 5) shows that whereas in 2004 80% (101/127) of were treated promptly, 
in 2008 this figure rose to 97% (65/67) of patients who took ALu or quinine (crude OR=8.36 
p=0.005, adjusted for SES OR=6.39 p=0.018), and 93 % (113/122) of patients who took a 
ALu, quinine or SP (crude OR=3.23 p=0.004, adjusted for SES OR=4.23 p=0.015). 
 
The self-reported adherence to the recommended drug regimen. only marginally improved. 
Adherence to SP treatment regimens improved over time (55/72 i.e. 76% in 2004 vs. 41/49 
i.e. 84% in 2008). However, just over two thirds of patients completed their courses of ALu 
(22/32 i.e. 69%). Quinine treatments were always under-dosed because the course was not 
taken for the full seven days. Overall, comparing the number of people who took an 
appropriate anti-malarial within 24 hours (indicator 5) and those who took it adhering full to its 
regimen (indicator 6) shows that in 2004 32% (32/101) of timely treatments were taken 
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following regimen and in 2008, although this figure rose to 51% (58/113) of patients who took 
ALu, quinine or SP, only 31% (20/65) of patients who took quinine or SP fully adhered to 
their regimen (strictly according to guidelines: crude OR=1.12 p=0.809, adjusted for SES 
OR=0.94 p=0.910; allowing for SP as appropriate treatment in 2008: crude OR=1.63 
p=0.212, adjusted for SES OR=1.40 p=0.475).  
 
Figure 21. Estimated effective coverage of fever treatment based on patients' or caretakers' 
accounts. Percentages are the proportion of fever cases 1) treated;  2) treated with a drug; 3) treated 
with an anti-malarial; 4) treated with a recommended anti-malarial; 5) treated with a recommended 
anti-malarial on the same or next day; 6) treated with a recommended anti-malarial on the same or 
next day and following the correct regimen (correct number of tablets, timely intake and duration), i.e. 
the full RBM indicator; 7) treated with a recommended anti-malarial on the same or next day, following 
the correct regimen and appropriately considering reported symptoms (quinine if symptoms of severe 
malaria are reported).   
 
 
There were some difference between adults and children. Generally coverage was higher in 
children under the age of five compared to the rest of the population. The proportion of cases 
treated with a recommended anti-malarial (including SP) within 24hrs increased from 73% 
(59/81) in 2004 to 88% (44/50) in 2008 in children under the age of five (OR=1.30, p=0.030) 
and from 57% (42/73) in 2004 to 90% (69/77) in patients over the age of five (OR=1.56 
p<0.001). The proportion of cases treated with either ALu or quinine within 24hrs in 2008 was 
72% (36/50) in children under the age of five and 38% (29/77) in all other patients. However 
the proportion of cases treated promptly and effectively and following the recommended 
regimen tended to be slightly lower in children under five than in adults. Allowing for SP the 
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proportion in children under five increased from 37% (16/43) to 56% (19/34) and in adults 
from 28% (16/58) to 67% (39/58) between 2004 and 2008. Strictly according to guidelines, 
i.e. excluding SP and conforming to the full RBM indicator for prompt and effective treatment 
of malaria, the figure in 2008 is 39% (13/33) for children and 12% (7/58) in adults. 
 
Determinants of access 
An analysis of the contribution of each of the access dimensions suggests that the 
availability of antimalarials thanks to the presence of a drug outlet (health facility or drug 
shop) is the main determinant of whether people get prompt and effective treatment for 
malaria (Table 14). There was no significant difference in promptness of treatment between 
patients who had been treated in health facilities and those treated in drug shop (OR=1.28 
p=0.613), but patients treated in drug shops were less likely to be treated with the 
appropriate drugs (OR=0.14 p=0.001). Patients living in villages with either a drug shop or a 
health facility were four times as likely to get prompt and effective malaria treatment than 
people from villages without outlets (OR=4.10 p<0.001 adjusting for differences in 
affordability and accessibility). The presence of outlets influenced promptness (OR=5.83 
p<0.001) and appropriateness (OR=4.75 p<0.001) of treatment to a similar extent. 
 
Affordability contributed to a lesser extent to receipt of treatment.  Both the univariate and 
multivariate model showed no difference in receipt of prompt and effective treatment across 
socio-economic groups.   However, people who paid more for their treatment were more 
likely receive it promptly and effectively (OR=1.74 p=0.008). This implies that even poorer 
people manage to find the resources to afford treatment. The cost of treatment influenced the 
appropriateness of treatment (OR=3.34 p<0.001) more than the timeliness (OR=1.67 
p=0.017).  It is worth recalling here that a somewhat un-expected pattern of ALu uptake was 
observed in 2008 whereby the three middle quintiles were less likely to be treated with ALu 
(cf. results in “Treatment of fever”).  
 
Accessibility is a determinant of access to treatment, but only if people are in far away farms 
at onset of their disease. People were twice as likely to be treated promptly and effectively if 
they were residing in their main homestead rather than in the farming fields at the onset of 
their fever (OR=2.08 p=0.032 in the multivariate model). The location at onset of disease 
mainly influenced the receipt of a recommended anti-malarial (OR=2.48 p=0.004) rather than 
the timeliness of treatment (OR=1.63 p=0.133). However, if people were in their main 
homestead at onset of disease, the distance to the nearest outlet did not have a major 
impact on treatment provided the outlet was present in their village (OR=0.88 p=0.082).   
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Table 14. Determinants of receiving prompt and effective antimalarial treatment according to 
current guidelines from either a health facility or a drug shop in the rural DSS villages between 
2004 and 2008 
  
Univariate model Multivariate model 
(n=264) 
  
N OR 
(95% CI) * 
p OR 
(95% CI) * 
p 
Availability Presence of outlet in the 
village of residence ** 
297 3.32  
(1.96 to 5.63) 
<0.001 4.10  
(2.17 to 7.73) 
<0.001 
SES  (baseline: middle 
quintiles) 
282  0.951   
         Poorest  0.94  
(0.44 to 2.03) 
0.893   
         Richest  1.07  
(0.59 to 1.95) 
0.803   
Affordability 
Cost of treatment *** 
(TSh1000 ) 
297 1.73  
(1.26 to 2.43) 
0.002 1.74 
(1.16 to 2.60) 
0.008 
Distance household to 
nearest outlet ** (1km) 
276 0.84  
(0.73 to 0.95) 
0.006 0.88 
(0.75 to 1.01) 
0.082 Accessibility 
Location at onset of fever 
(home vs. farming site) 
295 1.83  
(1.03 to 3.27) 
0.039 2.08 
(1.07 to 4.09) 
0.032 
* Adjusted for the effect of year of study 
** Presence/distance to health facility for those treated in a health facility and presence/distance to drug shop for 
those treated in a drug shop 
*** Drug + consultation 
 
4.5. Discussion  
The results presented here show improvements in understanding and treatment seeking for 
malaria in two rural districts in Tanzania after the implementation of the ACCESS 
programme. Specific improvements include a better understanding of the causes of malaria, 
an increase in health facility attendance and treatment in patients older than five years, and 
more timely use of antimalarials. Unfortunately, the change of malaria treatment policy from 
SP to ALu during the same period led to a lower availability of the first line drug in the private 
retail sector. As a consequence the proportion of patients taking a recommended malaria 
treatment dropped significantly in 2008.   
 
Given the before-after nature of this study and the absence of a control group it is difficult to 
attribute specific improvements to ACCESS interventions. However, plausible explanations 
can be given on the basis of accepted frameworks [72, 90].With this type of design 
improvements are attributed to the programme if improvements are found in every step of the 
causal pathway between intervention and outcomes and all other explanations can be 
formally discarded. In this study the main outcome of interest is prompt and effective 
treatment and steps in the causal pathway include :1) changes in understanding of malaria; 
2) changes in actions for the treatment of malaria and; 3) changes in access outputs, i.e the 
accessibility, availability and affordability of treatment, which were reported in a separate 
study [127] (Cf. Chapter 3). 
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It seems reasonable to credit the ACCESS social marketing campaigns for the observed 
changes in the understanding of malaria and the increased use of health facilities as a first 
treatment action. Indeed, no other efforts of this magnitude took place concurrently in the 
area. With regard to the lack of increase in health facility attendance in children, it is 
important to bear in mind that health facility attendance in this age group was already very 
high for a rural African setting with over 75% of children visiting a facility at some point during 
their illness. The high level of action already undertaken by mothers of small children at the 
start of ACCESS is undoubtedly the result of a long-standing effort in the area to improve 
comprehensively malaria control parameters [91, 126]. It is especially worthy of note that 
increases in health facility attendance were higher once adjusted for SES status. This would 
suggest the ACCESS social marketing campaigns were able to target even the less well off, 
which is far from always being the case [133]. This result is consistent with data from the 
evaluation of the Tanzania National Voucher Scheme, which found that road shows are able 
to disseminate messages more equitably than any other means of communication such as 
radios and billboards (Hadji Mponda, unpublished data).  
 
The more timely use of anti-malarials can be attributed to the combination of the ACCESS 
social marketing campaigns and the ADDO intervention. On one hand the ACCESS social 
marketing campaigns stressed the importance of prompt and effective treatment for malaria. 
On the other hand following the ADDO intervention treatment became more available and 
accessible [127] (Cf. Chapter 3). The good avaialabiltiy of ALu in health facilities in 2008, 
combined with the increase in health facility visits as a first treatment action is likely to also 
have contributed to the improved timeliness of treatment. It is worth highlighting here two 
positive outcomes with regards to the role of ADDOs and health facilities which emerged 
from this evaluation. Firstly self treatment at home did not increase significantly in neither 
children nor older patients suggesting that ADDOs did not undermine the role of the formal 
health sector, but rather complemented it.  Secondly, after the introduction of ADDOs, the 
proportion of children who were taken to a health facility and received an anti-malarial from a 
shop did not change (10-12%), which refutes claims that health facility staff refer patients to 
outlets in which they have a financial stake.  It is important the ADDOs continue to be 
adequately supervised for these gains to be sustained.  
 
The results presented here largely compatible with findings from the Smith et al. review [33], 
which concluded that interventions targeted at private sector providers generally show a 
good impact on provider practices. Similarly to the Kilifi Shopkeeper programme in Kenya 
[85, 113] and other studies targeting the private retail sector [114, 116-117] (but contrary to 
results by Winch et al. in Mali [86]),  the ADDO programme has achieved notable gains in 
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terms of the quality of advice given by shopkeepers. Ignoring the treatment policy change, 
the increase in the proportion of patients treated promptly and effectively according to the 
recommended regimen in the present study (from 32% to 63%) is comparable to the 
outcomes in Kilifi (from 2% to 29% treated promptly and effectively with the right dosage and 
duration) or in Mali (from 2% to 42% treated effectively with the right dosage and duration). 
However, this study has shown for the first time that improvements can be sustained even at 
much higher levels. Therefore key parameters can continue to be improved with targeted 
interventions, up to the 80% levels targeted by the Roll Back Malaria (RBM) Partnership [4]. 
 
The results presented here also confirm the reviewers’ conclusion that improving user 
practice is more challenging. Noticeable gains were made in terms of people’s actions for the 
treatment of fever (health facility attendance for patients older than five years, timeliness of 
treatment) but there was no clear improvement in the proportion of cases following the 
recommended regimen of anti-malarials. This appears to be the result of poor patient 
adherence, since mystery shopper surveys showed a substantial improvement in provider 
practice (Dillip et al, unpublished data). It is likely to be due to: 1) the introduction of a new 
treatment (ALu) with a more complicated regime than the previously recommended SP 
combined with; 2) the absence of messages targeted at users specifically focusing on  the 
importance of adhering to treatment regimens (although ALu was pre-packaged with clear 
instructions and pictograms).Future social marketing campaigns in the area should put more 
emphasis on this component.   
 
The community effectiveness chains show that treatment coverage with antimalarials is very 
high in the study area, but the change of treatment policy led to a significant drop in the 
proportion of patients taking a recommended malaria treatment. . Despite high levels of ALu 
stock in health facilities, the proportion of patients treated with ALu remained low partly 
because the drug was not widely available in drug shops. The decrease in the proportion of 
patients treated strictly according to guidelines should be seen in the light of the fact  that 
already in 2003 SP had a treatment efficacy of 50% [133], while ALu had a treatment efficacy 
of more than 95% [134]. The low availability of the first line drug in the private retail sector 
following the change of treatment policy from SP to ALu, coupled with the multiple stockouts 
of SP in public health facilities during the treatment transition clearly indicate that malaria 
treatment policy changes need to be considered in a more comprehensive way. Fortunately, 
ACTs will be made available in ADDOs in Tanzania in 2010 in the frame of the Affordable 
Medicine Facility for malaria [47].  
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Strategies to improve access to treatment should focus especially on the availability of points 
of care. The presence of a health facility or drug shop in the village of residence was the 
strongest predictor of prompt and correct treatment, whereas affordability (within the 
observed range of prices) and accessibility indicators contributed to a lesser extent. These 
results differ from those presented in a paper, which focused specifically on the farming 
season, and according to which fever cases which occurred in the farming sites were as less 
likely to be treated promptly and effectively as those which occurred in the main homestead 
[132]. This discrepancy is probably because of design issues, but the considerations from 
this analysis are largely consistent with a qualitative study on livelihood and health care 
which revealed that patients make considerable efforts to access treatment, including 
walking long distances and selling important livelihood assets [135]. Hence future 
interventions aimed specifically at improving access to treatment should focus on extending 
the network of health facilities and ADDOs to underserved villages and ensuring that drugs 
are available.  
 
The main limitation of this study is the selection of cases on the basis of reported fever only, 
since not every fever case is due to malaria. However considering every fever as a potential 
malaria case is consistent with the Integrated Management of Childhood Illness (IMCI) 
guidelines for treatment in areas of stable malaria [136]. This approach was warranted when 
the survey was designed in 2003 and the area experienced very high levels of transmission. 
This is no longer justified in the study area since 1) recent data suggest a drastic change in 
the epidemiology of malaria in the study area, and 2) a recent study piloting the use of Rapid 
Diagnostic Tests (RDT) for malaria in local health facilities found that only 40% of fever 
cases were actually due to malaria (D’Acrémont et al. unpublished data). It is difficult to 
assess how much the presence RDTs at the time of our surveys would have changed our 
observations.   
 
Another limitation concerns the variability observed in the samples and the inconsistency of a 
finding with another study conducted in the area. Despite a random sampling from the 
comprehensive DSS database households in 2008 were located further away from health 
facilities and drug shops despite an increase in the accessibility of these outlets [127] (cf. 
Chapter 3). Furthermore the distribution of patients across SES appeared to be unequal over 
the years, with wealthier households over-represented in the 2006 and 2008 samples.  To 
account for differences in SES across years all ORs of significant effects were reported 
crude and adjusted for SES.   
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Finally, it is worth pointing out that additional positive patterns of treatment emerged from this 
analysis which are not consistent with conclusions one might draw from  provider survey 
carried out in the study area [127] (cf. Chapter 3). Firstly, no patient in Ifakara was reported 
treated with artemisinin monotherapy although they were available in 10-20% of shops. And 
secondly, the severe stockouts of SP in the study area in 2006 did not appear to have an 
impact on treatment since the proportion of patients who obtained the drug did not decrease 
as a result. The reason for this apparent paradox is that availability data from health facilities 
is based on end-of-month balance in the store rooms. Hence, stocks may be delivered at the 
beginning of the month and dispensed in their entirety by the end of the month or drugs may 
not be in the store-room but still present in the dispensing room. 
  
4.6. Conclusions  
An integrated approach aimed at improving understanding and treatment of malaria has led 
to tangible improvements in terms of people’s perception and actions for the treatment of 
malaria. The positive results testify that even in a poor and remote African setting, the Abuja 
targets for access to treatment can be achieved. A higher impact on prompt and effective 
treatment according to treatment guidelines was hindered by a change of treatment policy, 
which led to low availability of the first-line drug (ALu) in the private retail sector. This shows 
clearly that ensuring consistent stocks of ALu in the private retail sector is crucial to improve 
prompt and effective treatment for malaria. Future interventions aimed at improving access to 
treatment by targeting users should have a focus on adherences to treatment regimens. 
Interventions targeting providers should aim at extending the network of health facilities and 
ADDOs to underserved villages.  
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5.1. Abstract 
Background 
The ACCESS programme aims at understanding and improving access to prompt and 
effective malaria treatment in rural Tanzania with a set of integrated interventions targeting 
both users and providers. The aim of this paper is to evaluate the programme’s impact on the 
community and health facility burden of malaria and to investigate the value of community-
based reporting for routine malaria control programme monitoring.  
 
Methods 
This work was implemented within the Ifakara Demographic Surveillance System (DSS) 
between 2004 and 2008. At community level the DSS staff routinely collected data on 
reported history of fever and severe malaria (convulsions) based on a two-week recall. In 
parallel we collected in-patient and out-patient fever and malaria diagnoses data from the 15 
health facilities in the area. Treatment seeking surveys conducted in the study area and 
nationally representative data were used to validate our measure of community fever.  
 
Results 
Between 2005 and 2008 community reported fever incidence rates in children under the age 
of five declined by 34%, from 4.9 to 3.2 average cases per child per year, while convulsions, 
a marker of severe malaria morbidity in children, decreased by  46%, from 4263 to 2320 
cases for every 100 000 children per year. The decrease in the community rates was 
paralleled by a decrease in the health facility fever rates in children, although the number of 
fever cases seen in health facilities did not change because of population growth. Our data 
showed very good internal and external consistency with independent local and national 
surveys. 
Conclusions 
There is evidence of a substantial decline in the community burden of malaria morbidity 
between 2005 and 2008 in the Kilombero and Ulanga DSS areas in Tanzania, most likely as 
a result of malaria control efforts. Meanwhile the health facility burden remained unchanged 
due to population growth. The good internal and external consistency of the data shows that 
history of fever in the previous two weeks in children under the age of five can be used as a 
morbidity monitoring tool.   
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5.2. Background  
  
“Without high quality surveillance, the billion dollar malaria effort is flying blind” [137].   
 
The massive increase in resources mobilised for malaria control calls for careful monitoring 
to ensure that money is spent effectively. Surveillance data are crucial at country level to 
know when targets are met and even more importantly to initiate mid-course corrections if 
progress is inadequate. Reliable evaluation data are also important as an evidence base to 
up-scale effective new interventions. The need for a comprehensive monitoring and 
evaluation plan has been recognised by donors and international technical agencies. This 
has led to the development of a comprehensive Monitoring and Evaluation (M&E) toolkit by 
the Global Fund to fight AIDS TB and Malaria (GFATM) to assist countries in developing 
robust M&E systems [72].   
 
The GFATM’s M&E toolkit is based on the widely applied input-output-outcome-impact 
framework and includes mortality and morbidity impact indicators. Mortality indicators are 
based on robust and validated methodologies [138-139]. They are widely used for the 
evaluation of malaria control efforts since the data can be obtained from nationally 
representative, cross sectional retrospective surveys such as the Demographic Health 
Surveys (DHS) [140], and the Multiple Indicator Cluster Surveys (MICS) [141].  However, 
mortality is multi-factorial and it is always difficult to tease apart the effect of malaria control 
from secular changes. The recommended morbidity indicators are parasite prevalence and 
anaemia prevalence. The Malaria Indicator Survey (MIS) [142] was especially designed to 
capture these two measures. Although the DHS, MICS and MIS also collect history of fever 
during the past two weeks, this measure is not widely used as a morbidity indicator and is not 
recommended in the M&E toolkit. Instead it is used as a basis for operational indicators such 
as “the percentage of children with fever in the previous two weeks who were treated with an 
antimalarial drug”. However, although parasite prevalence gives important information on the 
impact of control efforts on malaria transmission [143], it is not directly a morbidity indicator. 
In high endemicity areas control efforts may first have an impact on fever and then only later 
on prevalence due to the reduction of multiplicity of infections which reduces clinical 
episodes [144]. Anaemia prevalence has been shown to be a reliable indicator or malaria 
morbidity but is also an indirect measure with multi-factorial causality [145].  
 
The ACCESS Programme was implemented in two Tanzanian districts with the aim of 
improving access to malaria treatment. The programme’s interventions are based on an 
integrated approach which targets both users and providers and were accompanied by 
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monitoring and evaluation activities to assess its outcomes and impact [101]. Between 2004 
and 2008, the ACCESS Programme’s main intervention at user level was the implementation 
of social marketing campaigns for improved care seeking. At provider level key activities in 
health facilities included strengthening routine supportive supervision and the implementation 
of a quality management scheme. In parallel, the Accredited Drug Dispensing Outlets 
(ADDO) programme was piloted in the study area from 2006 onwards to improve the 
availability of drugs and quality of care people obtain from the private retail sector [87].  
 
The ACCESS M&E plan included the measurement of both outcome and impact indicators. 
Provider and user surveys conducted within the frame of programme showed an 
improvement in access outputs and treatment outcomes [102-127] (cf. Chapters 3 and 4) 
although treatment with antimalarials was already very high at baseline [88]. The proportion 
of recent fever cases treated with an antimalarial increased from 86% to 96% between 2004 
and 2008. This paper is concerned with the programme’s impact on morbidity and aims at 
assessing changes in the community and health facility burden of malaria between 2004 and 
2008 [146], In this frame we investigated the value of collecting history of fever in the 
previous two weeks at community level as a morbidity monitoring tool.  
 
5.3. Methods 
Study setting 
The ACCESS Programme’s monitoring and evaluation activities were imbedded within the 
Kilombero and Ulanga Demographic Surveillance System (DSS) in south-central Tanzania 
(Figure 22). It was established in 1996 and covers 25 villages (13 in Kilombero District and 
12 in Ulanga District). The population in 2004 was almost 74,000 and it increased to just over 
92,000 in 2008. There are six health facilities (one health centre and five dispensaries) in the 
Kilombero area and eight health facilities (one health centre and seven dispensaries) in 
Ulanga. Malaria transmission was intense and perennial with an entomological inoculation 
rate (EIR) of 350 [77], but has been declining over the past 10 years [78]. The area is 
characterised by a rainy season from November to May, with rain levels consistently 
increasing month by month until April [147]. More details on the study area can be found 
elsewhere [73, 101].  
 
Data collection and processing 
We collected data at community and health facility level between 2004 and 2008 with three 
independent instruments. The community based data included: 1) the collection of history of 
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fever and convulsions during the past two weeks with DSS based surveys and 2) three cross 
sectional treatment seeking surveys in 2004, 2006 and 2008 to elicit information about 
people’s actions in the event of fever. At health facility level we collected Health Management 
and Information Systems (HMIS) data from all the facilities in the area.  
 
Figure 22. Location of the Ifakara DSS site (source: Schellenberg et al. [73]) 
 
 
History of fever and convulsions - We integrated the collection of community reported fever 
and convulsions cases within the routine DSS data collection activities between May 2004 
and December 2008. Whereas fever (locally termed homa) is a proxy indicator for un-
complicated malaria, convulsions (degedege) are a sign of severe febrile illness, which 
includes cerebral malaria in children [96, 148]. Both signs are not highly specific for malaria, 
but under the assumption that other causes remain stable, they provide useful markers of 
malaria morbidity. DSS field workers visit every household in the area at four month intervals 
(three rounds per year) to collect data on birth, death, in-migration and out-migration.  Field 
workers collect information at village level by following a fixed schedule of household visits. 
Therefore, although each household is visited only every four months, data is effectively 
collected on a daily basis in each village. Given that each recorded case refers to fever in the 
past two weeks, each interviewed individual contributes two person weeks of observation. 
We therefore constructed the following approximated monthly fever and convulsions 
incidence rates for each of the 25 DSS villages [expressed in cases per 1000 person weeks 
(c/1000pw)]: 
 
2×
=
monthperterviewedinpeopleofnumbertotal
monthpercasesfeverreportedcommunityofnumber
ratefevercommunity  
2×
=
monthperterviewedinpeopleofnumbertotal
monthpersconvulsionfeverreportedcommunityofnumber
ratesconvulsioncommunity  
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Unfortunately, due to logistical constraints the data could only be collected on two thirds of 
the DSS population. However there was no indication that certain villages were consistently 
less visited than others and the distribution across ages was similar in every round and 
reflective of the DSS age distribution. Hence there is no reason to for this incomplete 
coverage to be biasing our estimates.  
 
Treatment seeking surveys - In 2004, 2006 and 2008 a village stratified random sample of 
approximately 100 community reported fever cases were followed up with treatment seeking 
surveys. These surveys were conducted by the DSS field workers between May and August 
each year (second round of data collection). Patients who had not recovered were not 
included and they were instead advised to seek care from a health facility. For the purpose of 
this analysis we only extracted data on the proportion of fever cases brought to a health 
facility at some point during the illness. A detailed analysis of the treatment seeking surveys 
is presented elsewhere [102] (cf. Chapter 4).  
 
HMIS data from dispensaries and health centres - Health facility data was collected by 
specifically trained field workers who visited all the 14 facilities in the area (two health centres 
and 12 dispensaries) on a two-monthly basis between January 2004 and December 2008. 
The data collected included all in-patient and out-patient diagnoses disaggregated by age 
group (children under the age of five and all other patients) on a monthly basis. We created 
catchment areas for each facility based on the village in which they are located. Some 
catchment areas included more than one health facility due to their proximity. Villages 
without a health facility were distributed equally between two health facilities were arbitrarily 
allocated to a given catchment area. By combining the data from the health facilities with the 
person time exposure data from the DSS database, we calculated the following monthly 
health facility fever and malaria incidence (c/1000pw) for each health facility catchment area: 
 
(
)
( )
malaria pneumonia respiratory in fections measles
typhoid urinary tract in fections diagnoses per monthHealth facility fever rate
person weeks exposed per month DSS
+ + + +
+ +
=  
( )
malaria diagnoses per monthHealth facility malaria rate
person weeks exposed per month DSS
=  
 
Mean imputation was carried out for the months were the data could not be obtained from 
health facilities: missing entries for a given month in a given health facility were replaced by 
the mean number of patients seen in the health facility over the years of observation. This 
method was considered appropriate since only 7.7% (153/1984) records were missing. 
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Statistical analysis 
We first estimated trends over time of the community fever and convulsions as well as the 
health facility fever and malaria rates. We then explored the validity of monitoring history of 
fever at community level by assessing the internal and external consistency of our data with 
surveys conducted in the study area and nationally representative surveys.  
 
Trends over time - Poisson regression models were fitted to estimate changes in the 
community and health facility burden of malaria. The fever, convulsions and malaria cases N 
in village or catchment area i were assumed to have arisen from a Poisson distribution, as is 
most appropriate for count data. We thus assumed that the rate of incidence is constant for 
every individual and that the variance is equal to the mean. Hence the following model was 
fitted: 
 
iiiiii umonthmonthyearY ++++++= 12...2)log(log 1221 βββαµ     (Model 1) 
 
where iµ  is the expected value of the rate ii YN  in village or catchment area i,  iY  are the 
person weeks exposed per month and )log( iY  is an offset term that ensures that the rate is 
being modelled on the log scale. The coefficient α  is the intercept term. Year is a continuous 
variable (from 2004 to 2008) and the exp( 1β ) is the estimated incidence rate ratio (IRR) of 
changes over the years and months. Month is a categorical variable denoting month of the 
year (from 1 to 12) which ensures that the estimate of exp( 1β ) is not confounded by monthly 
variations (seasonality). The random effect iu  explicitly allows for the clustering of rates in 
villages or catchment areas i and is assumed to follow a gamma distribution 
( )αα ,1~ Gammau i   with implies a mean 1 and variance α .  
 
Internal consistency - To address the internal consistency, we first correlated the health 
facility fever and community fever monthly rates to assess the temporal correlation between 
the two sources of data.  We then fitted a Poisson regression model on the community and 
health facility rates combined to estimate health the proportion of fever cases in the 
community that are brought to a health facility as well as changes in this proportion over 
time. These estimates were compared with independent information from the treatment 
seeking surveys. For this purpose cases and exposures were aggregated over villages and 
health facilities and the following models were fitted: 
  
HFmonthmonthyearY 11221 12...2)log(log γβββαµ ++++++=    (Model 2) 
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yearHFHFmonthmonthyearY *12...2)log(log 211221 γγβββαµ +++++++=  (Model 3) 
 
where HF  indicates the type of case that is being modelled and takes the value of 1 if the 
cases are health facility recorded cases and 0 if the cases are community reported. The 
coefficient exp( 1γ ) in Model 2 is an estimate of the ratio of health facility rates to community 
rates and therefore provides an estimate proportion of fever cases in the community that are 
brought to a health facility. The coefficient exp( 2γ ) of the interaction between type of case 
and year in Model 3 estimates the change over time of the proportion of fever cases brought 
to a health facility.  
 
External consistency - To assess the external consistency of our data, we compared our 
estimates with data from the 2004/5 DHS [26] and 2007/8 MIS [25]. Both surveys were 
carried out on a nationally representative sample of the population between October and 
January. First we compared the decrease in community fever from our surveys between 
2004 and 2007 with the decrease in fever reported in the DHS and MIS. We then compared 
the decreases in fever rates with decreases in under five mortality in both settings. Under five 
mortality rates for our study area were obtained from the DSS for 2004 and 2007 and were 
expressed as the number of cases per 1000 person years (c/1000py). Nation-wide estimates 
of under-five mortality for 2004 and 2007 were derived by disaggregating the 2007/8 MIS 
estimate using the methodology described by Masanja et al. [149] and are expressed as a 
probability of dying between birth and the fifth birthday for every 1000 live births (5q0). 
 
All data were double entered using Microsoft FoxPro and Microsoft Access (Microsoft  Corp. 
Seattle, USA)  and checked for coding errors and consistency.  Intercooled Stata 10 (Stata 
Corp., College Station, TX, USA) was used for data management and analysis. 
 
Ethics 
The National Institute for Medical Research of the United Republic of Tanzania 
(NIMR/HQ/R.8a/Vol.IX/236, 16th September 2003) granted ethical clearance for the study. 
 
5.4. Results 
The number of fever cases reported in 2004 appeared to be unrealistically high at community 
level and unrealistically low at health facility level (Table 15 and Figure 23) compared to 
values in subsequent years. A visual inspection of the rates suggests that more accurate 
reporting was achieved both at community level (Figure 23a and Figure 23b) and in health 
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facilities (Figure 23c and Figure 23d) after a year of data collection.  All the 2004 data was 
therefore excluded from any analysis.  
 
Table 15. Number of cases and person weeks of observation of community reported and health 
facility recorded cases between 2004 and 2008 
Level  Type of cases Year Cases Person weeks of 
observation (x 1000) 
Community  Fever 2004 18844 289,764 
  2005 16350 346,311 
  2006 14032 329,306 
  2007 18691 451,228 
  2008 11567 336,474 
 Convulsions 2004 590 291,321 
  2005 284 346,427 
  2006 213 330,576 
  2007 292 451,292 
  2008 152 340,666 
Health facility  Fever 2004 52875 3579,456 
  2005 67335 3573,468 
  2006 65342 3729,097 
  2007 77398 3818,092 
  2008 65223 4008,284 
 Malaria 2004 35011 3579,456 
  2005 45931 3573,468 
  2006 44562 3729,097 
  2007 55788 3818,092 
  2008 42358 4008,284 
 
The community fever and convulsions rates follow a clear seasonal pattern and have been 
decreasing over time. Seasonal peaks correspond with the middle of the rainy season 
(January to March) (Figure 23a and Figure 23b). The rates averaged over the year show a 
constant decrease in community fever rates between 2005 and 2008 from 47.2 c/1000pw 
(16350/346311) to 34.4 c/1000pw (11567/336475) in all ages. This corresponds to a 
decrease from 2.5 to 1.8 average cases per person per year i.e. an overall reduction of 28%. 
In children under the age of five fever rates decreased by 34% from 93.9 c/1000pw 
(5298/56403) to 61.6 c/1000pw (3419/55490), which means a decrease from 4.9 cases to 
3.2 cases per child per year. Convulsions are a much rarer event than fever and also 
decreased. Convulsion rates were 0.82 c/1000pw (284/346427) in 2005 (4263 cases for 
every 100 000 children per year) and 0.45 c/1000pw (152/340.667) in 2008 (2320 cases for 
every 100 000 children per year) which is equivalent to an overall reduction of 46% (Table 
15).  
 
The health facility rates exhibited much less seasonal variation and there was a less 
discernable pattern of change over time. Between 2005 and 2007 there appeared to be a 
trend of increasing rates but this was followed by a low value in 2008 driven by a particularly 
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low attendance in one of the health centres. In 2005 the median number of patients recorded 
per month was 523 (IQR=339 to 658) in dispensaries and 856 (IQR=693 to 1079) in health 
centres. These figures hardly changed in 2008 when the median number of patients 
recorded per month was still 523 (IQR=347 to 410) in dispensaries and 840 (IQR=745 to 
1220) in health centres. Between 2005 and 2008 malaria diagnoses consistently accounted 
for 67.4% of all fever cases in all the months of data collection (Table 15 and Figure 23c and 
Figure 23d).  
 
Figure 23. Community and health facility rates (note: y-axes differ across graphs) 
 
 
Trends over time 
Fitting Model 1 on the community reported rates shows a decrease in the incidence of both 
fever and convulsions. Overall community fever decreased by 10% per year (IRR=0.90 
95%CI=0.87 to 0.89) between 2005 and 2008. Rates decreased more steeply in children 
under the age of five at a rate of 13% per year (IRR=0.87 95%CI=0.85 to 0.87) (Table 16 and 
Figure 23). The incidence of convulsions in children also decreased considerably over the 
study period at an estimated rate of 21% per year (IRR= 0.79 95%CI=0.74 to 0.92).  
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Table 16. Estimated Incidence Rate Ratios (95% CI) and between village variance alpha (95% 
CI) of Poisson regressions fitted on monthly community reported fever and convulsion rates 
(2005 to 2008) with gamma distributed random effects to account for between village variance 
 Fever Convulsions 
 
All ages (n=1064) <5 years (n=1047) <5 years (n=1046) 
Year 0.90 (0.87 to 0.89) 0.87 (0.85 to 0.87) 0.79 (0.74 to 0.92) 
Month*    
 Jan 1 1 1 
 Feb 1.01 (0.97 to 1.05) 0.99 (0.91 to 1.07) 1.32 (0.90 to 1.94) 
 Mar 0.91 (0.88 to 0.95) 0.89 (0.82 to 0.97) 1.02 (0.70 to 1.50) 
 Apr 0.86 (0.82 to 0.90) 0.83 (0.75 to 0.91) 1.03 (0.66 to 1.61) 
 May 0.74 (0.70 to 0.78) 0.70 (0.63 to 0.77) 0.83 (0.52 to 1.34) 
 Jun 0.70 (0.66 to 0.72) 0.66 (0.61 to 0.72) 0.65 (0.43 to 0.97) 
 Jul 0.62 (0.59 to 0.65) 0.61 (0.58 to 0.68) 0.62 (0.41 to 0.94) 
 Aug 0.61 (0.57 to 0.65) 0.60 (0.54 to 0.68) 0.68 (0.39 to 1.20) 
 Sep 0.71 (0.67 to 0.74) 0.79 (0.72 to 0.87) 1.04 (0.67 to 1.62) 
 Oct 0.63 (0.60 to 0.65) 0.71 (0.66 to 0.77) 0.74 (0.49 to 1.11) 
 Nov 0.57 (0.54 to 0.60) 0.66 (0.61 to 0.72) 0.63 (0.41 to 0.97) 
 Dec 0.54 (0.50 to 0.57) 0.60 (0.53 to 0.68) 0.47 (0.24 to 0.89) 
Alpha 0.07 (0.04 to 0.12) 0.04 (0.02 to 0.08) 0.20 (0.11 to 0.38) 
*LLR test of inclusion: fever all ages chi=2514.23  p<0.001, <5yrs chi=562.93  p<0.001,  convulsions chi=63.27 p<0.001 
 
Model 1 was also used to estimate the extent to which the community fever cases were 
overreported in the first year of data collection (first round January to April 2004 but data was 
only collected from March onwards, second round May to August 2004 and third round 
September to December 2004). The extrapolation suggests an overall overestimation of 
79.6% in the first round of collection (actual number of cases reported 9456 vs. estimated 
5265 for 83 434 person weeks of observation); 43.7% in the second round of data collection 
(6432 vs. 4469 cases for 95 718 person weeks); and 39.7% in the third round (6048 vs. 4329 
cases for 99087 person weeks).  
 
Health facility rates were also estimated to have decreased over the study period, but to a 
much lesser extent. The IRR of fever and malaria rates in adults over time were estimated at 
values very close to one (fever IRR=0.98 95%CI=0.98 to 0.98, malaria IRR=0.97 
95%CI=0.97 to 0.98) suggesting an only very slight decrease over time. A more appreciable 
decrease was estimated for rates in children; health facility fever rates were estimated to 
have decreased by 6% per year (IRR=0.94 95%CI=0.94 to 0.95) and malaria rates by 7% 
per year (IRR=0.93 95%CI=0.92 to 0.93) (Table 17). 
 
Accounting for the seasonality of the data by including a categorical factor for the month of 
the year did not affect the estimated change over time. The log likelihood ratio test for the 
inclusion of months of the year was highly significant in all the models estimating trends over 
time (Table 16 and Table 17). However the inclusion of this variable only slightly affected the 
size of the IRR estimating the changes over the years in the community rates. More 
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specifically the models fitted excluding months of the year overestimated the decrease over 
time, but only by 1% point (fever all ages IRR=0.90 95%CI=0.89 to 0.91, fever children <5 
IRR=0.86 95%CI= 0.85 0.88, convulsions IRR=0.78 95%CI= 0.74 to 0.84). The exclusion of 
the variable did not affect the size of the IRRs for the health facility rates.  
 
Table 17. Estimated Incidence Rate Ratios (95% CI) and between health facility catchment 
variance alpha (95% CI) of Poisson regressions fitted on monthly health facility fever cases and 
malaria diagnoses rates (2005 to 2008) with gamma distributed random effects to account for 
between area variance (n=432) 
 Fever cases Malaria diagnoses 
 
All ages  <5 years All ages <5 years 
Year 0.98 (0.98 to 0.98) 0.94 (0.94 to 0.95) 0.97 (0.97 to 0.98) 0.93 (0.92 to 0.93) 
Month*     
 Jan 1  1 1 1 
 Feb 1.00 (0.98 to 1.02) 0.99 (0.97 to 1.01) 0.99 (0.97 to 1.01) 0.97 (0.95 to 1.00) 
 Mar 0.91 (0.89 to 0.92) 0.92 (0.89 to 0.93) 0.86 (0.85 to 0.88) 0.87 (0.84 to 0.89) 
 Apr 0.86 (0.84 to 0.87) 0.94 (0.92 to 0.96) 0.77 (0.76 to 0.79) 0.85 (0.83 to 0.87) 
 May 0.89 (0.87 to 0.91) 0.87 (0.85 to 0.89) 0.81 (0.79 to 0.83) 0.79 (0.76 to 0.81) 
 Jun 0.87 (0.85 to 0.88) 0.85 (0.83 to 0.87) 0.79 (0.77 to 0.81) 0.78 (0.75 to 0.80) 
 Jul 0.80 (0.78 to 0.81) 0.77 (0.76 to 0.79) 0.74 (0.72 to 0.75) 0.72 (0.70 to 0.74) 
 Aug 0.84 (0.82 to 0.85) 0.81 (0.79 to 0.83) 0.78 (0.76 to 0.79) 0.76 (0.74 to 0.79) 
 Sep 0.90 (0.88 to 0.91) 0.89 (0.87 to 0.92) 0.83 (0.81 to 0.85) 0.84 (0.82 to 0.86) 
 Oct 0.87 (0.85 to 0.88) 0.90 (0.88 to 0.92) 0.82 (0.80 to 0.83) 0.85 (0.83 to 0.86) 
 Nov 0.90 (0.88 to 0.91) 0.88 (0.86 to 0.91) 0.83 (0.81 to 0.84) 0.83 (0.81 to 0.86) 
 Dec 0.78 (0.77 to 0.79) 0.76 (0.74 to 0.77) 0.74 (0.72 to 0.75) 0.73 (0.71 to 0.76) 
Alpha  0.30 (0.12 to 0.72) 0.36 (0.15 to 0.86) 0.23 (0.10 to 0.57) 0.27 (0.11 to 0.65) 
*LLR test of inclusion fever all ages chi=1440.82 p<0.001, <5yrs chi=1063.87 p<0.001; malaria diagnoses all ages chi=1730 
p<0.001,  <5yrs chi=1005.58 p<0.001 
 
 
The inclusion of a random effect to account for the fact that different villages or catchment 
areas might have different rates did not affect the estimated change over the years either. 
However, the variance alpha of the random effects was significantly different from zero in all 
the models fitted (Table 16 and Table 17), suggesting that there is clustering between 
villages or catchment areas and that random effects should be included in the models to 
account for this.  
 
Internal and external consistency of the data 
The community fever rates correlate very well with fever rates from health facilities in children 
under the age of five (r=0.81 p<0.001) but less so in all patients (r=0.67 p<0.001) (Figure 24).   
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Figure 24. Community fever rates and health facility fever rates by age group between 2005 and 
2008 
 
 
Combining the fever rates at health facility and community level and comparing the results 
with the treatment seeking surveys shows reasonable but not all round internal consistency.  
According to the independent cross-sectional treatment seeking surveys, the proportion of 
fever cases brought to a health facility did not change significantly between 2006 and 2008 
and was estimated around 68% in children and 65% in all ages [children from 67.3% (37/55) 
in 2006 to 69.2% (27/39) in 2008 OR=1.05 95%CI = 0.67 to 1.63, all patients 61.2% (63/103) 
in 2006 to 69.7% (60/86) in 2008 OR=1.21 95% CI=0.89 to 1.64]. Model 2 estimated the 
proportion of fever cases brought to a health facility to be 72% (IRR=0.72 95%CI=0.70 to 
0.73) in children under the age of five and 45% (IRR=0.45 95%CI=0.45 to 0.46) in all patients 
between 2006 and 2008. According to Model 3 the proportion of fever cases brought to a 
health facility increased by 8% per year (IRR=1.08 95%CI=1.07 to 1.10) in children and by 
9% per year in all patients (IRR=1.09 95%CI=1.08 to 1.10) between 2006 and 2008. Hence 
the estimated proportion of fever cases brought to a health facility was the same according to 
the treatment seeking surveys and Model 2 in children (but not in adults); and Model 3 
suggests a higher increase over time in proportion of fever cases brought to a health 
compared to the treatment seeking surveys. 
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There is very good external consistency between our data and data from the national DHS 
and MIS. These surveys report a decrease in the percentage of fever in the past two weeks 
from 25% for the period October 2004 to January 2005 to 18% for the period October 2007 
to January 2008. This is equivalent to a 26% decrease in fever prevalence over the three 
years of observation. This was associated with a 8% decrease in mortality from 97.2 5q0 in 
2004 to 89.5 5q0 in 2007 (ratio of fever to mortality decrease = 3.3).  An extrapolation of our 
fever data (Model 1) estimated a fever incidence of 107.3 c/1000pw for the period October 
2004 to January 2005 and 73.2 c/1000pw for the period October 2007 to January 2008. This 
is equivalent to a 32% decrease in fever, very close to the 26 % decrease at national level.  
In the Kilombero and Ulanga DSS  this was associated with a 12% decrease in mortality from 
25.3 c/1000py to 22.2 c/1000py (ratio of fever to mortality decrease = 2.6). 
 
5.5. Discussion  
The data presented here document a decline in malaria morbidity between 2005 and 2008 in 
the highly malaria-endemic Kilombero and Ulanga DSS areas. Community reported fever 
incidence rates declined by 10% per year in the overall population and by 13% per year in 
children under the age of five. There is also an indication of a decrease in severe malaria 
morbidity as indicated by a 21% decrease in the incidence of reported convulsions in 
children. The decrease in the community burden of malaria in children is accompanied by 
decrease in the health facility fever rate in children (6% and 7% per year respectively) but not 
as much in the overall population (2% and 3% per year). However, due to population growth 
the average number of cases per month in health facilities remained constant, implying that 
there was no change in the health facility burden of fever and malaria. 
 
Data available from separate studies conducted in the study area provide evidence that the 
decline in community fever and convulsions is paralleled by a decline in malaria 
transmission. Data from two other projects documented a decrease in parasitaemia in 
children under five from 25% in 2004 [150] to 10% in 2008 (Mulokozi et al., unpublished 
data). While an older study reported an Entomological Inocluation Rate (EIR) of 349 infective 
bites per person per year (ib/p/y) between 2001 and 2003 [81], by 2008 the EIR had declined 
to 81 ib/p/y [78].  Under-five mortality decreased from 24.5 c/1000py to 18.9 c/1000py (cf. 
Chapter 6). These data for other malariometric indicators gives us confident that the 
decrease we observed in fever rates is to a large extent malaria-related. This is obviously 
important because we could not assess independently the proportion of true malaria cases 
among all the fever episodes. 
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The increased treatment coverage may have contributed to the decrease in morbidity. The 
first line treatment for malaria in Tanzania was Sulphadoxine Pyrimethamine (SP) until 2006 
when it was replaced by the Artemisinin Combination Therapy (ACT)  Artemether-
Lumefantrine (ALu) due to high levels of resistance to SP. The long half life of SP [151] and 
its prophylactic effect have been clearly documented [152]. The treatment of any potential 
malaria case with SP not only clears parasites in true cases of malaria but also provides 
chemoprophylaxis for four weeks in both those who were and those who were not infected, 
which in turn reduces the parasite burden in individuals and the infectious reservoir in the 
community.  This has led to the hypothesis that widespread presumptive treatment with the 
drug contributes to a decrease in transmission based on the observation the malaria started 
decreasing in Kenya before the widespread use of ITNs [153]. Conversely ACTs have 
gametocidal properties [154-156] and it has been suggested that this can have an impact on 
transmission [157]. In our study area malaria treatment has reached very high levels, with an 
increase in the proportion of fever cases treated with an antimalarial from 86% in 2004 to 
96% in 2008. SP was used to treat 30-40% of all identified cases between 2004 and 2008, 
while ALu was used in a third of cases in 2008 (with most of the remaining cases still treated 
with SP). Hence, it is reasonable to ascribe part of the observed decrease in malaria-related 
fevers to improved treatment. 
 
The increased vector control in the area over the same period most likely also explains a 
large part of the decrease in transmission and morbidity. A very high mosquito net coverage 
has been achieved in the study area following the nation-wide up-scaling [77, 158] of the 
KINET scheme for the promotion and subsidisation of nets [91]. Mosquito net coverage 
remained largely unchanged between 2005 and 2008 with over 90% of household 
ownership. However, this does not rule out continued effect over time since recent modelling 
work suggests that sustaining coverage with ITN at such levels may lead to constant 
decreases in transmission even if coverage does not increase (personal communication, 
Prof. Tom Smith, Swiss Tropical and Public Health Institute, Basel). Furthermore most nets 
were untreated in 2005 [77] but by 2008 nearly half of the nets were treated [78]. A recent 
study concluded that the addition of long-lasting insecticide treatment of bednets in the area 
was able to reduce the intensity malaria transmission 4.6-fold [78]. Increased IPTp may also 
have played a role in decreasing morbidity, especially in children. According to regional data 
the proportion of women who received two doses of SP during their pregnancy increased 
from 23% in 2004 to 44% in 2007 [25-26]. Unfortunately there is no way to conclusively 
estimate the relative contribution of each intervention to the observed decrease in 
transmission and morbidity on the basis of only empirical data. Future mathematical 
modelling may provide answers to these questions.  
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The good internal and external consistency of our data shows that reported history of fever in 
the previous two weeks can be used to monitor the community burden of malaria in children 
under the age of five reliably in highly malaria endemic areas.  As far as internal consistency 
is concerned, we were able to show that: 1) community fever rates were very highly 
correlated health facility fever rates in children under the age of five and; 2) estimates of 
health facility attendance for fever (i.e. the proportion of fever cases in the community 
brought to a health facility) resulting from the ratio of health facility to community rates are 
similar to those obtained from and independent treatment seeking survey. In addition our 
data showed good external consistency with national data. Although a slightly lower 
decrease in incidence of fever was observed at national level compared to our study site 
between 2004 and 2007 (25% vs. 32%), the ratio of fever incidence decrease to under-five 
mortality decrease was comparable in both settings (3.3 vs. 2.5). This finding is of high 
interest to malaria control programmes because it offers for the first time a validated 
community-based measure of malaria morbidity that can be used for monitoring. It follows 
that fever recall data collected by representative household surveys such as the DHS, MICS 
and MIS can be analysed to monitor morbidity trends and impact. 
 
However, there is an important caveat associated with the use of fever recall as a morbidity 
monitoring tool. Our experience shows that cases are substantially over-reported when the 
question “Have you had fever in the past two weeks” is asked for the first time, and this is 
consistent with finding from other studies [159-160].  A possible explanation is that 
respondents do not only report episodes which occurred in the past two weeks but also 
previous ones. According to our data, respondents are better able to limit reporting to 
episodes that occurred strictly within the requested time interval after three rounds. Therefore 
fever rates based on a two week recall in cross-sectional household surveys such as the 
DHS, MICS and MIS are likely to be overestimated. Fortunately, consistency checks 
between our data and the 2007/8 Tanzania MIS and the 2004/5 DHS suggested that over 
reporting is consistent between surveys and therefore does not jeopardise the comparability 
of data collected in the frame of different surveys and these estimates can still be used to 
assess changes over time. However, it implies that such data should not be used for 
example to derive the number of fever-related commodities required in a given population 
(typically antimalarial drugs and diagnostic tests) as estimates are likely to be too high.  
We were not able to validate the use of history of convulsions in the past two years in the 
frame of this study. It can be argued that the incidence of convulsions it the only marker of 
severe malarial disease that can be monitored at community level. There is evidence from a 
hospital study conducted in the Kilifi District Hospital in Kenya [161] that approximately 50% 
of convulsions in malaria endemic settings can be attributed to malaria. However we cannot 
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exclude the possibility that estimates of incidence of convulsions based on reported data are 
biased. Our estimates were about 10 times higher than those reported in Kilifi (from 4300 to 
2300 cases for every 100 000 children per year between 2005 and 2008 compared to 235 
cases per 100 000 per year in 2006). On one hand it is recognised that hospital estimates of 
incidence are lower than what would be expected at community level in most of sub-Saharan 
Africa where many cases are managed at home [5]. The authors themselves caution that 
many children with convulsions may have died without reaching the hospital and that a few 
may have been treated successfully in peripheral health facilities. On the other hand, it is 
likely that our estimates are too high because the same recall bias that was seen for simple 
fever estimates may have led to reporting bias. It is well possible that a rare and dramatic 
event such as a convulsion in a small child might have led to recall beyond the two weeks 
that we were asking for. 
 
Our data confirm that “caution is required when using health facility-based data to evaluate 
the health impact of malaria control efforts in Africa” [146]. The main concern with health 
facility records is obviously their quality. Our experience shows that in absence of constant 
supervision records were often not filled in. Acceptable reporting was only achieved after one 
year of repeated visits and we had to discard the data from the first year of data collection. 
Furthermore, health facility staff mostly relies on presumptive diagnosis of malaria in malaria 
endemic countries [82]. The data we presented here shows that the proportion of fever cases 
diagnosed did not change throughout the year. Both during the months of high transmission 
and during the months of low transmission approximately two thirds of fever cases were 
systematically diagnosed as malaria. Rapid diagnostic tests (RDT) for malaria were 
introduced in three out of the 14 health facilities in the area in late 2007. Although a decrease 
in malaria diagnoses was observed in those facilities (Robert Tillya, in preparation), this 
effect was diluted in our study when the data was aggregated over all the facilities  
 
Beyond data quality issues, relying exclusively on health facility data can lead to biases. 
Firstly, they do not take population growth into account. Our results clearly show that 
population growth can affect results, since despite decreases in health facility fever and 
malaria rates there was no impact on the absolute number of cases seen in health facilities 
which ultimately represents the burden of malaria at health facility level. Secondly, health 
facility users are not necessarily representative of the population at large when the proportion 
of cases brought to a health facility is low, which is often the case in resource-limited 
countries [5]. In our study, the decline in community fevers was matched by a decline in 
health facility fevers in children under the age of five, the majority of which attended a health 
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facility (72%) but not in the overall population for which health facility attendance was much 
lower (estimated between 45% and 57%).  
 
5.6. Conclusions  
The community burden of malaria morbidity declined between 2005 and 2008 in the 
Kilombero and Ulanga DSS most likely as a result of malaria control efforts. Meanwhile the 
health facility burden of the disease remained unchanged due to population growth. The 
good internal and external consistency of our data strengthens our conclusions and shows 
that history of fever in the previous two weeks can be used as a community-based morbidity 
monitoring tool.  
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6.1. Abstract  
Background 
The ACCESS Programme was implemented between 2004 and 2008 in the Kilombero and 
Ulanga Districts of south-central Tanzania to improve access to malaria treatment with a set 
of interventions targeting users and providers. This paper aims at assessing the ACCESS 
programme’s impact on mortality. 
Methods 
The local Demographic Surveillance System (DSS) provided monthly and yearly estimates of 
under-five, infant and child mortality rates expressed as cases per 1000 person years 
(c/1000py) between 1997 to 2008. We used Poisson regressions to assess the impact of the 
ACCESS interventions accounting for the effect of other malaria interventions and contextual 
factors. We also attempted to understand the relative contribution of malaria risk and food 
availability to monthly variations in mortality.  
Results 
Under five mortality decreased from an average of 28.4 c/1000py in the years before 2004 to 
18.9 c/1000py in 2008 but this was part of a longer secular trend dating back to 1997. The 
ACCESS interventions and Insecticide Treated Nets (ITN) coverage were independently 
associated with decreases in mortality, accounting for the effect of other malaria 
interventions and contextual factors (ACCESS: IRR comparing before 2004 vs. 2008=0.83, 
95%CI=0.68 to 0.99; ITNs: IRR for every 10% increase in net ownership=0.97, 95%CI=0.95 
to 0.98). Decreases in under five mortality were largely driven by decreases in infant 
mortality while child mortality (ages 1-4 years) remained constant. Infant deaths were more 
likely to occur in months of high transmission whereas child deaths were more frequent in 
months of low household food availability. 
Conclusions 
Improving access to malaria treatment appears to be a successful strategy along with 
increasing ITN coverage. Most of the decrease in under-five mortality has been driven by 
decreases in infant mortality. Little gains have been made in child mortality, which appears to 
be mainly driven by household food insecurity. Child survival programmes should recognise 
the important contribution of malnutrition to morbidity and mortality.  
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6.2. Background 
 
Prompt treatment of malaria episodes is a core component of malaria control and elimination 
strategies [4]. Impressive progress has been achieved in product development and in 
securing a substantial international support, so that most African countries have now 
switched to the highly efficacious Artemisinin-Combination Therapies (ACT). Despite this, 
surveys conducted between 2007 and 2008 in 11 African countries found that despite large 
increases in the supply of antimalarial treatments, only 32% of children with fever were 
treated with antimalarial drugs and only 15% with ACTs [32].  
 
The low coverage of antimalarial treatment is largely explained by people’s inability to access 
this class of drugs, and little progress will be made unless broader access issues are tackled. 
The ACCESS programme implemented between 2004 and 2008 in the Kilombero and 
Ulanga Districts of south central Tanzania was one of the first initiatives to address access 
issues in a comprehensive way, with a set of interventions and monitoring and evaluation 
(M&E) activities targeting users and providers [101]. Since, a number of initiatives have also 
put access on their agenda, including the Medicines for Malaria Venture (MMV) [162], the 
ACT consortium [163] and the Clinton Foundation [164]. Recently, the Global Fund to Fight 
AIDS Tuberculosis and Malaria (GFATM) has started planning the implementation of an 
innovative funding mechanism which aims at improving the availability and accessibility of 
effective antimalarial drugs in the private retail sector - the Affordable Medicines Facility for 
malaria (AFMm) [47].  
 
As a result of ACCESS interventions there is evidence of an increase in access to malaria 
treatment [127] (cf. Chapter 3) and better quality treatment for malaria  [102] (cf. Chapter 4). 
Recently, an impact on morbidity has been documented in the study area (cf. Chapter 5). 
The present paper is concerned with the impact on infant and child mortality of improved 
treatment seeking and treatment quality.  While technically feasible because of the presence 
of a full demographic surveillance site in the area, the major problem with such an 
assessment is the multiplicity of causes of death, and the difficulty to distinguish them. Not 
only do most children die at home [5] but causes are multifactorial in the sense that more 
than one cause is required to overwhelm a child’s body and lead to death.  Here we 
investigated the relative contribution of malaria risk, climate and food availability to monthly 
variations in infant and child mortality.  
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6.3. Methods 
 
Study setting 
The ACCESS Programme was implemented in the Kilombero and Ulanga Districts in south-
central Tanzania (Figure 25). The area has been extensively described elsewhere [73, 101]. 
The total population of the two districts was 517,000 in 2002 according to the national census 
[165]. Malaria transmission in the area is intense and perennial [77, 78]. The area is 
characterised by a rainy season from November to May.  
 
Figure 25. Location of the Ifakara DSS site  
 
 
 
The area is predominantly rural with over 95% of its population reporting farming as their 
main activity [73]. Rice is the main staple food and the most important cash crop in the area. 
Maize and cassava are also grown, but mainly for household consumption. Over 80% of total 
farmed land is used for growing paddy and farmers sell about 50% of they grow [74]. Most of 
the rice paddies lie in lowlands and are rainfed. Production per hectare is fairly low compared 
6. Assessing the impact on mortality        101 
 
 
to its potential [75], partly due to the low uptake of new high yield varieties and the reduced 
use of fertiliser, but also because of the reliance on manual labour for land preparation and 
weeding [74] [76]. As a consequence, rice production and people’s livelihood in the area is 
extremely reliant on adequate rainfall.  
 
Malaria control interventions 
Coverage and outcomes of ACCESS Interventions - The ACCESS programme was 
implemented in the whole of the Kilombero and Ulanga Districts between 2004 and 2008 to 
improve access to prompt and effective malaria treatment by targeting both users and 
providers [101]. Interventions were carried out at three levels: 1) the community, 2) the 
formal health sector and 3) the private retail sector for drugs. The community intervention 
consisted of a social marketing campaign for more effective care seeking. Key activities in 
the public health sector included refresher training for health facility staff based on Integrated 
Management of Childhood Illness (IMCI) algorithms and strengthening the role of the Council 
Health Management Teams (CHMT). The intervention in the private retail sector were 
implemented by the Tanzanian Food and Drug Administration (TFDA) and Management 
Science for Health (MSH) and consisted of the roll out of Accredited Drug Dispensing Outlets 
(ADDOs) in the study area from 2006 onwards to improve access to quality treatment in the 
private retail sector for drugs [57, 87]. In addition in 2006 Tanzania changed its first line 
treatment for malaria from Sulphadoxine-Pyrimethamine (SP) to Artemether-Lumefantrine 
(ALu). 
 
Between 2004 and 2008 the ACCESS and ADDO programmes achieved a very high 
coverage. The ACCESS Social marketing campaigns were conduced in 96% (78/81) of the 
villages in the Kilombero District and 95% (62/65) of the villages in the Ulanga District. 
Between 2006 and 2008, 135 ADDOs were opened in the Kilombero District and 55 the 
Ulanga District (equivalent to approximately three shops per 10 000 people in both districts). 
In 2004 and 2005 91% (94/103) of all health workers in the Ulanga District and 93% (39/42) 
of clinical officers in the Kilombero District attended a refresher training on malaria case 
management within the framework of IMCI organised jointly organised by ACCESS and the 
CHMT. Between 2006 and 2008 55 ADDOs were opened the Ulanga district and 135 in the 
Kilombero district (equivalent to approximately three shops per 10 000 people in both 
districts). The programme’s monitoring and evaluation activities showed and an improvement 
in access outputs in terms of availability and accessibility of retail outlets [127] (cf. Chapter 3) 
and hence better treatment outcomes: the percentage of fever cases treated within 24hrs 
increased from 67% to 89% between 2004 and 2008 [102] (cf. Chapter 4).  
 
6. Assessing the impact on mortality        102 
 
 
Other malaria control interventions - Three other major interventions took place in the study 
area and needed to be controlled for in the analysis. The KINET project for the promotion 
and subsidisation of Insecticide Treated Nets (ITNs) [126] was implemented between 1997 
and 1999 and resulted in a 73% ownership of nets by 2000 [77, 91] from an initial coverage 
of 37%. Since 2000, the KINET model has been upscaled nation-wide within the frame of the 
Tanzania National Voucher Scheme (TNVS) programme [158]. The area has also seen two 
changes in the national treatment policy for malaria. Chloroquine was abandoned in favour of 
Sulphadoxine-Pyrimethamine (SP) in 2001 due to widespread resistance. However, high 
levels of resistance to SP developed within two years of its introduction [133] and in 2007 the 
ACT Artemether-Lumefantrine (ALu, trade name Coartem®) replaced SP as the first line 
treatment for malaria. This change of treatment policy resulted in improved availability of 
antimalarials in health facilities in 2007 and 2008 due to the implementation of a push system 
of delivery [127] (cf. Chapter 3). In addition, in 2000 the Kilombero and Ulanga Districts 
decided to implement the “facility based” IMCI interventions which aim at improving case-
management in health facilities while at the same time strengthening the health system [34] 
[166]. 
 
Data collection and processing 
Mortality rates - The Ifakara Demographic and Surveillance System (DSS) area provided 
data on mortality.  The DSS was established in 1996 and covers 25 villages (13 in Kilombero 
and 12 in Ulanga) [73]. The population in 2004 was almost 74,000 and just over 92,000 in 
2008. We calculated estimates of under-five annual mortality rates (ages 0 to 5 years), infant 
mortality rates (ages 0 to 1) and child mortality rates (ages 1 to 5) as the number of deaths 
per 1000 person years of exposure (c/1000py).  
 
Malaria control interventions – In the absence of a control group we could only evaluate the 
effect of the ACCESS interventions and the changes of national treatment policy by 
comparing mortality rates before and after their introduction. One issue is the quantification 
of the year-to-year development in coverage of the interventions. We could at least obtain 
yearly ITN coverage data (percentage of households owning at least one mosquito net) from 
the DSS routine data collection for the 12 years of observation, and the time point for the two 
changes in first-line antimalarial is also well defined. To the best of our knowledge, no major 
other malaria or health intervention took place in the area during the period of observation. 
The number of health facilities did increase less rapidly than population growth. 
 
Contextual factors - We collected data on rainfall and agricultural production as the two main 
potential confounding factors. The Kilombero Agricultural Training and Research Institute 
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(KATRIN) provided monthly rainfall data (mm) which it collects from gauges located just 
outside Ifakara. We obtained yearly agricultural yield (tons/ha) of rice and maize from the 
Kilombero District Agricultural and Livestock Development Office (DALDO).   Because of the 
similarity of the environment in both districts we extrapolated the values for Ulanga from 
those of the Kilombero District. 
 
We constructed a proxy for monthly food availability (kg per household) on the basis the 
agricultural yield data and information describing the agricultural practices of the local 
farmers. We estimated food availability in a given month as the sum of the availability of rice 
and maize, with rice availability peaking in June and maize availability in March, when they 
are harvested [74, 167]. The initial amount of rice and maize in a given year was calculated 
by multiplying the rice yield of that year by 1.5 hectare (ha) for rice and 0.24 ha for maize, the 
average areas that a household dedicated to each of the two crops [74]. We assumed that 
1/10 of the rice harvest was already available in May when harvesting starts. Given that on 
average farmers sell half of their rice crops [74, 76], we applied a composite decay function 
for rice. The half that is kept for personal consumption was assumed to decrease linearly 
every month (1/12 of half of the initial amount per month). The half that is sold was assumed 
to decrease at an exponential rate (1/2 of the amount in the previous month every month), 
which ensured that bigger quantities are sold in the months following the harvest and most of 
the rice is sold by the beginning of the rainy season [167]. We applied a linear decay to 
maize (1/12 of half of the initial amount per month), given that it is usually only used for 
household consumption [167]. 
Statistical analysis  
We estimated the change in yearly under-five mortality rates before and after the ACCESS 
intervention, (excluding the years of intervention between 2004 and 2008) by means of a 
Poisson regression. The effect of ACCESS was assessed with a binary variable taking the 
value zero in the years from 1997 to 2004 and one in 2008. The following variables 
accounted for the effect of the other malaria interventions: 1) a binary variable denoting years 
before and after the IMCI training with value zero before 2003 and one thereafter; 2) a 
categorical variable denoting the first line treatment for malaria; 3) a binary variable denoting 
years of change in treatment policy with value one in years coinciding with a the first year of 
introduction of a new drug and zero otherwise; 4) a continuous variable denoting household 
mosquito net ownership. In addition the two following continuous variables accounted for the 
effect of contextual factors: 1) total annual rainfall; and 2) agricultural yield.  
 
First. we explored the univariate relationship between mortality and all the explanatory 
variables. We then fitted two multivariate Poisson models, one including the effect of 
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ACCESS and one excluding them. This was necessary because the change of treatment 
policy took place during the ACCESS years and their effects cannot be estimated in the 
same model due to co-linearity. 
 
To better understand the determinants of the inter-annual variations in under five mortality 
we regressed monthly infant and child mortality rates against monthly rainfall and food 
availability data. We used monthly rainfall as a proxy for malaria transmission on the basis of 
the very high correlation between monthly rainfall and the entomological inoculation rate 
(EIR) in the study area [78]. We also lagged rainfall by one and two months [168] since 
health facility studies conducted in the area show that the proportion of children with malaria 
infections is highest in January and February (Valérie D’Acrémont, personal communication), 
whereas rainfall peaks in March and April (probably because larval habitats get washed 
away with very heavy rain [169]). We used food availability as a combined proxy for nutrition 
and this was also lagged by one and two months to allow for delayed and cumulative effects 
of food availability on children’s health. We explored the relationships between mortality and 
these explanatory variables with univariate and multivariate models.  
 
Intercooled Stata 10 (Stata Corp., College Station, TX, USA) was used for all data 
management and analysis. Multivariate models were built by stepwise elimination of 
variables with a Wald test probability values less than 0.2.  
 
6.4. Results  
Impact of ACCESS interventions 
Annual under five mortality decreased from an average of 28.4 c/1000py (2405/84,576) in 
the years before 2004 to 18.9 c/1000py (299/15,793) in 2008. However, this decrease is part 
of a longer secular trend which started at least in 1997, when mortality was as high as 31.7 
c/1000py (284/8.951) (Table 18 and Figure 26). ITN household ownership increased steadily 
from 37% in 1997 to above 90% in 2005, remaining constant at this level throughout the 
study period (Figure 27). Over the study period the average rice yield was 1.8 ton/ha 
(SD=0.36) and the total annual rainfall was 1510mm (SD=392). There was no secular trend 
in rice yield or annual rainfall. Rice yield is very highly correlated with rainfall (r=0.835 
p<0.0001). In 2003 mortality peaked to 1997 levels and this coincided with a severe drought 
which affected rice crops very negatively. Two lesser peaks in mortality (in 2000 and 2005) 
also coincided with lower than average rainfall and hence agricultural yield (Figure 26 and 
Figure 28). 
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Table 18. Under five annual mortality rates between 1997 and 2008 
Year Cases Person years 
exposed 
Rate 
(c/1000py) 
1997 284 8952 31.7 
1998 249 8879 28.0 
1999 246 8673 28.4 
2000 298 10078 29.6 
2001 284 11266 25.2 
2002 345 11968 28.8 
2003 392 12167 32.2 
2004 307 12593 24.4 
2005 346 12824 27.0 
2006 318 13732 23.2 
2007 325 14657 22.2 
2008 299 15793 18.9 
 
 
There is evidence of a significant decrease in under five mortality from 1997 to 2008. 
Between 1997 and 2008 under five mortality decreased by 3% per year (IRR=0.97 
95%CI=0.96 to 0.98). This decrease was mainly driven by a decrease in infant mortality 
whereas child mortality did not change significantly. Infant mortality decreased from 99.68 
c/1000py (181/1,815) in 1997 to 62.48 c/1000py (186/2,977) in 2008 which is equivalent to a 
3% decrease per year (IRR=0.97 95%CI=0.96 to 0.98). The average child mortality over the 
study period was 10.68 c/1000py (417/39,041) (IRR=1.00 p=0.849).  
 
Figure 26. Yearly Under five mortality rates in the Kilombero and Ulanga DSS 1997 and 2008 
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Figure 27. ACCESS interventions and other major malaria control interventions  
 
 
Figure 28. Rainfall and rice production in the Kilombero Valley, between 1997 and 2008 
 
The only malaria control interventions which were found to be independently associated with  
a decrease in mortality were (1) the package of ACCESS interventions, and (2) the 
ownership of ITNs (Table 19).  Mortality rates were 17% lower in 2008 compared to 2004 
(before the ACCESS interventions – IRR 0.83  95% CI 0.68-0.99) and every 10% increase in 
mosquito net ownership was associated with a 5% decrease in mortality (IRR 0.95  95%CI 
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0.93-0.98). The IMCI training of health facility staff and the changes of treatment policy did 
not affect mortality significantly. There was no effect following the first year of introduction of 
a new antimalarial drug, but a 19% increase in mortality was estimated in the second year of 
introduction of a new drug. An analysis performed separately during the SP years and the 
ALu years suggests that this effect is entirely driven by increases in mortality during the 
second year of SP introduction (IRR=1.18, 95%CI=1.04 to 1.35 excluding the effect of 
ACCESS) whereas there was no significant effect associated with the second year of 
introduction of ALu. The effect of interventions did not vary significantly whether the variable 
denoting the ACCESS interventions was included in the model or not, i.e whether the model 
was fitted on 9 or 12 years of data (effect of the second year of a drug IRR=1.16 95%CI 1.04 
to 1.31, effect of ITN ownership IRR=0.97 95%CI=0.95 to 0.98, all others non significantly 
different from zero, Pseudo R-sq=0.430 LR Chi-sq=77.53 p<0.001).   
 
Table 19. Estimated effect of malaria control interventions and contextual factors from Poisson 
regression fitted on yearly under-five mortality rates between 1997 to 2008 
 
Univariate model 
(n=12) 
Multivariate model 
 (n=9) * 
 
IRR (95% CI) Sig. IRR (95% CI) Sig. 
Malaria control interventions 
 
   
ACCESS (before 2004 vs. 2008) 0.66 (0.59 to 0.79) <0.001 0.83 (0.68 to 0.99) 0.035 
IMCI (before vs. after 2003) 0.85 (0.79 to 0.91) <0.001   
1st line treatment (baseline=CQ) 1    
SP 0.91(0.84 to 0.98)   0.010   
Alu 0.70 (0.63 to 0.77) <0.001   
1st  year of a drug 0.88 (0.81 to 0.96)   0.004   
2nd  year of a drug 0.87 (0.80 to 0.94)   0.001 1.19 (1.04 to 1.37) 0.011 
ITN ownership (10% increase) 0.95 (0.94 to 0.97) <0.001 0.95 (0.93 to 0.98) 0.001 
Contextual factors  
 
  
Total annual rainfall (500 mm) 0.86 (0.82 to 0.89) <0.001   
Rice yield (500 kg/ha) 0.85 (0.82 to 0.89) <0.001 0.86 (0.79 to 0.92) <0.001 
 * Pseudo R-sq=0.454 LR Chi-sq=80.82 p<0.001 
 
There is evidence that non-malaria control factors also explain variations in mortality. Rice 
yield and rainfall were both strong independent predictors of mortality (Table 19), with 
increased rainfall and increased yield significantly associated with decreases in mortality. 
However, overall the multivariate models explained only approximately 20% of the variation 
in mortality (Model including the effect of ACCESS R-sq= R-sq=0.454, model excluding the 
effect of ACCESS Pseudo R-sq=0.430). This suggests that many other variables not 
accounted for also explain the observed decrease in mortality.  
Determinants of intra-annual variations in infant and child mortality rates  
Infant and child mortality both exhibited strong intra-annual variation (Table 20). Mortality 
rates in children were between 6 and 10 times higher than in infants. There was no evident 
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seasonal pattern, although monthly infant mortality rates tended to be lower between May 
and July, while child mortality rates were lower between June and September (the months 
with lower rainfall and higher food availability). The accepted pattern of the rainy season is 
from November to May with peaks in March and April, but our data suggest a strong year on 
year variability in monthly rainfall The average rice harvest produced a mean of 2675kg 
(SD=443kg) per household and the average maize harvest was 540kg (SD=100kg) per 
household. Food availability was at its maximum in June after the harvest and decreased 
constantly thereafter, reaching its minimum in January and February (Figure 29 and Figure 
30). 
 
Table 20. Descriptive statistics of inter-annual variation in infant and child mortality, rainfall 
and estimated food availability between 1997 and 2008 
 Infant mortality  Child mortality  Total rainfall 
 (mm) 
 
Estimated 
household food 
availability (kg) 
 
Rate (c/1000py) Rate (c/1000py) Median (IQR) Median (IQR) 
Jan 88.9(215/2.419) 11.0 (38/3.463) 215.1 (110.0) 525 (40) 
Feb 89.5 (196/2.191) 12.0 (40/ 3.089) 203.0 (136.1) 360 (30) 
Mar 86.7 (210/2.422) 13.9 (47/3.379) 307.2 (228.5) 730 (75) 
Apr 81.6 (192/2.353) 12.3 (40/3.255) 380.4 (289.0) 570 (65) 
May 66.4 (162/2.441) 10.7 (36/3.375) 83.9 (88.5) 980 (70) 
Jun 60.7 (144/2.372)  8.9 (29/3.245) 14.1 (22.3) 1810 (130) 
Jul 69.5 (171/2.459)  9.5 (31/3.263) 1.1 (6.0) 1860 (130) 
Aug 77.6 (193/2.489)  9.4 (31/3.282) 1.1 (24.8) 1520 (110) 
Sep 86.8 (209/2.408)  7.9 (25/3.148) 0.2 (5.5) 1260 (90) 
Oct 83.3 (208/2.496) 12.4 (40/3.216) 1.2 (14) 1060 (80) 
Nov 79.1 (193/2.439) 7.7 (24/3.098) 27.6 (80) 870 (60) 
Dec 79.2 (202/2.549) 11.1(36/3.229) 159.1 (206.8) 690 (40) 
 
 
Rainfall and food availability in the same month were strong predictors of infant and child 
mortality in univariate analyses, with every mm of rain increasing the death rate by 20-35%, 
and every 500kg increase in household food availability decreasing it by 8-12%. Child 
mortality was also negatively associated with food availability in the previous month and the 
previous two months. Strangely, rainfall in the previous two months appeared to have a 
protective effect on infant mortality (Table 21). 
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Figure 29. Monthly rainfall, food availability and infant mortality between 1997 and 2008. 
 
 
Figure 30. Monthly rainfall, food availability and child mortality between 1997 and 2008 
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Table 21. Estimated effect of rainfall and food availability from Poisson regressions fitted on 
monthly infant and child mortality rates between 1997 and 2008 (all effects adjusted for the 
effect of year) 
 Univariate model 
 
Multivariate model 
(n=142) * 
 
n IRR (95% CI) Sig. IRR (95% CI) Sig. 
Infant Mortality  
 
   
Rainfall (500 mm) 144 1.20 (1.06 to 1.36) 0.005 1.19 (1.01 to 1.40) 0.038 
Rainfall (500 mm) lag 1  143 1.02 (0.90 to 1.16) 0.814   
Rainfall (500 mm) lag 2  142 0.79 (0.69 to 0.90) 0.001 0.76 (0.65 to 0.89) 0.001 
Food availability (500 kg) 144 0.92 (0.89 to 0.96) <0.001 0.96 (0.91 to 1.01) 0.103 
Food availability (500 kg) lag 1  143 0.97 (0.94 to 1.01) 0.133   
Food availability (500 kg) lag 2 142 1.01 (0.97 to 1.05) 0.607   
Child mortality  
 
   
Rainfall (500 mm) 144 1.35 (1.02 to 1.80) 0.036   
Rainfall (500 mm) lag 1  143 1.21 (0.90 to 1.62) 0.199   
Rainfall (500 mm) lag 2  142 1.14 (0.84 to 1.53) 0.394   
Food availability (500 kg) 144 0.88 (0.80 to 0.97) 0.009 0.90 (0.82 to 0.99) 0.044 
Food availability (500 kg) lag 1  143 0.90 (0.82 to 0.98) 0.021   
Food availability (500 kg) lag 2 142 0.90 (0.82 to 0.99) 0.029 0.93 (0.84 to 1.03) 0.158 
* Infant mortality Pseudo R-sq=0.0523 LR chi-sq(4)=46.16 p<0.0001  Child mortality pseudo R-sq=0.0160 LR chi-sq(2)=9.13 
p=0.0140 
 
6.5. Discussion  
Under five mortality significantly decreased by 17% following the ACCESS package of 
interventions, from an average of 28.4 c/1000py in the years before the interventions to 18.9 
c/1000py in 2008, accounting for other malaria interventions (ITN coverage, changes in 
treatment policy and IMCI training of health facility staff) and contextual factors (rice yield and 
rainfall). The only other malaria control intervention which was found to be independently 
associated with under-five mortality is ITN coverage, with every 10% increase in household 
ownership decreasing the incidence of death by 3-5%. The decrease in under-five mortality 
was mainly driven by a decrease in infant mortality whereas child mortality remained 
constant between 1997 and 2008. An analysis of the inter-annual determinants of infant and 
child mortality suggests that this may be because the main determinant of child mortality is 
household food availability, which has not changed significantly over the study period. 
 
Our conclusion that the improvement in access to treatment has resulted in a decrease in 
mortality is based on a before-after assessment [90]. This type of design assumes a 
plausibility argument, i.e. that mortality reductions can be attributed to programmatic efforts. 
Plausibility is often defined by demonstrating improvements in population-level 
measurements of steps in the causal pathway.  In our study area we have evidence that a 
social marketing campaign for improved malaria treatment seeking for malaria combined with 
a strategy to strengthen the role of the private retail sector and changes in the delivery 
system of drugs in health facilities resulted in improved access to treatment at both the 
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provider and the user levels from 2004 to 2008 (cf. Chapters 3 and 4). The percentage of 
fever cases treated with an antimalarial increased from 85% to 96% (infants from 89% to 
90%, children under five from 90% to 94%) and the percentage treated within 24hrs 
increased from 67% to 89% (infants from 67% to 90%, children under five from 73% to 88%). 
These are very high treatment coverage indicators, well in excess of the 30% average in 
Sub-Saharan Africa [32].   
 
The very high levels of treatment obtained in the study area imply that virtually any potential 
malaria case is treated with an antimalarial. This is in some ways this is confirmed by an 
independent survey demonstrating a very high average drug level for antimalarials in the 
population [170]. It is important to point out that a significant proportion of fever patients was 
treated with SP even after the change of treatment policy. Although a high resistance to the 
drug had been documented in the area [133] it has been argued that using SP for 
presumptive treatment may have a significant impact on transmission thanks to its 
prophylactic effect [153]. The uptake of ALu was not as high as expected (only used in third 
of cases in 2008), it had a very high treatment efficacy upon its introduction [134] in 2007. 
Therefore it is reasonable to assume that the treatment access improvements we have 
observed have contributed to a decrease in mortality.  
 
A concurrent decrease in malaria morbidity and transmission indicators gives an independent 
argument  that the decrease in under five mortality is driven by a decrease in the malaria 
burden.  The incidence of fevers in the area decreased from 47 cases per 1000 weeks 
(c/1000pw) in 2005 to 34 c/1000pw in 2008 and the incidence of convulsions in young 
children decreased  from 4263 to 2320 cases for every 100 000 children per year (cf. 
Chapter 5). An older study reported an EIR of 349 infective bites per person per year (ib/p/y) 
between 2001 and 2003 [77], but by 2008 the EIR had declined to 81 ib/p/y [78]. Similarly, 
data from two other projects documented a decrease in parasitaemia in children under the 
age of five years from 25% in 2004 [150] to 10% in 2008 (Mulokozi et al., unpublished data). 
However it is important to recognise that this decrease started already in the mid-nineties 
when an EIR of up to 1400 ib/p/y was recorded [171] and parasitaemia in infants and 
children under the age of two years was over 50% [172-173].  
 
Given the imperfect study design and the complex nature of malaria transmission dynamics 
any attribution of the observed mortality decreases to specific interventions should be 
interpreted with caution.  Before-after designs are often the only feasible way to assess the 
impact of health interventions at population level (when it is not possible to have a concurrent 
and comparable control group) but they provide a weak argument for causality. The main 
concern is that there may be other factors explaining the observed decrease in mortality and 
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which can not be taken into account. With regards to malaria transmission, there is evidence 
of a non linear relationship between ITN coverage and EIR. It has been estimated that 35%-
65% use of nets in all adults and children can achieve community-wide benefits equivalent to 
or greater than personal protection [174]. Further, recent modelling work suggests that 
sustaining coverage with ITN at such levels may lead to constant decreases in transmission 
even if coverage does not increase (personal communication, Prof. Tom Smith, Swiss 
Tropical and Public Health Institute, Basel) It is therefore likely that the effect of improved 
treatment following ACCESS interventions is lower than what our analyses suggest and may 
perhaps only explain half of the 17% decrease that we have observed.  
 
Despite these study design limitations, our conclusions are strengthened by the broad 
consistency with other studies conducted in the study area. The 3-5% decrease in mortality 
for every 10% increase in bednet ownership is very similar to the results of a Cochrane 
review which synthesised the evidence from five cluster randomised trials conducted in sub-
Saharan Africa. Results showed a 17% protective efficacy of ITNs for an average of 60% 
coverage compared to control areas with no nets [175]. The absence of an impact in the first 
and second years of introduction of a new antimalarial drug in the public sector is 
disappointing, but is not entirely surprising considering that  both in 2001 and in 2007 the 
change of treatment policies resulted in a decreased availability of the first line treatment [68] 
(cf. Chapters 3 and 4). The increase in mortality in the second year of introduction of SP is 
most likely due to the rapid onset of resistance to the drug [133].  We were not able to find an 
impact of the introduction of IMCI in the study area. This is surprising since a study 
conducted in Tanzania which used our study as a control, found that under five mortality was 
13% lower in IMCI than in comparison districts [34]. This may reflect differences in the 
implementation of this strategy in programmatic versus non-programmatic settings.  
 
We found that the decrease in under-five mortality was mainly driven by decreases in infant 
mortality, whereas child mortality remained constant over the study period. This is consistent 
with various studies which showed that in highly endemic settings most malaria deaths 
occured in the first year of life [176-178], and that decreasing transmission mainly reduces 
infant mortality [179]. On the other hand, it is likely that the reason why child deaths (ages 1-
4 years) have not been decreasing between 1997 and 2008 is because they are only 
indirectly caused by malaria, whereas the primary driver is food availability and therefore 
malnutrition. It is important to stress that the fact that household food availability emerged as 
the only independent correlate of child deaths does not exclude that malaria is an important 
cause of death in this age group. Firstly, because months with higher rainfall largely coincide 
with the months of lower food availability, and the exact relationship between the amount and 
timing of rainfall, EIR and malaria infection in humans is not fully understood. Secondly, 
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because there is considerable body of evidence showing that children who are malnourished 
are more susceptible to malaria morbidity and mortality [180]. Animal and human 
epidemiological studies suggest that this is a consequence of a reduction in the function of 
the immune system [181]. Moreover in a cash crop society household food availability is also 
strongly related to the ability to mobilise resources to afford treatment [135]. It has also been 
argued that household food insecurity and its related stress [182] could impair mother’s 
ability to successfully prevent and treat malaria in their children [183].  
 
There are a number of factors which could affect our analyses, including changes in 
HIV/AIDS prevalence and treatment and other non malaria health interventions. However, 
regional data suggests that there the proportion of women living with HIV/AIDS has remained 
constant at around 7% between 2004 and 2008 [25,184] and knowledge of the HIV/AIDS 
epidemic suggests that it can only have risen between the mid nineties and 2004 [185]. Anti 
Retroviral Treatment (ART) was introduced in 2004 but only around 11-13% of HIV infected 
people in the DSS area received treatment by 2008 (Dr Erik Mossdorf, Chronic Diseases 
Clinic Ifakara, Tanzania and University Hospital Basel, Switzerland personal communication). 
The coverage of other child-survival interventions such as vitatmin A supplementation 
increased after its introduction in the routine Essential Drugs Programme (EDP) in 1997 
[186]. Other interventions such as oral rehydration therapy and iron supplementation for 
children also increased but antenatal care and immunisation coverage were already high and 
did not change [149].  
 
Finally, Economic growth and development could also explain part of the decrease in 
mortality and confound our results. The Gross Domestic Product (GDP) of Tanzania 
increased from 7.68 billion USD to 20.5 billion USD between 1997 and 2008 [187]. However 
most of the inhabitants of the study area are subsistence rice farmers. GDP figures do not 
reflect changes in their wealth and it is difficult to estimate how much better off they are as a 
result of the nation’s economic growth.  
 
6.6. Conclusions  
Malaria control interventions in the Kilombero and Ulanga districts are likely to be associated 
with decreases in under five mortality. It is difficult to quantify the individual contribution of 
each malaria control intervention given the before-after nature of the study and the lack of 
information on the many other factors which may provide alternative explanations for this 
decrease. However, plausibility arguments suggest that improving access to malaria 
treatment with social marketing campaigns and by strengthening the role of the private retail 
sector for drugs is a successful strategy. Most of the decrease in under-five mortality has 
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been driven by decreases in infant mortality, while child mortality appears to be mainly driven 
by household food insecurity. Future malaria control interventions should recognise and act 
upon the important contribution of malnutrition to malaria morbidity and mortality.  
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7. Overall discussion and conclusions 
This aim of this thesis was to evaluate the ACCESS Programme.  Findings should feed into a 
better understanding of access to malaria treatment and inform future interventions. The 
methodological issues of the analysis are presented in 7.1 with a focus on the design and the 
choice of study area. Sections 7.2 outlines the study’s implication for the interventions and 
monitoring and evaluation activities of the second phase of ACCESS (2008-2011) while 
section 7.3 examines the study’s implications for practice. 
 
7.1. Methodological issues  
Study design 
The main limitation with the evaluation presented in this thesis is the weakness of the 
arguments attributing causality. Randomised controlled trials are considered the gold 
standard to establish a causal relationship but it is not always possible to randomise people 
and results are typically not very generalisable since they offer an indication of controlled 
efficacy rather than real life effectiveness [188]. In the case of the ACCESS programme it 
would not have been practical or politically acceptable to randomise communities. It would 
have also excluded the possibility of monitoring the community impact of the programme 
since too few communities would have been in the DSS area. Hence a plausibility 
assessment [90]  was the only feasible way to assess the impact of ACCESS interventions. 
With this type of design improvements are attributed to the programmes if improvements are 
found in every step of the causal pathway between intervention and impact and all other 
explanations can be formally discarded. The comprehensive M&E plan of the ACCESS 
programme enabled to reach a high level of plausibility but it was not possible to rule out that 
improvements could have happened independently from the project, especially as a result of 
a secular trend.  
 
There would have been two ways to reach a higher level of plausibility: 1) by documenting 
changes in the understanding of malaria and its treatment and 2) by choosing a comparison 
group to control for the influence of confounding factors. The main health outcome of the 
programme was the increase in the proportion of fever cases treated with an antimalarial 
within 24 hours.  This improvement was ascribed to the ADDO intervention and the social 
marketing campaigns, on the basis of improved access outputs, (i.e. better availability and 
accessibility of treatment) and better knowledge. The access outputs were measured, and 
indeed improvements were noted [102] (cf. Chapter 4) but better knowledge was only 
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assumed as a necessary consequence of exposure to social marketing campaigns. Although 
it might be a perfectly reasonable assumption, measuring improvements in understanding 
within the frame of the EMIC treatment seeking surveys or with a household survey before 
and after the implementation of the interventions would have added strength to the argument 
that the social marketing campaigns were able to promote behaviour change.  
 
As far as the choice of a control is concerned, the Rufiji Demographic Surveillance Site 
(DSS) could have been an ideal comparison group. Two other large scale studies have 
evaluated interventions by comparing the Ifakara and the Rufiji DSS. The Interdisciplinary 
Monitoring Project for Antimalarial Combination Therapy in Tanzania (IMPACT-Tz) [105] 
[150] and the Integrated Management of Childhood Illness Multi-Country Evaluation (IMCI-
MCE) [34, 166] have made use of this design. The choice of an external control would have 
enabled, for example, to rule out the possibility that improved access outputs were just the 
result of a natural growth in the retail sector for drugs, and that better treatment outcomes 
are just a consequence of that. It would have also enabled to quantify better the impact of the 
programme on morbidity and mortality.  
 
Choice of location  
There were numerous advantages to conducting this study in the Ifakara DSS.  The DSS 
provided an excellent epidemiological framework for this study. The constant demographic 
surveillance enabled the assessment of the mortality and morbidity impact and facilitated the 
selection of random sample of households for the treatment seeking surveys [102] (Chapter 
4). The findings from qualitative investigations of people’s perception and understanding of 
disease could guide the adaptation of the questionnaire used for the treatment seeking 
surveys [81, 128].  Furthermore, there was a wealth quantitative data to support the 
interpretation of the findings of this thesis. This includes entomological and parasitological 
data  [77, 173, 189-190] (Chapters 5 and 6) collected since the 1990s. This data was further 
complemented by in depth descriptions of the agricultural practices of the farmers of the 
Kilombero Valley [74, 76, 167] and comprehensive agricultural production data from the 
Kilombero District Agricultural and Livestock Development Office (DALDO), most likely due 
to the proximity to the Kilombero Agricultural Research and Training Institute (KATRIN). In 
addition KATRIN itself had been collecting rainfall data since the nineties which it kindly 
agreed to share.    
 
However, studies conducted in DSS areas are not necessarily very generalisable to the rest 
of the country.  The Kilombero and Ulanga Districts in general, and their DSS areas in 
particular, have been the object of continued donor and research attention for decades.  The 
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use of antimalarials to treat fever was already much higher in the study area (73% feverish 
children treated within 24 hours) compared to the rest of the country (51%) [26]. The 
continued visits by DSS staff could be causing respondent fatigue and biasing our results. 
The possibility of a Hawthorne effect also needs to be considered [191-192], whereby people 
may be adapting their responses (and behaviour) simply because they are being studied, not 
necessarily in response to a particular intervention.  
 
Interventions 
Unfortunately this evaluation was not able to fully assess the effect of interventions at health 
facility level. A refresher course training was conducted between 2004 and 2005 in the health 
facilities of the Kilombero and Ulanga District to improve quality of care.  A follow-up was 
planned with a Quality Improvement and Recognition Initiative (QIRI). QIRI offers an 
integrated approach for the evaluation of quality of care combined with a strategy to establish 
the root causes of performance gaps and to develop implementable strategies to address 
them. A central element of this component is capacity building for joint supportive 
supervision and quality management,  conducted by the regional and district health 
management teams together with community representatives.  Due to logistic constraints the 
implementation of QIRI excercises had to be postponed to 2007 and hence their effect could 
not be evaluated in this thesis.  
 
7.2. Implications for the second phase of ACCESS 
Building on the experiences and results from the first phase, the aim of ACCESS II (2008-
2011) is to strengthen resources at community, health facility level, with a particular 
emphasis on sustainability.  The activities of the second phase will focus on: 
1) Improving households’ economic (income) base needed for improved health seeking 
and outcomes through strengthened Community Health Fund (CHF) and micro-
finance for income generation activities; 
2) Intensifying community sensitization on correct and prompt malaria treatment with 
ALu, as well as the empowerment of patients to demand their rights and quality 
services through a social marketing approach; 
3) Strengthening routine supportive supervision and implementation of quality (malaria) 
case management in all health facilities through the Quality Improvement and 
Recognition Initiative (QIRI), as well as the introduction of RDTs for malaria; 
4) Enhancing the flow of the project’s main findings and outcomes to the different 
stakeholders such as communities, district health authorities, and national and 
international policy makers in order to influence access policies and practices. 
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Recommendations for ACCESS II interventions 
Results from the treatment seeking surveys [102] (cf. Chapter 4) showed that the use of ALu 
was not widespread. This was largely due to the low availability of the drug in drug shops, 
but also because the drug was only prescribed to 2/3 of patients who visited health facilities, 
although it was present in virtually all the health facilities during the survey period. Possible 
reasons have already been elaborated on (Section 3.5) and include health facility staff 
rationing and patient preference for other drugs with simpler regimens. Future interventions 
in health facilities and social marketing campaigns should aim to address these issues. The 
introduction of Rapid Diagnostic Tests (RDT) for malaria should facilitate the process since 
studies suggest that providers and patients alike are more keen to use ALu in a cases of 
confirmed malaria (D’Acremont, in preparation).  
 
It is important that the availability of ALu in ADDOs continues to be monitored. This will be 
undertaken by the nation-wide evaluation of the Affordable Medicines Facility for malaria 
(AMFm) (Mwita, National Malaria Control Programme, personal communication). But within 
the frame of enhancing the flow of the programme’s main findings to district health authorities 
and strengthening routine supervision, ACCESS II should ensure that the Council Health 
Management Teams (CHMT) are fully aware of the importance of the availability of the first 
line treatment for malaria in the private health sector. 
 
Results from the treatment seeking surveys [102] (Chapter 4) suggest that more research is 
needed on methods to improve patient adherence to treatment. Noticeable gains were made 
between 2004 and 2008 in terms of timeliness of treatment (from 80% to 92-97% of doses 
taken within 24 hours), but no significant changes with regards to dosage (between 43% and 
76% of doses taken in the right dose). Data from mystery shoppers surveys conducted in 
between 2004 and 2008 in drug shops showed that the proportion of shopkeepers who gave 
correct advice for the treatment of malaria along with the antimalarial they sold improved 
significantly after the introduction of ADDOs (from 30% to 80%, Dillip et al., unpublished 
data). This suggests that inappropriate dosage of treatment is more likely to be the result of 
patient adherence rather than provider compliance, and that future social marketing 
campaigns should aim to address this component.   
 
Recommendations for ACCESS II monitoring and evaluation 
This thesis has shown the strength of combining an analytical framework with 
epidemiological methods to investigate the determinants of access to treatment.  On the 
basis of the Access framework [52] (cf. Section 1.6 for details), data from provider surveys 
were combined with data from treatment seeking surveys to determine the relative 
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contribution of the availability, accessibility and affordability of malaria drugs to prompt and 
effective treatment. Unfortunately the data generated in this evaluation did not able a 
systematic and quantified assessment of the effect of each access dimensions. Table 22 and 
Table 23 give an overview of all the dimensions which should be extracted in future provider 
and user surveys to quantify the contribution of all the access.  
 
Table 22. Determinants of malaria treatment at user level  
Dimension Indicators Available in 
this 
evaluation  
Availability  (does not need to be assessed at user level for the purpose of this 
evaluation) 
 
Affordability  1. SES of household YES 
 2. Ability and willingness to pay for treatment  NO 
 3. Amount paid for drug and treatment 
4. Indirect costs (transport, bribes) 
YES 
NO 
Accessibility 5. GPS location of household YES 
 6. Location at onset of fever  YES 
 7. Loss of time/time taken to travel to the outlet NO 
Adequacy 8. Waiting hours NO 
 9. HF workers/shop attendants perceived as polite and 
professional 
NO 
 10. Patient expectation to be diagnosed with a diagnostic tool 
(microscopy or RDT) 
NO 
Acceptability  11. Personal opinion about each drug  NO 
 12. Personal opinion about importance of prompt treatment for 
fever 
NO 
 13. Advice to take the drug by a community member  NO 
 14. Advice from community member about importance of 
promptness of treatment 
NO 
 
Table 23. Determinants of malaria treatment at provider level  
Dimension Indicators Available in 
this 
evaluation  
Availability  1. Availability of outlets (HF and drug shops)  YES 
 2. Availability of drugs in outlets  YES 
Affordability  3. Prices of drugs  YES 
Accessibility 4. GPS location of outlets YES 
Adequacy 5. Waiting hours NO 
 6. Opening hours  NO 
 7. HF staff qualification NO 
 8. HF staff operate on a first come first served basis NO 
 9. presence of diagnostic tools in the HF NO 
Acceptability  10. Providers’ opinion (HF staff or shop attendants) about each 
drug and the importance of prompt treatment of fever 
NO 
 
 11. Providers’ opinion about diagnostic tools in the HF NO 
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7.3. Implications for practice 
 
This evaluation has shown that with a set of integrated interventions the Abuja target of “80% 
of children treated with an antimalarial drug within 24hours of fever onset” is reachable even 
in a rural Africa setting. A recent review conducted by Smith et al. concluded that very little is 
known about what interventions work in improving prompt and effective treatment for malaria 
[33]. The overwhelming finding from the review was that despite the wealth of research 
conducted on the topic, few interventions have been thoroughly evaluated - out of 58 studies 
conducted on the topic only 23 met the inclusion criteria. This thesis has presented data from 
a thorough evaluation and has shown that: 1) social marketing campaigns stressing the 
importance of prompt treatment for malaria combined with 2) a private sector intervention 
which has improved the availability of quality malaria care in drug shops and 3) good 
availability of antimalarial drugs in the public sector following the implementation of a push 
system of delivery can result in over 80% of fever cases in children treated promptly for 
malaria. Only 56% of cases reported adhering to the recommend drug dosage, but these are 
still very high values for a rural sub-Saharan African setting. A recent report found that on 
average only 30% of fever cases in children are treated promptly and adequately for malaria 
in sub-Saharan Africa [32]. Most importantly, it means that the 2007 targets set by the MTSP 
were nearly reached in the study area (cf. Section 1.4).  
 
However, this evaluation has also shown the importance of integrated strategies. 
Improvements in treatment for malaria were associated with a decrease in malaria morbidity 
and morbidity, but the high level of ITN ownership in the study area also contributed to these 
decreases.   Nevertheless, despite the improvements seen in terms of reduced malaria, little 
gains have been made in terms of child mortality (ages 1 to 5) as the main driver of mortality 
in this age group appears to be food availability and malnutrition. It is crucial that policy 
makers and donors recognise the need for integrated approaches rather than focusing only 
on one element of child survival. Furthermore, malaria control strategies should be 
implemented within a wider frame of child survival interventions which recognises and acts 
upon the synergy between malnutrition and infectious diseases. As it is beyond the scope of 
this evaluation to advise on these issues, the following sections will concentrate on the 
implications for the scale up the strategies evaluated in this thesis. 
 
Behaviour change campaigns 
Experiences from the Kilombero Valley offer a compelling case to justify the use of heath 
education campaigns to improve people’s understanding of malaria and their actions for its 
treatment. This evaluation documented impressive improvements in terms of prompt and 
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effective treatment for malaria, but treatment coverage was already much higher at baseline 
than in the rest of the country. This is most likely due to the long standing efforts in the area 
to improve malaria control parameters comprehensively since the mid 1990s with the KINET 
social marketing campaigns [126]. The Smith et al. review pointed out that most interventions 
targeting users alone with education campaigns have only been assessed in terms of 
changes in knowledge [121-122, 193] and the reviewers have argued that this is not enough 
to show that they can change behaviour. This evaluation has shown that changes in 
knowledge can translate into changes in practice if efforts are made on the provider side to 
improve the availability and accessibility of sources of treatment. This is confirmed by results 
from two other interventions which involved both users and providers contemporarily such as 
the HMM strategy by Pagnoni et al. in Burkina Faso [118] and the shopkeeper programme 
reported by Marsh et al. in Kenya [113] .    
 
However, there are two main caveats with regards to social marketing campaigns. Firstly 
they do not seem to be able to change user behaviour in terms of adherence to 
recommended treatment regimens. The results from this evaluation are confirmed by a study 
conducted in Kenya [194] that targeted users with a health education campaign and showed 
a significant effect with regards to the use of a correct antimalarial, but not on dosage. 
Generally interventions that specifically provide information on how to take antimalarial, 
including pre-packaging and pictorial instructions have shown greater improvements on 
patient adherence [124, 195] . This evaluation was unable to find a significant difference 
between adherence to ALu, which had been pre-packaged with pictograms, and to other 
drugs such as SP and amodiaquine. However, it is worth pointing out that ALu had just been 
introduced and its dosage is not as straight forward as the other drugs (quinine, SP and 
amodiaquine). Had it not been pre-packaged adherence to it might have been even lower 
than observed. Furthermore adherence was only based on patient report, while another 
study conducted in the area, which followed up patients from the clinic to their homes and 
counted the pills left in their blister packs, found over 90% adherence (Mulokozi et al., 
unpublished data). 
 
Secondly more sustainable approaches need to be developed. The ACCESS social 
marketing campaigns evaluated in this thesis are too costly to be uspscaled. This issue is 
currently being addressed in the frame of the ACCESS II where community based strategies 
which make use of existing structures are being explored. This includes using women’s 
groups as a platform to disseminate public health messages and introducing malaria 
“modules” in the school curriculum.  
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Strengthening the role of the private sector 
ADDOs have proven to be a successful model and upscaling them nation-wide, as is 
planned, can potentially extend the improvements observed in the study area to the rest of 
the country. The results from this evaluation confirm considerations from Smith et al. that 
interventions targeting the private retail sector generally have a positive impact on provider 
practice and can improve community drug use. The implementation of the ADDO programme 
in the study setting had all features outlined by Goodman et al as key for a successful private 
sector implementation [41]: 1) the planning process began with a comprehensive situation 
analysis including the legal and market environment [57]; 2) the intervention had a wide “buy-
in” since it was developed closely with the national drug regulatory authorities, with support  
from central and local officials and 3) it was accompanied with a community intervention 
promoting its use (i.e. the ACCESS social marketing campaigns). 
 
However, for the successes documented in this thesis to be sustained, it is crucial that the 
programme continues to be monitored closely. There is limited evidence that private sector 
interventions such as the ADDO programme can operate at a nationwide scale [41]. 
Furthermore many concerns have been raised with regards to private sector health care 
delivery in developing countries [196]. The two main sources of objection are that 1) private 
provision increases inequity because it naturally favours those who can afford treatment and 
2) the quality of care is not up to the standard offered in health facilities and can put lives at 
risk. In the specific case of malaria a further concern is that the misuse of ACTs and the use 
of artemisin monotherapies could compromise the effectiveness of artemisin derivatives.  
 
In view of its upscaling it is important that ADDOs remain a system that is complementary to 
health facilities and stick to their mandate to “improve the quality of medicines and 
pharmaceutical services in previously under served areas” [87]. With regards to equity 
concerns, this evaluation has found that the main determinant of prompt and effective 
treatment is the availability of outlets whereas there were no differences across SES groups. 
Despite increases in prices in drug shops the market shares of the private sector continued 
to grow since shops were more available and accessible. Based on these considerations the 
ADDO programme could even contribute to more equitable access, if it manages to promote 
the opening of its outlets even in remote areas where there are currently no facilities. This 
evaluation has provided some evidence that ADDOs were opened in previously underserved 
areas but three out of 25 villages in the DSS area still have neither a health facility nor an 
ADDO. Some schemes which include reduced accreditation fees have been suggested to 
encourage the opening of ADDOs in more remote areas (Liana, MSH Tanzania, personal 
communication), but MSH and TFDA will have to ensure that these schemes are fulfilling 
their aims, or come up with other ones. As far as quality of care is concerned, experience to 
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date suggests that the quality of the advice given by ADDO dispensers is good and that they 
usually refer cases they cannot manage to health facilities (Dillip et al., in preparation). 
However constant supervision and refresher courses will be needed to ensure that they 
continue to do so. Finally, TFDA, in collaboration with district health authorities should 
enforce a ban on the sale of cheap artemisinin monotherapies so that they are not available 
in ADDOs. This thesis found that no patients were treated with such drugs in the study area 
because of their high price, but their availability at low prices is bound to change this picture. 
 
However, for the full potential of the ADDO programme to be realised, ACTs need to be 
made available in all outlets at an affordable price. This evaluation has shown that the main 
failure of the programme was its inability to promote the widespread availability of ALu in its 
outlets [127] (cf. Chapter 3). ALu was made available at a highly subsidised price to ADDO 
retailers but the end user price was still 2-5 times as expensive as other monotherapies such 
as SP. This appears to have led to low demand for the drug and therefore low stocking rates, 
which in turn resulted in a very low use of ALu in the community despite it being widely 
available in all health facilities: although 63% of all fever cases were treated promptly and 
effectively only 22% were treated with a recommend antimalarial (ALu or quinine). The 
introduction of the AMFm in Tanzania could provide a viable solution to these types of 
problems, by subsidising ACTs at source and making them available at a similar price to 
previous generations of drugs. If ADDOs can be upscaled by maintaining the good quality of 
care shown in this evaluation, they will provide an ideal platform for the implementation of the 
AMFm and access to malaria treatment could be substantially improved.  
 
Drug distribution systems in the public health sector  
A “push” system of drug distribution in public health facilities has led to impressive drug stock 
levels, which would suggest it is a successful approach. Tanzania has nearly completed its 
conversion from the kit system of drug delivery (a “push” mechanism), to the Indent/ILS (a 
“pull” mechanism) (cf. Section 1.7). This transition was motivated by recurrent drug stock-
outs due to the inelasticity of the kit system, but this evaluation suggests better stocks can be 
achieved with this type of system. Antimalarials were only available 40% of the time when 
the Indent system was operating but over 80% when a temporary push system was 
implemented as a short term strategy. Nevertheless, it is important to recognise that this 
evaluation did not focus on drug delivery mechanisms. Based on the studies that have been 
conducted in Tanzania on drug procurement it is likely that the wide availability of ALu in 
health facilities was as much a result of its availability at central level as a consequence of 
the delivery system (cf. Section 1.7). There are many reasons why push systems are not 
desirable: they typically do not respond rapidly to differing seasonal and geographical needs 
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and this often leads to either stockouts or wastages. Such issues were not studied here and 
therefore recommendations should not be made in terms of drug delivery mechanisms based 
on this evaluation.  
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